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Abstract 
 Comparability assessments are frequently performed during 
biopharmaceutical drug development to evaluate the effects of manufacturing 
process changes on the structural integrity, safety and efficacy of candidate 
protein drug products. Physiochemical analytical evaluations (an essential 
element of any comparability exercise) involve multiple assessment techniques 
mapping the different aspects of protein structural integrity (primary and higher-
order structures).  Although significant advances in regards to primary structure 
evaluations have been made including peptide and oligosaccharide mapping 
techniques combined with mass spectrometry, the need for more sensitive 
approaches for the evaluation of higher order structures of proteins, especially in 
their final pharmaceutical dosage forms, remains an important challenge.  In this 
dissertation, the ability of using multiple protein conformational stability studies 
(combined with novel data visualization approaches) as surrogates for evaluating 
and comparing different proteins’s higher-order structure are explored in the 
context of comparability.  Empirical phase diagrams (EPDs) and radar charts, 
constructed using large data sets from high throughput, lower-resolution 
biophysical techniques, are used to detect major (point mutations of FGF-1) and 
minor (different glycosylation patterns of an IgG1 mAb and Fc molecules) 
structural differences between proteins. In addition, for the IgG1 Fc glycoforms 
expressed in yeast, the effect of N-linked glycosylation site occupancy, as well as 
iv 
 
the effect of different charge states in various nonglycosylated forms, within the 
CH2 domain was examined. Using this approach, differences in conformational 
stability were detected under stress conditions that did not necessarily detect 
structural integrity differences in these proteins in the absence of these stresses. 
Thus, an evaluation of conformational stability differences may serve as an 
effective surrogate to monitor more subtle differences in higher-order structure 
between protein samples as part comparability assessments.  
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1.1 Overview  
 Protein based drugs (also known as protein therapeutics or 
biopharmaceuticals) are structurally complex, highly specific macromolecules 
used therapeutically to compensate for body deficiencies (e.g., hormones and 
clotting factors), as medical treatments (e.g., cytokines and monoclonal 
antibodies) as well as to prevent diseases (e.g., polyclonal antiserum and certain 
vaccines).
1
 A protein molecule’s structural complexity makes it quite challenging 
to preserve biological activity and stability throughout manufacturing, storage 
(shelf-life) and administration. The primary structure of a protein is defined by the 
sequence of twenty different amino acid residues covalently linked to each other 
through peptide bonds, in addition to any enzymatic, post-translational covalent 
modifications of certain amino acid residues such as N-linked glycosylation of 
asparagine, phosphorylation of serine and sulfation of tyrosine.  The local folding 
into secondary structures is the first step in for the formation of higher-order 
structures in proteins:  for example, α-helices and β-sheets formed through 
hydrogen bonding between the main chain NH and C=O groups. The packing of 
such secondary structural elements into a three dimensional folded, globular unit, 
called a domain; a folded, protein molecule may contain one or multiple domains. 
This, formation of the overall three dimensional shape of protein is referred to as 
the tertiary structure of a protein. Lastly, the arrangement of multiple polypeptide 
3 
 
chains, that each form independent tertiary structures, into an oligomeric complex 
is termed as a protein’s quaternary structure.  
Protein drug molecules are prone to different degradation mechanisms 
(chemical or physical) during manufacturing and storage, which ultimately can 
lead to the loss of structural integrity and potency (through structural alterations) 
as well as potentially increases in immunogenicity reactions upon 
administration.
2-5
 Chemical degradation pathways involve covalent bond 
modifications, as in Asn deamidation, Asp isomerization, Met oxidation, 
polypeptide chain proteolysis and disulfide bond shuffling.
2
 Physical degradation, 
on the other hand, includes distinct pathways such as protein structural 
alterations,
6
 surface adsorption,
7
 aggregation 
8
 and precipitation.
9
 There are many 
causes leading to the physical and chemical degradation of proteins including 
exposure to different environmental stresses (e.g., agitation,
10
 UV light 
11
and 
temperature 
12
) as well as changes in solution and formulation conditions (e.g., pH 
13
, ionic strength 
14
 and additives 
15
). A better understanding of the possible 
degradation mechanism of a protein therapeutic is key step in the formulation 
development of safe and effective product candidates to be evaluated in clinical 
trials.    
 In 1982, the first biotechnology derived protein product (Humulin
®
) based 
on recombinant DNA technology was approved in the U.S. to be used for insulin-
dependent diabetes mellitus patients. The doors were then opened for 
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development of more biotechnology based pharmaceutical products, and in 1986, 
the first monoclonal antibody (mAb), Muromonab (Orthoclone, OKT3), came to 
the market as an immune suppressant for patients subjected to organ transplant. 
Currently there are more than 150 protein-based drugs approved by the FDA and 
EMEA, 35 of those are mAbs, and more than 900 medicines and vaccines are 
being developed, with 30 mAbs in late-stage development. 
1, 16, 101
 
 In the mid-1980s and early-1990’s, the demand for production capacity to 
make larger amounts of protein drugs increased substantially, causing 
manufacturers to develop new technologies and scale-up their manufacturing 
process to meet up higher demands. The need for an efficient and scientifically 
based protocols to evaluate the effect of process changes and production scale-up 
on the structural integrity and clinical safety and efficacy of protein drug 
candidates was realized then by the biopharmaceutical industry and government 
regulators, which gave birth to the terms such as “well characterized 
biotechnology products” and “comparability” in FDA guidance in April, 1996. 
17
  
The general concepts of comparability were then further defined and expanded by 
additional regulatory guidances from the European Medicines Agency (EMEA) in 
2003, 
18
 the International Conference on Harmonization (ICH) (Q5E) in 2003 
19
 
and by the World Health Organization (WHO) in 2009. 
20
      
 
1.2 Comparability study definition, concept, and goals. 
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 The primary and higher order structure of protein drug molecules are 
delicate in nature, especially compared to small molecule drugs, and are highly 
sensitive to environmental changes and stresses in general. Changes in the 
manufacturing process for a protein therapeutic may occur during clinical 
development or after commercialization. These changes are frequently applied in 
either the manufacturing steps of the active drug substance (e.g., facility, 
equipment or process changes) or in the finished drug product (e.g., formulation 
excipients, container-closure system, dosage form changes). 
21, 22
 A manufacturer 
may apply changes in their manufacturing processes for variety of reasons such as 
improving yields and purity, ensuring better patient convenience, or facilitating 
compliance with new regulations. Comparability studies are performed to assess 
the effect of these process and product changes on the “critical quality attributes” 
(CQAs) by comparing the pre and post-change protein products through a series 
of tests performed in a head-to-head fashion. Critical quality attributes are defined 
as the collective product qualities defining the identity, purity, potency, safety and 
stability of the protein drug product.
19
 
 Changes in critical quality attributes of a biological drug due to 
manufacturing process changes were historically anticipated since, as was 
commonly said, “the process is the product”, a phrase used to summarize the 
potential sensitivity of a biological product towards manufacturing changes. 
Given numerous advances in analytical technologies to characterize proteins 
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along with a greatly improved understanding of protein structure and stability, the 
ability to better assess whether a given process and product change affected the 
structural integrity, efficacy or safety profile of a given protein drug became 
possible.  These advances in our scientific understanding therefore allowed for the 
implementation of comparability studies in the biopharmaceutical industry.  The 
scientifically based assessment of comparability between the pre and post-change 
product relies on the ability to show experimentally using “appropriate assays” 
that the pre and post-change products are “highly similar” in terms of 
physiochemical and biological characteristics, degradation profile, 
pharmacokinetics and immunogenicity.
19
 Physiochemical characterizations, 
biological assays and stability degradation profiles of the drug product are 
considered the corner stone of any comparability exercise. The ability to establish 
highly similar analytical profiles removes the need for additional clinical 
evaluations such as pharmacokinetic, efficacy and/or immunogenicity studies. 
The ICH Q5E regulatory guideline describes comparability exercises and some of 
elements to consider in order to determine physiochemical similarity between a 
drug product made by two different manufacturing processes.
19     
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1.3 Elements of a protein comparability study 
1.3.1 Physiochemical characterization  
 Extensive physiochemical analytical characterization of the pre- vs. post-
change active pharmaceutical ingredient (protein itself) and the final drug product 
(final dosage form with protein and excipients in the primary container) are 
typically the first steps of a comparability evaluation.  In these studies, the effect 
of manufacturing process changes on the integrity of a protein’s sequence in the 
polypeptide chain, as well as the integrity of the secondary, tertiary and 
quaternary structures are evaluated.  
 For protein primary structure evaluations, peptide mapping is frequently 
used to assess the integrity of the amino acid residues and sequence within a 
specific protein molecule. This technique involves the chemical or enzymatic 
treatment of the protein to generate a specific set of peptide fragments, which in 
turn are then separated using Reversed Phase High Performance Liquid 
Chromatography (RP-HPLC) method equipped with diode-array ultraviolet (UV) 
for detection. Isolated peptide fragments are then mass characterized using online 
mass spectrometry (MS) methods. Peptide mapping has proven to be a valuable 
technique in comparability studies, since each protein upon using specific 
proteolytic enzymes would give specific peptide fragments that are used as a 
fingerprint for the protein under evaluation. 
23-26 
Comparing the peptide map 
profiles for the pre and post-change proteins can show alterations in the protein 
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polypeptide backbone such as fragmentation or changes in individual amino acid 
residues (e.g., mutation, oxidation, deamidation, or post-translational 
modifications). The correct disulfide pairing can also be evaluated using the same 
technique by comparing peptides under reduced and non-reduced conditions. 
Alterations in a protein molecule’s primary structure can have multiple possible 
outcomes ranging from modifications in safety (immunogenicity), efficacy 
(binding or enzymatic activity) or stability (folding/aggregation) profiles. In 
contrast, however, sometimes these changes have no significant biological effects. 
The nature and extent of the physicochemical changes (if they occurred during the 
process change) must then be fully evaluated in comparison with the “pre-
change” protein (i.e., protein made from the original manufacturing process). 
Based on the outcomes from these types of evaluation studies, additional 
analytical characterization studies might be recommended to more thoroughly 
understand the nature of any structural changes and rule out any hidden effects on 
the protein’s critical quality attributes.   
 Various post-translational modifications (PTMs) such as N-glycosylation, 
O-glycosylation and/or C-terminal Lysine clipping, are frequently observed upon 
changing cell culture manufacturing process, which is partially responsible for the 
heterogeneous nature of proteins since they are produced by cells.
27
 The risk of 
having a change in the PTM of a protein depends on the nature of changes in the 
manufacturing process (e.g., cell line and cell culture media component changes 
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have higher risk of leading to PTM compared to changes in purification during 
downstream processing).
25
 Additionally, the type of the glycoprotein under 
evaluation and the extent (percent by mass) of glycosylation (erythropoietin is 
40% N-glycosylated vs. 2% N-glycosylation in an IgG1 monoclonal antibody) 
28
 
plays a crucial role on the effect of process changes on PTMs as well. Mass 
spectrometry based techniques are frequently used to obtain insight into a 
glycoprotein’s glycosylation composition and distribution. Mass spectrometric 
ionization based techniques such as matrix-assisted laser desorption/ionization 
(MALDI-MS) and electrospray ionization (ESI-MS) are frequently used for this 
purpose. 
28-32
 A more detailed picture about the glycan structure and composition 
can be achieved using oligosaccharide mapping were the glycan residues are 
enzymatically cleaved from the protein and then labeled with a fluorescent 
molecule (e.g., 2-Aminobenzamide is frequently used) for detection. 
33, 34 
The 
different fluorescently-labeled glycans are then passed through an normal phase 
HPLC system equipped with a fluorescence detector for separation and analysis. 
Using such a method, extent of similarity between the pre- and post-change 
protein in terms of the correct glycosylation site, branching, sequence and sugar 
types is feasible. This is an important result given that glycosylation plays a 
critical role in defining protein conformation, clearance, functionality, folding and 
stability.  
10 
 
 Ensuring native-like higher order structures (secondary, tertiary and 
quaternary structures) in a protein produced from both the pre- and post-change 
manufacturing process is essential since the overall three dimensional 
configuration not only defines a protein’s stability and functionality, but also its 
efficacy and safety when being used a drug candidate. Differences in higher order 
structures could stem from physical changes in structural integrity (i.e., partial 
unfolding, conformation changes and aggregation) as well as from modifications 
in either the back-bone structure (mutation, deamidation) and/or PTMs such as 
glycosylation. These differences in higher order structure (HOS) sometimes are 
only detected during long term storage or during accelerate storage which involve 
changes to the surrounding environment (e.g., temperature shifts or agitation). In 
addition to the properties of the protein molecule itself, pharmaceutical additives 
(i.e., excipients such as salts, surfactants, sugars), solution conditions (such as pH 
and ionic strength) as well as the nature of the final dosage form (liquid vs. 
lyophilized) can also impact the HOS of a protein.  
 The assessment of higher order structural integrity and conformation 
stability of proteins in comparability studies can be performed using multiple 
biophysical and calorimetric techniques.  Far-ultraviolet Circular Dichroism (CD) 
and Fourier Transform Infrared Spectroscopy (FT-IR) have been widely used in 
studying the overall secondary structure content of proteins where this method 
gives distinctive signals that corresponding to the different secondary structural 
11 
 
folds (i.e., α-helices and β-sheets). Detailed studies regarding the use of CD 
spectra for structural comparisons in comparability studies have been published 
recently.
99, 100
 Common techniques for the evaluation of the overall tertiary 
structure of proteins are fluorescence spectroscopy and near-UV CD. Owing to 
the unique fluorescence properties of aromatic amino acid residues (Tryptophan, 
Tyrosine and Phenylalanine) and their sensitivity toward polarity of its 
surrounding environment, changes in a protein’s structural integrity and 
conformational stability upon partial or full unfolding can be monitored. 
Furthermore, extrinsic fluorescence dyes (e.g., 1-anilino-8-naphthalenesulfonate, 
ANS, as well as Sypro orange) have been employed successfully in monitoring 
partially unfolded intermediates (molten globular states) which have been shown 
to play a role in initiating protein aggregation process. 
13, 86
 Such dyes have the 
unique property of being relatively nonfluorescent in polar environments and with 
greatly enhanced fluorescence in less polar, more hydrophobic milieu. These 
features allow scientists to examine the onset of structural unfolding of a protein 
as more hydrophobic patches within the protein are exposed to the solution/dye 
when the protein solution is stressed (e.g., during heating or agitation). 
Differential Scanning Calorimetry (DSC), another powerful analytical technique 
to monitor protein conformational stability, measures heat capacity difference 
between the protein solution and a reference buffer as a function of temperature. 
As a protein starts unfolding, heat capacity increases resulting in an endothermic 
12 
 
peak centered at the thermal melting temperature (Tm), or the midpoint of the 
protein unfolding event(s). As part of a comparability study, DSC can provide 
information about the overall conformation stability of the proteins under 
evaluation. Structural alterations in a protein as a result of manufacturing process 
changes could be detected in the form of a Tm shift or a change in the shape of 
the endothermic peak. Multi-domain proteins (such as a monoclonal antibody) 
show multiple endothermic peaks in a given DSC thermogram. Structural changes 
in one of these domains can be reflected in corresponding changes to the 
associated DSC peak.   
 Other emerging analytical techniques for use in comparability studies to 
evaluate higher order structure of proteins are Nuclear Magnetic Resonance 
(NMR) spectroscopy and Hydrogen/Deuterium Exchange Mass Spectrometry 
(H/DX-MS). Although these techniques are very powerful in terms of obtaining 
detailed information about the folded protein structure, their use has been limited 
due to some drawbacks including protein size and formulation restrictions in 
addition to being technically challenging and time consuming techniques. 
Research is currently being done to overcome these drawbacks. For example, the 
effect of different anions and excipients on an IgG1 mAb local flexibility was 
evaluated using H/DX-MS.
35, 36
 An increase in the local flexibility of a certain 
peptide fragment in the CH2 domain of the mAb was seen upon using thiocyanate 
(as anion) and arginine (as an excipient) that was correlated with decreased 
13 
 
thermal stability of the CH2 domain and increase in aggregation propensity.  
These results demonstrate the intricate interrelationships between different 
excipients and their effect on protein dynamics and physiochemical stability of a 
monoclonal antibody. 
  Only a limited number of case studies evaluating the effect of changes in 
the manufacturing processes on protein structure and function from a 
comparability point of view have been published. In one study, the effects of 
changing the final dosage form a lyophilized formulation to a liquid dosage form, 
in addition to the impact of transferring the bulk drug substance to the commercial 
site, was evaluated for two monoclonal antibodies. 
25
An increase in a specific Asn 
deamidation for one of these mAbs was observed which did not have any effect 
on the structural integrity, biological potency or the pharmacokinetic profile in 
animal models. This Asn deamidation was attributed to the transfer of the bulk 
process to the commercial site at an increased scale which required longer hold 
times in solution. Additional analytical evaluations of the mAb’s conformational 
stability as well as functionality using newer analytical methods was carried out, 
with no differences being observed between the two dosage forms of the two 
mAbs. The impact of changing formulation composition on protein 
conformational stability has been addressed in a comparability study.
37
 In this 
work, the effect of formulation exchange on a human growth hormone protein 
was evaluated. The authors concluded that the formulation change affected the 
14 
 
structural integrity of the protein and additional considerations needed to be given 
regarding the choice of final excipients. Selecting an appropriate formulation 
conditions for insulin was emphasized in another study as they reported that 
changes observed on the physical and chemical stability of insulin (due to changes 
in its crystallization process) were dependent on the raw materials and excipients 
used in formulation.
38
 
 Alterations in glycosylation patterns of proteins as a result of 
manufacturing method changes have been reported. 
25 
The effect of such changes 
on the conformational stability of protein varied depending on specific conditions. 
For example, the role of glycosylation on the conformational stability of 
erythropoietin was investigated in one study.
39 
Glycosylated erythropoietin was 
found to be more resistant to guanidine hydrochloride (GndHCl) and acidic pH 
induced unfolding compared to the nonglycosylated form of the protein. 
Glycosylation profiles have been found to affect the structural integrity and 
conformational stability of mAbs as well. In one study, three intact IgG1 mAbs 
were compared before and after glycan residue removal using a variety of 
analytical techniques.
40
 An increase in fluorescence signal upon deglycosylation 
was observed indicating structural perturbations, a conclusion that was further 
reinforced by DSC results indicating a structural change in the CH2 region of all 
three IgG1 mAbs. A similar study looked at the influence of a series of 
differentially glycosylated IgG1-Fc mAbs with varying glycan length generated 
15 
 
through an enzymatic reaction on the conformational stability.
41
 Using DSC, 
glycosylation length was found to play a role in IgG1 conformational stability 
specifically at the CH2 domain where glycosylation resides. In addition to 
influencing conformation, glycosylation was found to have an effect on the 
protein susceptibility for proteolysis. The existence of the glycan and the type of 
the terminal sugar in the glycan residue were reported to influence the 
susceptibility of an IgG to papain digestion.
42, 43 
 
1.3.2 Biological activity characterization 
 Biological activity of a protein, an equally important critical quality 
attribute as physiochemical properties, defines the ability of a drug product to 
achieve a specifically defined biological function, ideally through an understood 
mechanism of action that leads to a desired clinical effect. Techniques used to 
characterize the biological activity of a protein serve as complement 
physiochemical assays in confirming the correct higher order structure of the 
protein. Determining bioactivity for monoclonal antibody based protein drugs is 
usually done using a variety of in vitro binding assays such as Enzyme-linked 
immunosorbent assay (ELISA) and Surface Plasmon Response Spectroscopy 
(SPR). Another group of bioassays, that directly measures biological 
functionality, are often also used with mAbs including in vitro cell proliferation 
and in vitro animal models. Using functionality bioassays (if feasible) in 
16 
 
comparability studies is sometimes preferred over simple antigen binding assays 
because some degraded, aggregated and chemically modified product could still 
bind nonspecifically to the target molecule in a simple binding assay. Protein 
molecules containing multiple regions with different functionalities should have 
multiple functionality and/or binding bioassays reflecting each and every 
structural region. For example, monoclonal antibodies are composed of two 
antigen binding regions (Fab), responsible for antigen binding, and one 
crystallizable region (Fc), responsible for immune effector function. Each one of 
these regions may need to be tested for its ability to bind to its specified target to 
perform its desirable function. 
 Case studies examining protein functional activity changes due to changes 
in manufacturing process have been reported. An oxidized form of the protein 
filgratism (a human granulocyte-colony stimulating factor used primarily for 
patient with severe neutropenia) was found to be 25% potent, whereas, filgratism 
dimer had 67% potency compared to the intact molecule.
44
 In addition to 
influencing protein conformation, glycosylation can play a critical role in defining 
biological functionality. In the case of a mAb, the presence of a core fucose unit 
in the N-linked oligosaccharide was found to be responsible for decreasing the 
antibody-dependent cellular cytotoxicity (ADCC), highlighting the importance of 
glycan identification in comparability studies for the pre- and post-change mAb 
products.
45
 As another example, TNK-Tissue Plasminogen Activator (TNK-tPA) 
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is a glycosylated protein which contains four glycosylation sites, three are N-
linked and one site is O-linked. In one comparability study,
46
 with a biosimilar 
molecule under development, the biosimilar protein had a similar glycosylation 
pattern as the innovator drug product, except for one N-glycosylation site which 
was found be only partially glycosylated. The close proximity of the partially 
glycosylated glycan to the active site raised concerns about its influence on the 
clot lysis biological activity, resulting in the need for more detailed studies to 
investigate such effects. Another marketed protein product called Myozyme 
(Alglucosidase alpha), used to treat patients with Pompe disease, that was 
produced in two different sites in the U.S. from the same company was found to 
be not similar in terms of biological activity.
47
 These differences observed in the 
biological activity were attributed to glycosylation differences between proteins 
from the two manufacturing sites. 
 
1.3.3 Accelerated and Forced Degradation stability studies  
 Forced degradation studies comprise the group of analytical tests applied 
on the drug product to elucidate the physicochemical mechanism(s) of protein 
degradation, whereas, accelerated stability studies measure the rate of given 
degradation mechanism(s) over time at various temperatures in specific 
formulations. Evaluating the effect of storage period, excipients and 
environmental stress on the accelerated (and long term) stability of protein drug 
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products is an essential part of formulation development and comparability 
evaluations. Protein drugs encounter different environmental stresses during 
production, storage, shipment and patient administration. Thus, accelerated 
stability studies and forced degradation studies are needed to determine the 
stability profile of a protein drug by subjecting the protein to various stresses 
including elevated or changing temperatures, freezing, thawing, agitation and 
oxidative stresses, light, exposure to different interfaces and pH changes.
48-51
 The 
design of successful forced degradation and accelerated stability studies depends 
on having the appropriate analytical tools to detect, quantify and characterize any 
degradants, impurities and side products generated during these studies.   
 For the stability component of a comparability exercise, regulatory 
guidelines such as ICH Q3C 
52
, ICH Q5C 
53
 and ICH Q5E 
19
 can be used for 
initial guidance regarding the type of forced degradation and stability studies to be 
applied. For example, ICH Q3C guideline mentions the importance of developing 
analytical assays to quantify residual impurities of xylene leaching from rubber 
stoppers during freeze-drying process. Similarly, ICH Q5E guideline talks about 
divalent cations leaching from vial stoppers which in turn activate trace amounts 
of proteases leading to the degradation of the protein drug. These two real-life 
examples highlight the importance of assessing the effect of process changes 
made in the final dosage form. Stressing the drug product samples obtained from 
different manufacturing processes can potentially magnify any small changes in 
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protein stability helping scientists to reach a conclusion concerning the protein 
drug’s structural integrity, safety and efficacy. It should be pointed out that the 
regulatory guidance documents discussing forced degradation and accelerated 
stability studies lack detailed descriptions regarding the analytical procedures and 
storage conditions, thus leaving it up to protein drug manufacturers to identify 
specific methods and conditions to test degradation behavior of their specific 
protein product.  
 Designing a successful comparability stability study also depends on the 
type of process or product change being evaluated. For instance, a change in the 
final dosage form from a liquid to a lyophilized drug product will result in a more 
stable product and would thus not necessarily be expected to have a similar 
stability profile.  In this case, showing similarity of degradants type would be of 
primary interest. In an opposite scenario, changing from a lyophilized dosage 
form to a liquid one, would not only require evaluating the types of degradants 
but also the protein drug product under additional stress conditions (e.g., 
mechanical stress) to get an insight about the aggregation behavior of the liquid 
formulated protein drug. Exposure to new surfaces from changing the primary 
containers or formulation additives has been reported to induce protein 
aggregation and oxidation in some protein drug products. In one study,
25
 an 
assessment of the impact of changing the primary packaging from a vial to a pre-
filled syringe in terms of conformational integrity and stability of two mAbs was 
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evaluated. Similar molecular structure, biological activity and degradation profiles 
were seen for both mAbs in a liquid formulation filled in the vials and syringes 
with the one exception: a small but statistically significant difference in subvisible 
particles levels was noted. This relative increase in subvisible particles in the two 
containers was attributed to the presence of trace amounts of silicon oil in the 
syringes, which has been reported to have an undesirable effect on proteins 
stability and aggregation.
54, 55
 
 In another protein comparability exercise, the biophysical stability of three 
lots of an IgG1 mAb that were manufactured and filled at different locations was 
assessed.
56  
These three lots were incubated for multiple time points (0, 8 and 16 
weeks) under either refrigeration (4 
0
C) or heat stressed conditions (40 
0
C). No 
differences between the different lots of the protein in terms of conformational 
stability as well as in aggregation behavior were detected for the refrigerated lots. 
However, variations between the different lots stored at 40 
0
C at different time 
points were seen using extrinsic fluorescence spectroscopy (using ANS as a dye), 
and differences between two of the lots were also detected using intrinsic (Trp) 
fluorescence spectroscopy. Different aggregation levels were seen for the heat 
stressed samples as well using static light scattering (SLS) and size exclusion high 
performance liquid chromatography (SE-HPLC). This example illustrates, as 
mentioned before, the importance of applying stress on the protein sample to 
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extract additional information about the protein’s critical quality attributes such as 
HOS that may otherwise not be observed.  
 
 
1.3.4 Pharmacokinetics Studies 
 In addition to analytical comparability testing described above, 
pharmacokinetic studies may need to be evaluated in the form of either non-
clinical or clinical studies in which the pharmacokinetic profile of the protein drug 
is evaluated using animal models (rodents or primates) and/or in humans. These 
studies are applied as part of comparability assessments to demonstrate product 
comparison for the pre- and post- change products after drug administration in a 
relevant animal model or patient population. The need for performing 
pharmacokinetic studies depends on a variety of factors including the type of 
structural, functional or stability differences observed analytically in the product 
after applying the process change. In cases involving an observed non-similarity 
between the products under comparison, it may be necessary to perform 
pharmacokinetic study in human subjects to demonstrate comparability.
57
 These 
pharmacokinetic studies are performed using the same route of administration and 
dose regimens providing comparative results (e.g., absorption, bioavailability as 
well as elimination parameters like clearance and elimination half-life) that should 
be highly similar for the two samples being compared.
57 
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 Structural differences introduced in the post-manufacturing process 
change drug product can vary in the extent to which they affect pharmacokinetic 
parameters. Glycosylation plays a central role in defining the circulation and half-
life in the human body for glycoproteins. In one example, using a rat animal 
model, 50% loss in the amount of circulating protein (ceruloplasmin, a copper 
carrying protein in the blood) was observed after a 20% reduction in sialic acid 
content of the glycan attached to the protein. 
58
 In some glycoproteins lacking 
sialic acid, it has been shown that they have a higher affinity to mannose receptors 
in the liver cells, leading to a faster clearance and catabolism compared to the 
fully sialylated ones.
59 
The same fate was observed for antibodies containing 
mannose terminated N-glycans.
60, 61
 Multiple comparability studies have 
examined glycoproteins with different distributions of glycosylation patterns due 
to a process change (especially those including changes in cell line or cell 
culture). In one study, the amount of sialic acid in addition to the relative 
distribution of neutral oligosaccharides were different between the pre and post-
change for mAb proteins after changing the producing cells form a murine 
myeloma cell line (NS0) to Chinese hamster ovary cell line (CHO).
62
 Another 
study demonstrated that using a different clone of the same cell, or changing the 
cell culture components, resulted in a significant increase in acidic glycoforms of 
a mAb compared to the original cell line.
25
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  Pharmacokinetic parameters, in addition to being sensitive to changes in 
the glycosylation patterns, have also been reported to be sensitive to changes in 
the overall charge state of the protein as well. Proteins with specific charge 
heterogeneity profiles have been shown, after modifying the manufacturing 
method, to  have a different charge distribution profile.
63
 Changes in the overall 
charge state of a protein could alter the electrostatic and hydrophobic interactions 
between the protein and the negatively charged cell membrane leading to a 
different pharmacokinetic profile.
64
 Using animal studies, minor shifts in the pI of 
a protein (in the range of 0.1-0.2 pI units) have been demonstrated to have no 
effect on the pharmacokinetic profile.
65
 Meanwhile, shifts of above 1.0 pI units 
could have a measurable effect. In one study, protein cationization resulted in a 
longer tissue retention times and a faster clearance, 
66 
whereas protein 
anionization tended to cause a decrease in tissue retention time but still increased 
the whole body clearance 
67
 (demonstrated in rats and mice, respectively).  At the 
molecular level, changes in the charge heterogeneity profile of a protein molecule 
could rise from alterations in the primary sequence of the protein as a result of 
amino acid mutations or chemical degradation (e.g., Asn deamidation).
68
  Post-
translational modifications (e.g., sialic acid on the glycan residues and C-terminal 
lysine) on proteins could contribute to the charge heterogeneity profile of a 
protein.
68
 Protein aggregation may also affect the pharmacokinetics profile 
directly or indirectly through neutralizing antibodies produced from the immune 
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cells in the body. For example, insulin oligomers have been reported to have a 
slower absorption and bioavailability upon subcutaneous administration compared 
to non-aggregated form of the protein.
69
 
 Taken together, changes to a protein’s glycosylation pattern, charge 
distribution and aggregation profiles upon manufacturing changes could have a 
measurable effect on its pharmacokinetic profile, which may or may not have an 
effect on the drug pharmacodynamics, efficacy and safety profiles. The evaluation 
of such pK affects are almost always carried out first using animal models (either 
rodents or primates), and if results are inconclusive, human clinical 
pharmacokinetic comparability studies may be necessary. 
 
1.3.5 Clinical Immunogenicity Studies 
 Since proteins are complex macromolecules of high molecular weight and 
naturally occurring structural heterogeneity, any changes to the native structure 
could potentially reveal antigenic sites that could stimulate an immune response.  
An immune response could be stimulated by many factors that are generally 
divided into two categories: extrinsic and intrinsic. Patient immunogenic 
susceptibility and patient health status (administering co-medications) in addition 
to the dose and route of administration are all considered extrinsic factors related 
to the immunogenicity of a protein based drug.
70
 Intrinsic factors are those related 
to the protein or the drug product itself including aggregation propensity, 
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impurities (e.g., residual host cell protein not removed by the purification steps) 
and leachables (from container-closure system, which may not be immunogenic 
by itself but could induce protein aggregation).
71-73
 The consequences of an 
immune reaction against a protein drug could vary significantly, ranging from 
clinically minor to severe, life-threatening effects. In one unfortunate story, a 
specific erythropoietin-α drug product (Eprex
®
) has been associated (in 1998 and 
peaked in occurrence in 2002) with pure red cell aplasia (PRCA).
74
 An increase in 
neutralizing antibodies titers in patients with chronic renal failure against the 
protein drug was found, which was correlated after investigation with changes 
made in the product formulation.
75
 Human serum albumin (HSA), used as a 
stabilizer, was removed from the original formulation and substituted by 
polysorbate 80 surfactant. This substitution facilitated instability either by the 
leaching of compounds (tungsten in one theory) 
76
 from the rubber plunger of the 
pre-filled syringe causing the protein to unfold and aggregate. Another theory 
suggested that polysorbate 80 formed micelles with the protein resulting in an 
adjuvant-like nanoparticle that stimulated the immune system.
77
 The route of 
administration plays a critical role as well in product immunogenicity. It was 
found that patients who received Eprex
®
 through an intravenous injection (i.v) did 
not get PRCA unlike those received the drug subcutaneously (s.c).
78
 As part of the 
corrective actions to prevent PRCA in the future, European regulatory authorities 
26 
 
recommended changing the route of administration for Eprex
®
 from s.c to i.v in 
addition to going back to using HSA as the stabilizer of choice.
74
  
 Other intrinsic factors that could influence immunogenicity include 
protein degradation, during manufacturing or storage, resulting in exposure of 
previously unseen epitopes that could activate the immune system. Glycoproteins 
bearing different kinds of monosaccharides or different linkages than the naturally 
occurring ones in the human body could potentially stimulate the immune 
response as well. These glycan differences are introduced from various 
mammalian cell lines used to produce a recombinant protein. For example, the 
presence of galactose-α-1, 3 glycans have been associated with causing 
anaphylactic shock and an immune response in patients using cetuximab and 
bovine thrombin, respectively.
79, 80
 N-glycolylneuraminic acid (Neu5Gc or 
NGNA) is a sialic acid glycan that contains an additional oxygen atom compared 
to the naturally occurring N-acetylneuraminic acid (Neu5AC or NANA) glycan in 
humans. The presence of this sialic acid form (NGNA) has been associated with 
immunogenicity risks.
81
 A comparison between cetuximab and panitumumab 
(both antibodies specific for binding epidermal growth factor receptor), 
concerning the addition of Neu5Gc to the glycan structure during expression in 
cell culture, showed that cetuximab only was incorporating NGNA to the glycan 
structure.
82
 The addition of NANA to the culture media helped reduce the 
incorporation of NGNA to the glycoprotein drug.  Finally, complete 
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deglycosylation of a glycoprotein has been associated with increasing 
immunogenicity incidences. Mechanisms underlying such as effect are not fully 
understood, however, aggregation resulting from the exposure of normally hidden 
hydrophobic patches, decreasing solubility and the exposure of antigenic sites or a 
combination of factors have been proposed, for example,  immunogenicity 
incidences due to deglycosylation were reported for interferon-β 
83, 84 
and 
Granulocyte Macrophage Colony-Stimulating factor (GM-CSF).
85 
 
Protein aggregation events are thought to have a significant impact on the 
immunogenicity potential of protein drugs. Protein aggregation can be 
exacerbated by multiple factors including changes in solution conditions (pH, 
salts, excipients, etc.) 
35, 36, 50
 and exposure of the protein solution to different 
environmental stresses (temperature, agitation, freeze-thaw, etc.).
86-88
 An 
immunogenic response in patients receiving an interferon alpha was attributed to 
the presence of aggregated species in the drug product, seen after alterations 
applied into the formulation components.
89 
A positive correlation between protein 
aggregation and immunogenicity has been shown as well for other therapeutic 
proteins, such as insulin,
90
 human growth hormone 
91
 and bovine serum albumin
92
 
manifesting the important role of protein aggregate detection and characterization 
in protein drug products.
93, 94
   
 Immunogenicity prediction in humans using either in vitro models or 
animal studies is difficult, and the development of new approaches to obtain more 
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reliable immunogenicity tests remains highly desirable.
95
 The need to evaluate 
post-manufacturing change protein drug products for immunogenicity becomes 
even more important for products with a past history of immunogenicity (the pre-
change product), as well for those protein products with manufacturing changes 
that are considered extensive (cell line) or result in observations for increased 
levels of aggregates or particles. 
 
1.4 Analytical challenges for future comparability studies 
 
 Overall, the type and extent of any comparability exercise depends 
primarily on the nature of the protein (size, complexity, microheterogeneity), the 
magnitude and type of manufacturing changes, and the analytical tools available 
to monitor the structural integrity of a protein. An in depth understanding of the 
protein including its inherent susceptibility to the different chemical and physical 
degradation mechanisms, combine with accumulated clinical and manufacturing 
experience with product, is essential for a successful comparability exercise. 
Accurate structural determination for protein-based drugs is a difficult task for 
pharmaceutical and biotechnological industry, in contrast to small molecule 
drugs, because of their complex three-dimensional structures and 
microheteogeneity. Major advances have been made in developing analytical 
tools for primary structure analysis, ranging from chromatographic (size 
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exclusion, reversed phase and ion-exchange HPLC) and electrophoretic (capillary 
isoelectric focusing and capillary sodium dodecyl sulfate) separation methods that 
are typically linked with mass spectrometry detection (intact molecular weight, 
peptide maps, and oligosaccharides maps) to well characterize a protein’s primary 
structure including post-translational modifications. Although major advances 
have been made in developing analytical tools for primary structure analysis, 
major challenges regarding the development of improved analytical techniques 
for determination of higher order structural integrity of proteins still exist. In fact, 
the current requirement for performing functional biological potency assays to 
ensure biological activity is considered an overall check on the higher order 
structural integrity of a protein. Although multiple high resolution analytical 
techniques, with the ability to better characterize the high order structures of 
proteins are available (x-ray crystallography, H/DX-MS and NMR), development 
of these methodologies for use with protein drug candidates within a 
pharmaceutical dosage form (containing excipients) still remains as a major 
challenge.  
 More well established, commonly available, lower resolution biophysical 
techniques such as circular dichroism, intrinsic and extrinsic fluorescence 
spectroscopy, differential scanning calorimetry, static light scattering and 
turbidity assays are used for the evaluation of secondary/tertiary structures and 
colloidal stability of a protein as part of a pharmaceutical drug product containing 
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formulation components. These biophysical methods can be setup as high 
throughput assays in which analysis can be performed automatically across 
various environmental conditions such as changes in solution pH and temperature.  
Environmental stresses, such as elevated temperatures and extreme pH conditions, 
are frequently used stress factors to evaluate the overall conformational stability 
of proteins during formulation development, but the use of these types of data sets 
for comparability analysis has not been explored. By using data sets acquired 
from multiple low-resolution biophysical techniques that monitor different aspects 
of a protein’s higher-order structural stability as a function of environmental 
stress, differences in structural integrity may potentially be detected when these 
differences are not readily apparent when monitored using lower resolution 
methods under non-stressed conditions (i.e., at low temperatures at neutral pH 
conditions). Additionally, the evaluation of conformational stability differences 
may not only be an effective surrogate to monitor differences in higher-order 
structure between protein samples, but also a useful complement to traditional 
accelerated stability and forced degradation studies often used in analytical 
comparability studies as described above.    
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1.5 Possible applicability of high throughput biophysical analysis of protein 
stability to comparability studies  
 
 Physiochemical characterization for the higher order structural integrity of 
a protein in two different drug products under comparison is one of the essential 
elements of a comparability study (as discussed above). Although various lower 
resolution analytical techniques have been used and developed to test higher order 
structural comparability between two protein drug samples (i.e., CD, fluorescence 
and DSC), as discussed above, the use of higher resolution techniques such as 
NMR, X-ray crystallography and H/D exchange mass spectrometry (that provide 
structural details about the protein’s folded structure and dynamics)  remains 
limited in their wide spread use (e.g., due to high molecular weight, presence of 
formulation components, and/or analytical complexity) as part of analytical 
comparability studies. With that being said, the need for a new approaches to 
better monitor the higher order structural integrity of proteins during 
comparability studies is of a great interest. 
 Although lower resolution biophysical techniques such as circular 
dichroism, intrinsic/extrinsic fluorescence spectroscopy, differential scanning 
calorimetry, static light scattering and turbidity assays are commonly used 
techniques to monitor the structural integrity and conformational stability of 
protein-based drugs, no single technique provides sufficient information to 
32 
 
establish the higher order structural integrity of complex macromolecules such as 
proteins. Therefore, the use of more than one technique is generally needed for 
better characterization. The multi-dimensional nature of such analysis makes 
collection, analysis and visualization of larger data sets problematic. Historically, 
data analysis of protein conformational stability data was performed by either 
visual inspection or data fitting of thermal unfolding curves to sigmoidal 
functions of results from individual instruments. These types of approaches can 
result in data interpretation that is not only subjective, but limited in terms of the 
scope and utility.  
 In 2003, a new data visualization methodology was introduced as a tool 
for analysis of protein physical stability data obtained from high throughput 
biophysical instruments, and its application toward formulation screening 
purposes for protein based drugs was extensively evaluated.
96
 This methodology, 
called Empirical Phase Diagram (EPD), is a data visualization tool that is based 
on using data sets from multiple low-resolution biophysical techniques to 
construct a color coded diagram reflecting the different structural phases that the 
protein would experience during an applied stress conditions (e.g., pH, 
temperature, ionic strength or protein concentration). The idea of developing such 
a methodology stemmed from the fact that most comparative experiments using 
protein thermal melting curves conventionally use visual assessment and Tm/Tonset 
values to determine differences between the different formulations under 
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comparison, which makes data interpretation across multiple samples difficult and 
potentially highly subjective. Using bovine granulocyte colony stimulating factor 
(bGSCF) as a model protein combined with second derivative absorbance 
spectroscopy as a model biophysical method to characterize the physical stability 
of the protein across multiple pH and temperature conditions, the first EPD was 
constructed. This EPD, interestingly, was able to detect six different structural 
phases that the protein experienced under a combination of two stress conditions 
used (temperature and pH) that by visual observation of the individual data sets 
were not easily detected.  
 An EPD analysis involves the collection of protein physical stability data 
under different experimental conditions using multiple low-resolution biophysical 
techniques. The stability data from the experimental conditions and techniques are 
then entered into m x n input matrix in which m represents the experimental 
techniques (i.e., circular dichroism, fluorescence spectroscopy, turbidity, etc.) and 
n represents the experimental conditions (i.e., number of pH values x number of 
temperature measurements). After data normalization, singular value 
decomposition of the m x n experimental data matrix is calculated to extract three 
orthogonal basis vectors associated with the three largest singular values. These 
results are then mapped to red-green-blue (RGB) color scheme that can be 
visualized as a function of the stress conditions (e.g., temperature and pH). After 
an EPD is generated, what remains is the interpretation of the change of colors of 
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the different areas of the EPD. The colors of the different areas within an EPDs 
have no physical meaning, instead the change in color signifies a structural 
change in the protein as detected by the data from experimental techniques. A 
scientist must refer to the original experimental biophysical data and consider the 
physical process that generated regions with different colors. Changes in the 
biophysical signal which corresponds to change in protein’s physical stability 
would be seen in the EPDs as changes from one color to another, a change that 
would be interpreted as a transition of the protein from one conformational state 
to another. 
96, 97
 
 Realizing the potential applications of this EPD methodology, a 
subsequent optimization was carried over the following years with a wide variety 
of proteins in terms of the number and type of biophysical techniques included in 
the EPD, clustering analysis and color interpretation.
97
 In 2012, radar charts were 
introduced as an additional data visualization tool for displaying protein physical 
stability data obtained from multiple biophysical instruments.
98
 The major idea of 
this data visualization approach is to arrange multiple axes, representing the 
different biophysical techniques, at evenly spaced angles to form a polygonal 
figure. Polar axes are adjusted to display values from each analytical instrument 
between zero (representing the starting point or in this case the native state of a 
protein) and 1 (representing the end point or in this case the structurally altered 
state). Data acquired from the different biophysical methods are therefore 
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normalized and mapped to points in the polar coordinates in the radar chart. Radar 
diagrams are composed of multiple charts arranged in two dimensional 
coordinates of environmental stress conditions (e.g., temperature and pH).  
Structural changes of the protein as monitored by the different methods are then 
visualized in the form of differences in the area of the polygons, where the native-
like state of a protein would have a polygon with smaller area compared to 
structurally disrupted states of the same protein. Unlike EPDs, radar diagrams 
have the advantage of displaying protein physical stability results from a larger 
number of experimental techniques, allowing the evaluation of protein structural 
integrity and conformational stability as a function of the specific biophysical 
techniques across the experimental conditions.
98
   
 In this work, the possible use of high throughput biophysical analysis of 
protein physical stability data along with the data visualization techniques is being 
evaluated as a way to compare the structural integrity and physical stability of 
different versions of the same protein to each other (as would be done in 
comparability studies). Our approach (as will be discussed in detail below) is 
based on using a variety of different proteins with different sizes, post-
translational modifications and inherent stability. Structural differences in the 
form of known “major” (i.e., point mutations) or “minor” (i.e., post translational 
modifications) alterations in protein structure were specifically introduced into 
three different proteins: FGF-1, IgG1 mAb, and IgG1-Fc protein. These different 
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proteins were subsequently extensively characterized in terms of physical stability 
properties using multiple low-resolution biophysical techniques described above 
to monitor different aspects of the higher-order structural of these proteins across 
a wide range of pH and temperature conditions. These large data sets of 
biophysical data where then used to construct EPDs and radar charts for data 
visualization and structural comparison between the different proteins. Using this 
approach, differences in structural integrity and conformational stability were 
detected at stress conditions that could not be detected by using the same 
techniques under ambient conditions (i.e., no stress). Thus, an evaluation of 
conformational stability differences may serve as an effective surrogate to 
monitor differences in higher-order structure between protein samples.  
 
1.6 Chapter reviews 
1.6.1 An Empirical Phase Diagram Approach to Investigate Conformational 
Stability of “Second-generation” Functional Mutants of Acidic Fibroblast 
Growth Factor (FGF-1). (Chapter 2) 
 FGF-1 is a 16 kDa protein that belongs to β-trefoil family of proteins. It is 
composed of a six stranded β-barrels closed off at one end by three β-hairpin 
structures. FGF-1 is an intrinsically unstable protein molecule that is involved in 
the angiogenesis process. It is being investigated from a pharmaceutical 
perspective as a candidate for treatment of ischemic disease, including wound 
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healing in diabetic ulcers, peripheral artery disease, and non-treatable (i.e., ‘‘no 
option’’) coronary occlusions. Since FGF-1 has intrinsically low thermodynamic 
stability in conjunction with three reactive cysteine residues, it is vulnerable to 
irreversible unfolding and aggregation during production and storage, with 
associated negative consequences for shelf-life, potency, and immunogenicity.  
FGF-1 is a heparin binding protein and has significant natural affinity for many 
polyanions, and based on this observation, FGF-1 for human therapeutic use has 
been formulated with the addition of heparin. The use of heparin as an excipient, 
however, adds considerable complexity including increased expense, its own 
pharmacological properties (e.g., as an anticoagulant), animal derived material 
from pig tissues (with potential for infectious contamination), and the possible 
induction of adverse inflammatory or allergic reactions in a segment of the 
targeted patient population. Thus, although heparin or related polyanions used as 
formulation additives help to address the FGF-1 stability issue, they introduce 
other undesirable properties. To solve this problem, a site directed mutagenesis 
approach is used with the goal of altering the temperature and pH stability profile 
of the FGF-1 mutants to more closely resemble that of wildtype FGF-1 in 
complexation with heparin. In this chapter, the structural integrity and 
conformational stability of ten FGF-1 mutants were characterized and compared 
to the FGF-1 wild-type alone and with heparin. Twelve EPDs were constructed 
and used to broadly assess the physical stability of these mutants in response to 
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variations in pH and temperature.  In addition, the EPD ability to distinguish 
stability differences between the FGF-1 variants was evaluated. 
 
1.6.2 High-Throughput Biophysical Analysis and Data Visualization of 
Conformational Stability of an IgG1 Monoclonal Antibody (mAb) After 
Deglycosylation. (Chapter 3)  
 Monoclonal antibodies are glycosylated, multidomain proteins (~MW of 
150 kDa) and the extent and type of glycosylation has been shown to influence 
the conformational stability of mAbs. In this chapter, the structural integrity and 
conformational stability of an IgG1 mAb, after partial and complete enzymatic 
removal of the N-linked Fc glycan, was compared to the untreated mAb over a 
wide range of temperature (10° to 90°C) and solution pH (3 to 8). Subtle to larger 
stability differences between the different glycoforms were observed. Improved 
detection of physical stability differences was then demonstrated over a narrower 
pH range (4.0-6.0) and smaller temperature increments. An additional data 
visualization method (radar plots) was incorporated to the data assessment as 
well. Differential scanning calorimetry and differential scanning fluorimetry were 
then utilized and also showed an improved ability to detect differences in mAb 
glycoform physical stability. Based on these results, a two-step methodology was 
used in which mAb glycoform conformational stability is first screened with a 
wide variety of instruments and environmental stresses, followed by a second 
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evaluation with optimally sensitive experimental conditions, analytical techniques 
and data visualization methods. In this chapter, high-through-put biophysical 
analysis to assess relatively subtle conformational stability differences in protein 
glycoforms is demonstrated. 
 
1.6.3 Global stability assessment of an IgG1-Fc; mutation, glycosylation and 
charge variation effects. (Chapter 4) 
    In this chapter, a model IgG1-Fc protein (~50 kDa protein containing 
two CH2 domains and two CH3 domains) was produced from yeast Pichia pastoris 
and different glycosylation forms were generated to provide insight about the 
effect of glycosylation differences, and charge heterogeneity differences (due to 
point mutations and enzymatic treatments of the Fc glycoforms) on the structural 
integrity and conformational stability of the CH2 domain from different Fc 
glycoforms.  
 Using this yeast expression system, two glycosylation forms of IgG1-Fc 
were produced and purified. These forms are comprised of different site 
occupancy:  a high mannose di-glycosylated form, where the Fc protein is 
glycosylated in the two CH2 domains (glycan-glycan), and high mannose mono-
glycosylated form, where the Fc protein is glycosylated at a single CH2 domain 
(glycan-Asn). These two glycoforms of the IgG1-Fc molecule were separated 
using cation exchange and hydrophobic interaction chromatography to obtain the 
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individual glycoforms of high purity. An aglycosylated IgG1-Fc mutant 
containing Gln in both CH2 domains (instead of Asn) was also produced using the 
same expression system and purified using hydrophobic interaction 
chromatography. The three Fc glycoforms (di-, mono-, and a-glycoylated species) 
were then used to study the effect of glycosylation level on the global stability of 
the CH2 domain. 
  In addition to site occupancy, the global physical stability of differentially 
charged forms of the aglycosylated Fc molecule, specifically in the CH2 domain, 
is an additional aspect of antibody stability that was then evaluated in this chapter. 
Differentially charged forms of the aglycosylated Fc protein were created upon 
treating the di-glycosylated and mono-glycosylated IgG1-Fc molecules with 
PNGase F enzyme creating a di-charged (Asp-Asp) and a mono-charged (Asp-
Asn) IgG1-Fcs in the CH2 domsain as an outcome of the enzymatic 
deglycosylation mechanism. These two molecules were compared to the non-
glycosylated (Gln-Gln) IgG1-Fc mutant. An assessment of these charge 
differences within the CH2 domain in terms of their impact on structural integrity 
and physical stability of the Fc protein was also evaluated. 
 
1.6.4 Conclusions and future work. (Chapter 5) 
 This final chapter summarizes what we learned about the structural 
integrity and conformational stability of the various proteins examined in 
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Chapters 2-4 (point mutants of FGF-1, deglycosylated forms of an IgG1 mAb, 
and different glycoforms of an IgG-1 Fc) and as well as the potential utility of 
using new data visualization methods for displaying high throughput biophysical 
stability data (as discussed in the previous chapters) in analytical comparability 
studies.  Suggestions for future work are also discussed. 
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Chapter 2 
 An Empirical Phase Diagram Approach to 
Investigate Conformational Stability of “Second-
generation” Functional Mutants of Acidic 
Fibroblast Growth Factor (FGF-1) 
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2.1 Introduction 
 Acidic fibroblast growth factor-1 (FGF-1) is a potent angiogenic factor 
being investigated as a pro-angiogenic biopharmaceutical drug candidate for 
treatment of ischemic disease, including wound healing in diabetic ulcers, 
peripheral artery disease, and non treatable (i.e. ‘‘no option’’) coronary 
occlusions.
1–4
 Significant hurdles, however, remain in the successful realization of 
FGF-1 as a biopharmaceutical drug, principally related to its intrinsically low 
thermodynamic stability
5
 in conjunction with three reactive cysteine residues (free 
thiols) buried within the protein interior.
6
 These features contribute to irreversible 
unfolding and aggregation of this 16 kDa protein during production and storage, 
with associated negative consequences for shelf-life, potency, and 
immunogenicity. 
 A substantial number of formulation studies have been performed on FGF-
1 with the goal of identifying pharmaceutical excipients that can stabilize the 
protein during long term storage and administration.
7–9
 FGF-1 has significant 
affinity for polyanions such as heparin/heparan sulfate, which as formulation 
additives can dramatically stabilize FGF-1 against unfolding by both heat and 
extremes of pH
10
 as well as against metal catalyzed oxidation of free cysteine 
residues.
7,9
 Based on these observations, FGF-1 for human therapeutic use has 
been formulated with the addition of both heparin and antioxidants. The use of 
heparin as an excipient, however, adds considerable complexity including 
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increased expense, its own pharmacological properties (e.g., as an anticoagulant), 
animal derived material from pig tissues (with potential for infectious 
contamination), and the possible induction of adverse inflammatory or allergic 
reactions in a segment of the targeted patient population. Thus, although heparin 
or related polyanions used as formulation additives solve the FGF-1 stability 
issue, they introduce other undesirable properties. 
 An alternative approach to the use of co-solutes to increase protein 
stability is to directly alter the protein’s physical properties by chemical 
modification or mutagenesis. One approach that has been used to increase the 
circulating half-life of proteins is ‘‘PEGylation’’ [covalent attachment of 
polyethylene glycol (PEG), a biocompatible polymer]. This increases the 
molecular mass of a protein and thereby reduces renal clearance (i.e., glomerular 
filtration of biomolecules is size dependent) and substantially increases the 
circulating half-life.
11
 Furthermore, the attached PEG molecule can mask regions 
of the protein surface that would otherwise be susceptible to proteolytic attack or 
immune recognition, increasing the circulating half-life and reducing 
immunogenicity.
12
 PEGylation has either little effect or destabilizes the 
thermodynamic stability of proteins
13
; thus, the beneficial properties of 
PEGylation are primarily associated with modulation of renal clearance and 
reduction of the irreversible pathways associated with degradation and 
insolubility. One problem with PEGylation is that it can interfere with functional 
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regions on the protein’s surface, reducing receptor/ligand affinity by two or more 
orders of magnitude.
12,14
 
 Mutating proteins to improve properties for human therapeutic application 
is a practical approach since over 30 mutant proteins have been approved for use 
as human biopharmaceuticals.
15
 These include mutations that contribute to 
increased yields during purification, increased in vivo functional half-life, or 
improved activity. Examples include mutations of buried free-cysteine residues in 
beta-interferon (BetaseronVR ) and interleukin-2 (ProleukinVR ) as well as other 
mutations hypothesized to increase thermostability. Thus, a mutational approach 
to improve the physical properties of proteins is a viable route to develop 
‘‘second-generation’’ protein biopharmaceuticals. 
 In the present report, mutations are introduced into human FGF-1 with the 
goal of altering the temperature and pH stability profile to more closely resemble 
that of FGF-1 in complexation with heparin. These mutations target increases in 
thermostability as well as a reduction in the number of buried free cysteine 
residues. Furthermore, these mutations select positions with limited surface 
accessibility. Using empirical phase diagrams (EPDs) to broadly assess the 
structural integrity of proteins in response to variations in pH and temperature, 
mutants of FGF-1 are identified to achieve the design goal of matching, or 
exceeding, the protective effects of heparin as an additive.
16,17
 These mutants 
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represent potential ‘‘second-generation’’ forms of FGF-1 that may be successfully 
formulated for use as a human therapeutic in the absence of heparin. 
 We also take advantage of the revised EPD approach used in this study to 
compare the relative conformational stability of FGF-1 mutants to assess the 
value and utility of this multidimensional vector based approach as a novel 
analytical comparability tool.
18,19
 Comparability assessments in 
biopharmaceutical development are conducted to determine the similarities (and 
differences) of various preparations of a biopharmaceutical drug used in clinical 
development in terms of a protein drug’s physicochemical properties as they 
relate to its safety and efficacy.
20,21
 Currently, one of the major analytical 
challenges in this area is to identify new biophysical approaches that complement 
in vitro/in vivo potency assays to better assess higher order structure and 
conformational stability of biopharmaceutical drug candidates. Although the 
series of FGF-1 mutants evaluated in this study are different molecular entities, 
the updated EPD data analytical approach used in this study could potentially be 
applied to biopharmaceutical comparability assessments of different preparations 
of the same protein drug. 
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2.2 Experimental section 
2.2.1 Materials 
 Recombinant FGF-1 proteins (WT and mutants, except for Symfoil-4P) 
utilized a synthetic gene for the 140 amino acid form of human FGF-1
40–43
 
containing an additional amino-terminal six His tag as previously described.
44
 The 
design strategy of the Symfoil-4P mutant used complete gene synthesis and was 
reported previously.
26
 The FGF-1 protein mutants used in this study are listed in 
Table I. The QuikChange 
TM
 site directed mutagenesis protocol (Agilent 
Technologies, Santa Clara, CA) was used to introduce all point mutations and was 
confirmed by nucleic acid sequence analysis (Biomolecular Analysis Synthesis 
and Sequencing Laboratory, Florida State University). All expression and 
purification protocols followed previously published procedures involving 
sequential chromatographic steps using Ni-NTA resin and heparin Sepharose CL-
6B affinity resin.
44
 Three of the mutant proteins, SYM6ΔΔ/K12V/P134V, 
SYM10ΔΔ (=SYM7ΔΔ/K12V/P134V/H93G) and Symfoil-4P, which have no 
affinity for heparin, were purified by Ni-NTA chelation and Superdex 75 size 
exclusion chromatography as reported  previously.
6,26
 The purified protein in each 
case was exchanged into 50 mM sodium phosphate, 0.1 M NaCl, 10 mM 
ammonium sulfate, 2 mM dithiothreitol (DTT), and pH 7.5 (‘‘crystallization 
buffer’’). The purified A66C mutant protein contains a mixture of reduced and 
oxidized forms. To isolate the fully oxidized form of A66C, the purified protein 
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was exchanged into crystallization buffer without DTT and subsequently air 
oxidized at room temperature for 3 weeks. An extinction coefficient of E280 nm 
(0.1%, 1 cm) =1.26 
7,45
 was used to determine protein concentration for FGF-1 
with the exception of C83T/C117V/L44F/ F132W, SYM6ΔΔ/K12V/P134V, 
SYM10ΔΔ, and Symfoil- 4P. Due to the variation in number of Trp and Tyr 
residues in these mutants, the extinction coefficient was determined by the 
method of Gill and von Hippel or densitometry analysis as reported 
previously.
6,10,11
 The resulting E280 nm (0.1%, 1 cm) values utilized were: 
C83T/C117V/L44F/F132W, 1.58; SYM6ΔΔ/K12V/P134V and SYM10ΔΔ, 1.31; 
Symfoil-4P, 0.32. 
 Heparin sodium salt, grade 1-A from porcine intestinal mucosa, was 
purchased from Sigma–Aldrich (St. Louis, MO). All other chemicals were 
purchased from Sigma–Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburg, 
PA). 
 
2.2.2 Methods 
2.2.2.1 Sample preparation  
 The purified FGF-1 proteins (WT and mutants) were dialyzed against 20 
mM citrate-phosphate buffers at pH 3–8 and adjusted to an ionic strength of 0.15 
M with NaCl, using a 3.5 kDa molecular-weight cutoff (Pierce, Rockford, IL) 
membrane. The dialysis step was carried out overnight at 4 
0
C. A mixture of WT 
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FGF-1 and heparin was prepared by adding heparin to the protein solution to 
achieve a 3:1 (w/w) ratio of heparin to protein. 
 
2.2.2.2 Circular dichroism spectroscopy  
 Far-UV CD spectra were recorded using either a Jasco J-810 (Tokyo, 
Japan) or Chirascan (Applied Photophysics) instruments, both equipped with a 
peltier type temperature controller. The protein concentration used was 0.2 
mg/mL using a 0.1 cm path length quartz cuvette in a total volume of 0.2 mL. Full 
CD spectra were collected before and after temperature ramping at 10 
0
C for 
wavelengths ranging from 260 to 200 nm with a resolution of 0.2 nm and a 
bandwidth of 1 nm over the pH range 3–8 at one unit intervals. The CD signal 
intensity changes at 228 nm were followed as the temperature was raised from 10 
to 90 
0
C at 2.5 
0
C intervals with a scanning speed of 15 
0
C/h and 5 min 
equilibration time at each temperature. 
 
2.2.2.3 Intrinsic fluorescence spectroscopy and static light scattering (SLS)  
 Intrinsic fluorescence measurements were recorded using a two-channel, 
four positions PTI Quantum Master fluorometer (Brunswick, New Jersey) 
equipped with a peltier temperature controlled cell holder. Spectra were obtained 
using excitation at 280 nm with emission spectra recorded between 290 and 390 
nm at a resolution of 1 nm. Spectra were also obtained from 10 to 90 
0
C at 2.5 
0
C 
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intervals in a 0.2 cm path length rectangular reduced volume cuvette containing 
0.2 mL protein solution. Buffer spectra were collected and subtracted from 
protein samples. Fluorescence emission peak positions and intensities were 
determined by a ‘‘dpoly’’ method using Origin 7.0 software. SLS intensity for the 
same sample was followed by using a right angle detector located 180
0  
relative to 
the other detector, and the peak intensity change at 280 nm was followed as the 
temperature was raised. 
 
2.2.2.4 Extrinsic fluorescence spectroscopy  
 Measurements were performed using ANS to detect exposure of apolar 
regions of the protein as the temperature was increased. A protein concentration 
of 0.08 mg/ mL was used, and ANS was added to the protein solution to achieve 
an optimal ANS: protein molar ratio of 10:1. The resulting mixture was excited at 
374 nm, and the emission spectra were recorded from 400 to 600 nm with a 
resolution of 1 nm. 
 
2.2.2.5 Empirical phase diagrams  
 EPDs are designed to summarize and visualize physical characterization 
data as a colored diagram with two-dimensional axes of environmental stress 
conditions such as temperature and pH. The theory and calculation procedures to 
create EPDs are described in detail elsewhere.
16,17
 The EPDs of FGF-1 and its 
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mutants were constructed based on the following biophysical measurements: 
intrinsic fluorescence intensity ratio at two wavelengths (I305/I330 nm), intrinsic 
fluorescence peak intensity, CD at 228nm, SLS and ANS fluorescence intensity at 
480nm. Complete data sets are presented in Supporting Information section. Data 
from the individual biophysical measurements (except for the I305/I330 nm 
fluorescence intensity ratio) were normalized as described previously.
16,17
 All 
calculations were performed using MATLAB software (The Mathworks Inc., 
Natick, MA). 
 Two revisions of the data analysis methodologies are used in this work to 
improve the ability of EPDs to compare the conformational stability profiles of 
the FGF-1 mutants. First, the EPD data analysis technique was extended to better 
pursue direct color comparison of EPDs from multiple samples. Previously, 
regions of color transition, but not the color itself, have been compared between 
EPDs. Similar colors in different EPDs could not be interpreted, even if proteins 
had similar conformational states, because each EPD was generated separately 
using an arbitrary RGB color mapping scheme. In contrast, the colors of EPDs 
made with the revised methodology can be directly compared with each other, 
assuming the meaning of the results from the different biophysical measurements 
is consistent between different samples. In brief, experimental data sets are 
represented as n-dimensional vectors where n refers to the number of experiment 
techniques (five in this case). The condition space of the original EPD method 
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consists of two environmental conditions (typically temperature and solution pH) 
whereas in this revised version the space is extended to incorporate multiple 
samples. Therefore, a sample condition space is defined with three components: 
sample, temperature, and solution pH. For a total of m conditions (=number of 
samples x number of temperature measurements x number of pH measurements), 
singular value decomposition of the m x n experimental data matrix is calculated 
to extract three orthogonal basis vectors associated with the three largest singular 
values, which are then mapped to RGB colors and visualized as EPDs. 
 The EPDs generated in this way are considered to display similar 
conformational behaviors across the different proteins based on an assumption 
that the collected experimental data represents similar physical behavior. If, 
however, the same data values represent different conformational states, these 
proteins are not processed together to generate EPDs for comparison purposes. 
For this reason, we divided WT FGF1 with and without heparin, as well as the 10 
mutants into two groups (I and II) to generate EPDs (Table I), due to the 
significant differences in their intrinsic fluorescence behavior (see Supporting 
Information). This evaluation was done manually by visual assessment of the 
fluorescence data from each protein. Group I proteins include WT FGF-1 (A), 
WT FGF-1 with heparin (B), and the mutants L26D/ H93G (C), 
C83T/C117V/K12V (D), P134V/C117V (E), K12V/C117V (F), A66C (G), and 
K12V/C117V/P134V (H). Group II proteins include C83T/C117V/L44F/ F132W 
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(I), SYM6ΔΔ/K12V/P134V (J), Symfoil-4P (K), and SYM10ΔΔ (L). Mutants in 
Group I contain a single Trp residue which is quenched in the protein’s native 
state. Mutants in Group II contain either an unquenched Trp residue in the native 
state or do not contain a Trp residue. These differences lead to different 
fluorescence peak positions and intensities and the data sets cannot be directly 
compared. In summary for this work, the EPDs for FGF-1 proteins in each group 
(I and II) were created together as can be seen in Figures 5 and 6, respectively; 
therefore, the colors of EPDs should be compared directly within these two 
groups but not between the two groups. 
 The second revision implemented with the EPD methodology is the 
application of mathematical clustering analysis to computationally identify 
regions of structural transitions (e.g., color changes). Previously, structural 
transitions in the EPDs were estimated by visual inspection of the EPD with 
comparisons to the individual biophysical data sets. The subtle or gradual change 
in colors often presented in the EPD, however, makes the location of the 
transitions difficult to be determined visually. Therefore, clustering analysis that 
utilizes the same m x n experimental data matrix as the EPD can provide 
complementary information for structural transitions. 
 In this research, k-means clustering algorithm was chosen for the 
clustering analysis and implemented using a MATLAB toolbox downloaded from 
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http://www.dcorney.com/ClusteringMatlab.html. The performance of various 
clustering algorithms will be the subject of future work. 
 k-Means clustering is a mathematical procedure in which a number (m) of 
experimental observations are partitioned into k groups or clusters. Clusters are 
based on the proximity of observations to proximate means. Observations are 
defined as n-dimensional vectors (a1, a2, . . ., an). The method then partitions m 
observations into k-sets (k < n) P ¼ [P1, P2, . . .Pk] to minimize the ‘‘within-
cluster sum of squares’’. More formally: 
 
 
               
     
 
   
  
 
in which µi is the mean of point in Pi. 
 The number of clusters (k) is determined after several diagnostic runs with 
various integral numbers. Generally, k = 2–5 works well for protein 
characterization data because k should, to a first approximation, correspond to the 
number of conformational states portrayed in the EPD. When constructing an 
EPD, the clustering results are used to draw the boundary between different 
clusters. The clustering results identify regions of conformational changes in 
FGF-1 mutants (due to environmental stresses such as temperature and pH), and 
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help to identify and compare regions displaying native state behaviors, and can be 
used to compare mutant FGF-1 proteins across the two groups, even though the 
two groups of EPDs display two different color sets. 
 
2.3 Results 
2.3.1 Selection of FGF-1 mutants 
 A combination of wild-type (WT) and 10 different FGF-1 mutants were 
chosen for analysis in this study. The mutant proteins were developed via a series 
of protein stability and folding studies with FGF-1 and were identified 
experimentally as having enhanced stability, functional half-life, or mitogenic 
activity.
6,22–28
 The previously described thermodynamic stability properties and 
available in vitro mitogenic activity as well as in vivo half-life values are 
summarized in Table I. The rationale used for the selection of mutants examined 
in this study is based on the results in Table I (WT FGF-1 and mutants are labeled 
A–L). For example, the L26D/H93G (C) mutant (developed as part of a study 
evaluating the effect of the consensus β-turn motif Asx-Pro-Asx-Gly on FGF-1 
stability and folding 
28
) combines a destabilizing mutation (L26D), and an 
essentially off-setting stabilizing mutation (H93G), resulting in the overall 
thermostability essentially unchanged in comparison to WT FGF-1 (A) (ΔΔG = 
0.9 kJ/mol, calculated based on differential scanning calorimetry). This mutant is 
therefore a thermostability control for the EPD analysis. Two of the FGF-1 
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mutants [SYM6ΔΔ/ K12V/P134V (J) and SYM10ΔΔ (L)] were selected to 
evaluate the effect of significantly elevated thermostability. These mutants 
(developed to test the effect of symmetry on FGF-1 protein folding and design 
22,29
) exhibit diminished mitogenic activity towards 3T3 fibroblasts, which is 
postulated to be due to an effect of enhanced stability which prevents structure 
(dynamic)  changes essential to the formation of receptor complexes.
29
 
Alternatively, the P134V/C117V (E) mutant has enhanced stability (ΔΔG = - 9.3 
kJ/mol) yet exhibits similar mitogenic activity in comparison to WT FGF-1 (A). 
Other examples include K12V/C117V (F) and K12V/C117V/ P134V (H) which 
are stabilizing mutations that, in the absence of heparin, achieve similar mitogenic 
potency to that of WT formulated in the presence of heparin (mutants E, F, and H 
were designed to stabilize N- and C-termini β-strand interactions, a region of 
known structural weakness within FGF- 1 
24
) The mutants C83T/C117V/K12V 
(D), C83T/ C117V/L44F/F132W (I), and oxidized A66C (G) have eliminated one 
or more free thiols, in comparison to WT FGF-1 (A). These mutations 
substantially increase their in vitro functional half-life with varying effects on 
thermostability (by mutating exclusively at solvent-inaccessible positions, thereby 
limiting immunogenic potential 
6,27
). Finally, Symfoil-4P (K), a synthetic ultra 
stable β-trefoil protein (designed as a hyperthermophile, purely symmetric 
polypeptide 
26,29
), was selected to evaluate its EPD profile in the context of its use 
as a nonfunctional protein engineering ‘‘scaffold.’’
26
 For the biophysical 
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characterization work performed in this study, the FGF-1 mutants in Table I were 
subdivided into two groups (I and II) due to the significant differences in their 
intrinsic fluorescence behavior (see ‘‘Methods section’’). 
 Due to the large amount of biophysical stability data generated in this 
work for WT FGF-1, both with and without heparin, as well as the 10 mutants of 
FGF-1, one mutant [K12V/C117V/P134V or (H) in Table I] was selected as an 
example to be compared with WT FGF-1 with heparin (B in Table I) and without 
heparin (A in Table I) in the main text. The data generated in this study for the 
other nine FGF- 1 mutants are provided in Supporting Information. The 
biophysical characterization of WT FGF-1 in the presence and absence of heparin 
by the original EPD methodology has been determined previously,
10 
 but was 
repeated in this work to provide a direct comparison to the FGF-1 mutants, 
especially in terms of evaluating of stability profiles using the revised EPD 
methodology. 
 
2.3.2 Biophysical measurements of FGF-1 and mutants 
2.3.2.1 Circular dichroism 
 Far-ultraviolet (UV) circular dichroism (CD) analysis was used to 
characterize the secondary (and tertiary) structure of WT FGF-1 (A in Table I), 
WT FGF-1 with heparin (B in Table I), and 10 mutants of FGF-1 (C-L in Table I). 
The mutant K12V/C117V/P134V was selected as an example to represent CD 
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spectra at different solution pH values (pH 3–8) at 10 
0
C (Fig. 1A). The CD 
spectra of K12V/C117V/P134V from pH 4 to 8 are similar in nature, with a broad 
positive peak at around 228 nm and a strong negative peak near 205 nm. The 
negative peak near 205 nm is consistent with the expected class II β-protein 
structure.
5,30
 The positive band at 228 nm is presumably a combination of 
contributions from β-turns, loops and aromatic side chains 
31–33 
and is potentially 
tertiary structure sensitive. At pH 3, the positive peak at 228 nm is greatly 
diminished, which suggests an alteration of protein tertiary structure under acidic 
conditions. Because significant secondary structure still appears preserved, this 
suggests the possible preserve of a molten globule state.
34,35
 WT FGF-1 (with and 
without heparin) display similar CD spectra from pH 5 to 8 with a positive peak at 
228 nm and a negative peak at 205 nm (Supporting Information Figs. 1A and 2A). 
For WT FGF-1 without heparin at pH 3 as well as WT FGF-1 with heparin at pH 
3–4, the CD spectra show a negative peak broadened toward 215 nm, which could 
be explained by the formation of intermolecular β-sheet structure.
5–7,9
 At pH 4, 
WT FGF-1 without heparin shows a CD spectrum similar to K12V/ 
C117V/P134V at pH 3, with only a negative peak at 205 nm (Supporting 
Information Fig. 1A). 
 To monitor structural changes of the proteins, CD signals at 228 nm were 
collected as a function of temperature from 10 to 90 
0
C. At elevated temperature, 
the positive peak diminished under all pH conditions examined, whereas the 
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negative peak shifted toward 215 nm (data not shown). As a result, at pH 5–8, the 
CD signals at 228 nm decreased from positive to negative as the temperature 
increased, as shown in Figure 1C for mutant K12V/C117V/P134V, Figure 1B for 
WT FGF-1, and Figure 1D for WT FGF-1 with heparin. This structural transition 
occurs between 40 and 50 
0
C for WT FGF-1, 50–60 
0
C for K12V/C117V/P134V 
and 60–70 
0
C for WT FGF-1in the presence of heparin. Thus, K12V/C117V/ 
P134V shows a significantly higher thermal stability than WT FGF-1, although it 
is still less stable than WT FGF-1 with heparin. 
 The CD thermal transitions monitored at 228 nm at pH 3–4 are different 
when comparing K12V/ C117V/P134V, WT FGF-1, and WT FGF-1 with 
heparin, for example, for K12V/C117V/P134V at pH 4, the CD signal at 228 nm 
shows a similar positive to negative transition as pH 5–8, albeit at lower 
temperature (30 
0
C). In contrast, the CD signal at 228 nm for 
K12V/C117V/P134V at pH 3 does not show a major structural transition. 
Similarly, WT FGF-1 at pH 3–4 does not show any significant structural 
transitions. In contrast, WT FGF-1 with heparin at pH 3–4 shows a transition 
from negative to less negative ellipticity, probably due to the precipitation of 
protein out of solution. 
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2.3.2.2 Intrinsic fluorescence spectroscopy 
 Intrinsic fluorescence spectra were used to monitor the tertiary structure of 
WT FGF-1 (with and without heparin) as well as the 10 FGF-1 mutants. Because 
the WT FGF-1 contains eight Tyr and a single Trp residue quenched in the native 
state, the proteins were excited at 280 nm to simultaneously collect fluorescence 
from both Tyrosine and Trp residues. The intrinsic fluorescence spectra of 
K12V/C117V/P134V at 10 
0
C are displayed in Figure 2A. The spectra from the 
mutant at pH 5–8 have a single peak at 305 nm, which corresponds to the 
emission of Tyr residues. In contrast, the spectra at pH 3 show a major peak at 
305 nm, but a significant broad shoulder at 340 nm, which corresponds to the 
emission of the previously quenched Trp residues. Trp fluorescence is not 
observed at pH 5–8 because when the protein is properly folded at near neutral pH 
conditions, the fluorescence of the single Trp residue is quenched by positive 
charges from neighboring His and Lys residues.
5,36
 At pH 3, the structure of WT 
FGF-1 is altered, and the nearby His and Lys side chains are moved away from 
the indole ring of Trp, resulting in dequenching of Trp fluorescence. The intrinsic 
fluorescence spectrum of the K12V/ C117V/P134V mutant at pH 4 show 
intermediate behavior compared with pH 3 and 5–8. The intrinsic fluorescence 
spectra of WT FGF-1 and WT FGF-1 with heparin at 10 
0
C are shown in 
Supporting Information Figures 1C and 2C, respectively. The fluorescence 
spectra for WT FGF-1 both with and without heparin at pH 3–4 is composed of 
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contributions from Trp and Tyr, whereas Tyr contributions dominate as described 
above for pH 5–8. 
 The ratio of the fluorescence intensity at 305 nm and 330 nm (I305/I330) 
has been shown to sensitively monitor the change in FGF-1 tertiary structure as a 
function of pH or temperature.
10
 A higher value (~ 3) of I305/I330 for proteins in 
Group I (see Table I) indicates a more native-like, properly folded structure, 
whereas a lower value (~1) indicates altered structure. Thus, intrinsic fluorescence 
spectra were obtained from 10 to 90 
0
C at 2.5 
0
C intervals and I305/I330 values 
were calculated and plotted as a function of temperature to monitor changes in 
tertiary structure for the K12V/C117V/P134V mutant and WT FGF-1 with and 
without heparin (Fig. 2B–D). 
 As shown in Figure 2B for the K12V/C117V/ P134V mutant at pH 3, the 
fluorescence intensity ratio started at ~1 and increased gradually as the 
temperature was increased, without any obvious structural transition, indicating 
that the higher order structure is already altered at pH 3 at 10 
0
C. In contrast, the 
fluorescence intensity ratio for pH 5–8 started at about 3 and then decreased to 
~0.7. The fluorescence intensity ratio for the mutant at pH 4 is between the values 
observed at pH 3 and pH 5–8 (starting at ~2 and decreasing to ~1.1 between 25 
and 40 
0
C). The thermal transitions for the mutant occurred between 20 and 55 
0
C 
for pH 4–7, with an apparent bi-phasic transition observed between pH 5 and 8. 
The first transition is more gradual than the second phase. For WT FGF-1 with 
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and without heparin, the fluorescence intensity ratio at both pH 3 and 4 shows no 
obvious structural transitions, indicating the expected structural alterations in WT 
FGF-1 at both pH values. In contrast, for pH 5–8, the ratio quickly decreased 
from 3 to ~0.7. By comparing the temperature at the completion of this structural 
transition for pH 5–8, the transition ended at ~45 
0
C for WT FGF-1, ~55 
0
C for 
the K12V/ C117V/P134V, and about 60 
0
C for WT FGF-1 with heparin. 
 For FGF-1 mutant proteins in Group II (see Table I), however, the ratio of 
the fluorescence intensity at 305 nm and 330 nm (I305/I330) has a different 
biophysical meaning because these mutants contain either an unquenched or 
missing Trp residue. Both a His and Lys residue, which quench the Trp residue in 
WT FGF, were deleted from SYM6ΔΔ/K12V/ P134V (J in Table I) and 
SYM10ΔΔ (L in Table I). Thus, the I305/I330 value is close to 1 even in the 
native state of protein (Supporting Information Figs. 4F and 5F). In contrast, 
C83T/C117V/L44F/F132W (I in Table I) has one extra Trp residue, which is not 
quenched in the native state. As a result, the I305/ I330 value is below 1 across 
the temperature range from pH 3 to 8 (Supporting Information Fig. 8F). In the 
case of Symfoil-4P (K in Table I), the protein contains no Trp residues but does 
have three Tyr residues, so the I305/I330 value is above 3 up to 70– 80 
0
C 
(Supporting Information Fig. 6F). Due to the difference of I305/I330 values in the 
native state, Symfoil-4P (K in Table I) has a different color scheme in the EPDs 
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(discussed below in Fig. 6) even in the low temperature region compared with the 
other mutants in Group II. 
 
2.3.2.3 1-Anilino-8-naphthalnesulfonate fluorescence 
 1-Anilino-8-naphthalnesulfonate (ANS) has been extensively used to 
detect the exposure of apolar binding sites on the surface of proteins and to detect 
the presence of molten globule-like states.
30, 37, 38
 At pH 3 and 4, substantial ANS 
fluorescence was observed for K12V/C117V/P134V (Fig. 3A), WT FGF-1 
(Supporting Information Fig. 1H), and WT FGF-1 with heparin (Supporting 
Information Fig. 2H) at 10 
0
C. Above pH 5, however, much less fluorescence is 
observed in the presence of these samples at 10 
0
C. Thus, ANS fluorescence 
spectra indicate that the tertiary structure of FGF-1 is altered in acidic condition 
even at low temperature, consistent with CD and intrinsic fluorescence results. 
 The ANS fluorescence intensity at 480 nm was monitored from 10 to 90 
0
C at 2.5 
0
C intervals. K12V/ C117V/P134V manifested an increase in ANS 
fluorescence intensity at ~40 
0
C for pH 5 and ~50 
0
C at higher pH values (Fig. 
3B). As shown in Figure 3C, at pH 5–8, WT FGF-1 shows an increase in ANS 
fluorescence intensity starting at 20 
0
C. By including heparin with WT FGF-1, the 
onset temperature of ANS binding was delayed to 55 
0
C for pH 5–8 (Fig. 3D). At 
pH 3–4, the major trend is a decrease in ANS fluorescence intensity as 
temperature increases for all three proteins. At pH 4, the K12V/C117V/ P134V 
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mutant shows slightly more neutral pH-like structural transitions (compared with 
WT FGF-1 with and without heparin), probably because the K12V/C117V/P134V 
mutant has more native-like structure at pH 4. 
2.3.2.4 Static light scattering 
 Both acidic pH conditions and elevated temperatures cause 
aggregation/precipitation of WT FGF-1.
2, 3 
Due to the low protein concentration 
used during dialysis, however, no gross precipitation was observed after dialysis 
at pH 3–4. The temperature induced aggregation of FGF-1 was followed by the 
static light scattering (SLS) signal at 280 nm. As shown in Figure 4A, very little 
scattering was observed at low temperatures for the K12V/C117V/P134V mutant 
under all pH conditions. An increase in light scattering intensity started at ~45 
0
C 
for pH 5–8 and ~55 
0
C for pH 4. No significant aggregation could be detected by 
light scattering for pH 3 up to 90 
0
C. A decrease in light scattering signal was 
observed for pH 5–8 above ~60 
0
C due to the precipitation of protein. For WT 
FGF-1 at pH 3, light scattering initiated at a higher level than other pH conditions, 
probably due to acidic buffer induced aggregation, although no obvious visible 
precipitation was observed. The onset of WT FGF-1 aggregation at pH 4–8 
started at ~40 
0
C. For WT FGF-1 with heparin, the light scattering signal for both 
pH 3 and 4 started at higher values than all other pH conditions, immediately 
followed by a gradual increase and then decrease. This aggregation started at ~45 
0
C for pH 5 and ~60 
0
C for all other pH values. At a solution pH between 6 and 8, 
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protein aggregation started at 40 
0
C, 45 
0
C, and 60 
0
C for WT FGF-1, 
K12V/C117V/P134V, and WT FGF-1 with heparin, respectively. Again, the 
K12V/C117V/P134V mutant displayed improved stability under acidic 
conditions. 
 
2.3.2.5 Empirical phase diagrams 
 The EPD approach has been developed to combine large amounts of data 
from multiple measurements to evaluate the overall conformational stability of 
proteins and other macromolecular systems under different environmental 
stresses.
16, 17, 39
 As shown in Figures 5 and 6, EPDs were generated for WT FGF-1 
(with and without heparin) and for the 10 different FGF-1 mutants. All of the 
measurements as a function of temperature and solution pH (as described above 
and in Supporting Information section) were summarized into RGB color plots in 
a two-dimensional space of pH and temperature using the revised EPD approach 
described in ‘‘Method section.’’ As explained in more detail in ‘‘Method 
section,’’ the EPDs for the FGF-1 mutants were generated in two groups (I and 
II). Group I (Fig. 5) includes proteins A–H in Table I and Group II (Fig. 6) 
includes proteins I–L in Table I. Colors can be compared directly within each 
group. A clustering method was then used to generate three distinct regions for 
each group of EPDs (not each EPD). The location of boundary of the individual 
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regions can be used to compare the conformational stability among and between 
the two groups. 
 As shown in Figure 5, the EPD for WT FGF-1 (A) has two distinct 
regions, a blue area (Region 2) and a green area (Region 1). The green region 
(Region 1) covers the low temperature and neutral pH range, which represents the 
native, most stable form of the protein. A structural transition occurs at ~44 
0
C for 
pH 6 and 7, which are the most stable pH conditions for WT FGF-1 (A). 
Although a third light blue region is present around the boundary between 
Regions 1 and 2, which represents molten globule-like behavior,
34, 35
 this subtle 
color difference was not defined as a separate region by this clustering analysis. 
On the addition of heparin to WT FGF-1 (B), a third region (pink) appears 
between Regions 1 and 2 as well as at low temperatures at pH 3 and 4. The 
formation of this third region is primarily due to the strong negative CD signal at 
low temperatures for pH 3 and 4 and at high temperatures at pH 5–8 (Fig. 1D). 
From inspection of the CD spectra of WT FGF-1 with heparin (B) (Supporting 
Information Fig. 2A), it is apparent that intermolecular β-sheet structure has 
formed at pH 3 and 4 at 10 
0
C and pH 5–8 at higher temperatures. As the 
temperature increased, protein aggregates started to form as indicated by 
increased light scattering (Fig. 4C), which is followed by a slight decrease 
presumably due to precipitation of protein. This third region in the EPD appears 
to be unique to WT FGF-1 with heparin (B). The structural transition between 
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Regions 2 and 3 for WT FGF-1 with heparin occurred at 60 
0
C, which is about 16 
0
C more stable than WT FGF-1 without heparin. 
 The EPDs for 6 of the FGF-1 mutants are also shown in Figure 5. The 
EPDs for the mutants show 2 regions (green for Region 1 and blue for Region 2). 
The K12V/C117V/P134V (H) mutant is most stable at pH 6 and 7, with a 
transition at 52 
0
C, which is ~8 
0
C higher than WT FGF-1. At pH 4, structural 
transitions are present at ~30 
0
C, which differs from WT FGF-1 and most of the 
other mutants where transitions at pH 4 cluster with pH 3. Thus, K12V/ 
C117V/P134V (H) has enhanced resistance to acidic unfolding. The 
K12V/C117V (F) mutant is similar to K12V/C117V/P134V (H), except for a 
lower overall thermal stability (~4 
0
C less). 
 The EPDs for the other four mutants of FGF-1 are shown in Figure 6. The 
EPDs of C83T/C117V/ L44F/F132W (I), SYM6ΔΔ/K12V/P134V (J), and 
SYM10ΔΔ (L) have Regions 1 (purple) and 2 (orange). Region 2 is at low 
temperature and in the neutral pH range. It thus represents the native, stable 
region. Both SYM6ΔΔ/K12V/P134V (J) and SYM10ΔΔ (L) show a very high 
degree of enhanced physical stability. In contrast, the EPD of Symfoil-4P (K) 
manifests a Regions 1 (purple) and 3 (light blue/green) due to the difference in the 
I305/I330 value, as explained above, where Region 3 represents the native stable 
region. As expected, SYM10ΔΔ (L) and Symfoil-4P (K), a synthetic ultra stable 
β-trefoil protein, are the most conformationally stable mutants observed by the 
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EPD analysis. The EPDs and clustering of the FGF-1 mutants are consistent with 
the thermodynamic conformational stability data previously obtained for the 
mutants (see Table I). 
 
2.4 Discussion 
 The stability of FGF-1 is strongly dependent on complexation with 
polyanions such as heparin.
7, 8 
This stabilization is important endogenously where 
the biological activity of this (and many other) growth factors requires interaction 
with polyanionic proteoglycans and protein receptors on the cell surface. In 
addition, the use of FGF-1 as a therapeutic agent requires the presence of heparin 
or other polyanions because the protein is unstable during storage and 
administration in its absence. In this work, we have analyzed a series of FGF-1 
mutants with the goal of reducing or eliminating the need for exogenous heparin 
by enhancing the protein’s intrinsic stability. Refer to Table I for the description 
of each FGF-1 mutant and Figures 5 and 6 for the summary of the biophysical 
stability results which will be the focus of the rest of this discussion. Rather than 
the usual reliance on evaluating protein stability from a single, unique biophysical 
technique (e.g., CD, intrinsic and ANS fluorescence, light scattering, etc.), we 
have evaluated the protein stability data from multiple experimental methods 
holistically in the form of a multivariable vector-based approach designated the 
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EPD to provide a broad picture of the physical behavior of the FGF-1 mutants as 
a function of temperature and pH.
17
 
 Increases in stability in this context can be viewed as an expansion of the 
apparent phase boundaries obtained in the EPD (i.e., the region of abrupt color 
change). For example, when comparing WT FGF-1 in the absence and presence 
of heparin, this boundary is moved to significantly higher temperature (Fig. 5) 
with an accompanying dramatic increase in biological activity (the EC50 is 
approximately 120 x lower as shown in Table I). Several of the mutants [e.g., 
Symfoil-4P (K), SYM6ΔΔ/K12V/ P134V (J), and SYM10ΔΔ (L)] display even 
greater increase in conformational stability, but demonstrate little biological 
activity. In contrast, a number of the FGF-1 mutants [K12V/C117V (F), 
C83T/C117V/ L44F/F132W (I), A66C (G), and K12V/C117/P134V (H)] display 
improved free energies of unfolding relative to WT, major increases in mitogenic 
activity in the absence of heparin (Table I), with EPDs similar to those of WT in 
the presence of heparin (Fig. 5). Thus, these FGF-1 mutants seem to be good 
candidates for future therapeutic applications from a stability and potency point of 
view. 
 Because the biophysical data for WT FGF-1(with and without heparin) 
and the other six mutants (Table I and Fig. 5) were mathematically processed 
together as the same data set, the colors from these EPDs can be directly 
compared with each other. Different color regions within the same EPD reflect 
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different physical states of protein under the indicated pH and temperature 
condition. Color changes indicate transitions in these states. Note that these are 
not necessarily thermodynamic states because reversibility between them is 
frequently not present. To facilitate the visualization of different color regions in 
EPDs, a clustering method was used to divide each EPD into different regions 
based on the input data (see below for further discussion). 
 The FGF-1 mutants in Figure 6 have different fluorescence ratios 
(I305/I330 nm) in their native states. This effect is due to the deletion of a Lys, 
and thus the Trp fluorescence in SYM6ΔΔ/K12V/ P134V (J) and SYM10ΔΔ 
mutants (L) (see Table I) is not quenched in the native state. Thus, the I305/I330 
profile for these two mutants is quite different from the others (see Supporting 
Information Figs. 4F and 5F). C83T/C117V/L44F/F132W (I in Table I) has an 
additional Trp residue which is not quenched in the native state. Symfoil-4P (L in 
Table I) does not have any Trp residues. As a result, EPDs for these 
SYM6ΔΔ/K12V/P134V (J) and SYM10ΔΔ (L) mutants were generated 
separately (Fig. 6), and their colors are compared with each mutant within this 
group. Nonetheless, the location of the cluster boundaries for the phase transitions 
shown in the EPDs for the various mutants can be compared with each other. 
 FGF-1 is known to form molten globule-like states under conditions of 
acidic pH as well as at moderately elevated temperatures at higher pH. This 
molten globule conformation is visually identified as a light blue region between 
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the dark blue (Region 2) and green (Region 1) areas identified by the clustering 
boundary for the WT FGF and many of the mutants’ EPDs in Figure 5. This 
observation of the formation of a molten globule state for FGF-1 under 
environmental stress is consistent with previous work.
10
 It should be noted, 
however, that the clustering methodology used in this work was not able to 
identify this subtle color change. Thus, the current version of the clustering 
analysis identifies the transition region between large conformational changes 
(e.g., between the native and unfolded, aggregated states of the FGF-1 mutants) 
but is not currently able to consistently identify the more subtle color changes 
represented by the molten globule state. The clustering methodology used in this 
work is a prototype version, and by exploring different clustering methods (work 
in progress), automatic clustering analysis might be able to identify the more 
subtle color differences (e.g., the molten globule state for FGF-1) that are 
observed visually by human sight in the future. Nonetheless, this version of the 
clustering analysis was able to identify several FGF-1 mutants, for example 
K12V/C117V/ P134V (H), which display an expanded native state (Region 1 in 
Fig. 5). These FGF-1 mutants are stable, bioactive forms of the growth factor that 
are not heparin dependent. 
 A second purpose of this study was to test the ability of EPDs to 
distinguish the conformational stability of a series of mutant proteins. We have 
previously successfully utilized the EPD method for the development of stabilized 
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pharmaceutical formulations of macromolecular systems such as 
biopharmaceutical drugs and  vaccines.
17, 39
 Instead of relying on one or only a 
few biophysical parameters, EPDs use a two-dimensional ‘‘stimulation/response’’ 
color pattern diagram. As is evident from Figures 5 and 6, both dramatically 
different and highly similar EPDs are produced with only a few mutational 
differences between proteins. Thus, this approach offers a unique methodology to 
compare proteins that is not based on structure alone, but rather uses the way a 
protein responds to environmental stress (e.g., pH and temperature) as a 
comparative principle. The EPD approach is not limited to temperature and pH 
but can also be used to evaluate the effect of protein concentration as well as 
solute and ionic strength among other solution variables.
17, 39
 We have recently 
shown that use of methods sensitive to the internal motions of proteins (e.g., 
isotope exchange, ultrasonic spectroscopy, solute spectral quenching, etc.) in the 
context of EPDs can also provide insight into more dynamic aspects of a protein 
behavior. Thus, the EPD approach would seem to offer an improved method to 
analyze the effect of mutation on protein structure. 
 In addition, it should be possible in the future to evaluate the revised EPD 
methodology developed in this work to compare stability of different mutants, as 
a new analytical approach to assess comparability.
18, 19
 During the pharmaceutical 
development of a protein therapeutic drug candidate or vaccine, comparability 
assessments are performed to determine if a protein’s key physicochemical 
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properties have changed (or not) across different preparations used during clinical 
trials. These analytical assessments typically involve a combination of routine 
quality control tests (e.g., sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, size exclusion-high performance liquid chromatography, 
isoelectric focusing, etc.), more sophisticated analysis using mass spectrometry 
and biophysical methods (e.g., intact MW analysis, peptide and oligosaccharide 
maps, differential scanning calorimetry, analytical ultracentrifugation, etc.), and 
stability profiles under accelerated and storage temperature conditions. 
20, 21
 It has 
recently been shown that comparison of accelerated temperature stability profiles 
can be an effective and sensitive way to perform comparability assessments.
20
 
Because the EPD methodology provides a rapid, high throughput approach to 
collect and evaluate conformational stability data under accelerated conditions of 
temperature and pH, this approach could potentially be useful as a comparability 
assessment tool. The EPD method is currently being evaluated in our laboratories 
for its utility in examining the conformational stability of different preparations of 
the same protein with modest changes in post translational modifications (e.g., 
glycosylation patterns). 
 In summary, the conformational stability of WT and 10 different FGF-1 
mutants was examined as a function of temperature and solution pH by a series of 
biophysical techniques, and the resulting data sets were analyzed with an EPD 
methodology. The revised version of the EPD methodology used in this work 
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resulted in effective and convenient comparisons of the effect of temperature and 
solution pH on the structural properties of a wide range of FGF-1 mutants. The 
conformational stability profiles of several of the FGF-1 mutants were 
comparable to the WT FGF-1 in the presence of heparin. Thus, candidate FGF-1 
mutants were identified with enhanced stability profiles in the absence of heparin 
and can be considered promising second-generation therapeutic FGF-1 
candidates. These mutants are currently undergoing preclinical pharmacokinetic 
studies in animal.
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Table 1: Summary of Stability Parameters and Biological Activity Values for WT FGF-1 and 10 FGF-1 Mutants. 
FGF-1 protein (reference) Symbol 
ΔΔG 
(kJ/mol) 
EC50 (ng/mL) 
( - ) heparin 
EC50 (ng/mL) 
( + ) heparin 
Half-life 
(h) 
Heparin 
Binding 
Group I       
WT (without and with heparin) A and B _ 58.4 ± 25.4 0.48 ± 0.08 1.0 Yes 
L26D/H93G 28 C - 0.9 N.A. N.A. N.A. Yes 
C83T/C117V/K12V 6 D - 1.9 0.93 ± 0.25 0.36 ± 0.12 40.4 Yes 
P134V/C117V 24 E - 8.8 46.8 ± 6.7 N.A. N.A. Yes 
K12V/C117V 24 F - 9.3 4.2 ± 1.7 N.A. N.A. Yes 
A66C (oxi) 27, 46 G - 10.2 5.43 ± 3.96 
46 0.36 ± 0.20 46 14.2 46 Yes 
K12V/C117V/P134V 24 H - 19.1 1.80 ± 0.90 N.A. N.A. Yes 
Group II       
C83T/C117V/L44F/F132W 6 I - 0.4 0.74 ± 0.19 0.51 ± 0.15 42.6 Yes 
SYM6ΔΔ/K12V/P134V 29 J - 35.0 741 ± 302 N.A. N.A. No 
Symfoil-4P 26 K - 44.1 N.A. N.A. N.A. No 
SYM10ΔΔ 29 L -47.0 N.D. 
29 N.A. N.A. No 
Conformational stability (ΔΔG, calculated based on DSC), mitogenic activity (EC50), and in vivo half values are listed from the references 
provided. FGF-1 proteins in Group I contain a single Trp residue which is quenched at the native state. FGF-1 proteins in Group II contain 
either an unquenched Trp residue in the native state or do not contain the Trp residue. N.A., not available; N.D., not detected.
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Figure 1  
                     
Far UV CD analysis of WT FGF-1 and a representative FGF-1 mutant. (A) CD 
spectra of the K12V/C117V/P134V mutant measured at 10_C at different pH 
values. (B–D) CD signal at 228 nm as measured as a function of temperature at 
indicated pH values for (B) K12V/C117V/P134V, (C) WT FGF-1, and (D) WT 
FGF-1 with heparin. Data points are an average of two independent analyses. 
Complete CD data sets for the other nine FGF-1 mutants are provided in 
Supporting Information section. See Table I for a further description of each 
mutant including K12V/C117V/P134V (H in Table I). 
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Figure 2 
                        
Intrinsic fluorescence analysis of WT FGF-1 and a representative FGF-1 mutant. 
(A) Fluorescence emission spectra (excited at 280 nm) of the 
K12V/C117V/P134V mutant measured at 10_C at different pH values. (B–D) 
Fluorescence intensity ratio (I305/I330) as measured as a function of temperature 
at indicated pH values for (B) K12V/C117V/P134V, (C) WT FGF-1, and (D) WT 
FGF-1 with heparin. Data points are an average of two separate experiments. 
Complete intrinsic fluorescence data sets for other nine FGF-1 mutants are 
provided in Supporting Information section. See Table I for a further description 
of each mutant including K12V/C117V/P134V (H in Table I). 
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Figure 3 
              
ANS fluorescence analysis of WT FGF-1 and a representative FGF-1 mutant. (A) 
ANS fluorescence spectra of K12V/C117V/P134V measured at 10_C at different 
pH values. (B–D) ANS fluorescence intensity ratio as measured as a function of 
temperature at indicated pH values for (B) K12V/C117V/P134V, (C) WT FGF-1, 
and (D) WT FGF-1 with heparin. Data points are an average of two independent 
experiments. The complete ANS fluorescence data sets for the other nine FGF-1 
mutants are provided in Supporting Information section. See Table I for a further 
description of each mutant including K12V/C117V/P134V (H in Table I). 
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Figure 4 
             
Static light scattering analysis of WT FGF-1 and a representative FGF-1 mutant 
as a function of temperature at the indicated pH values. (A) K12V/C117V/P134V, 
(B) WT FGF-1, and (C) WT FGF-1 with heparin. Data points are an average of 
two independent experiments. The complete static light scattering data set for the 
other nine FGF-1 mutants is provided in Supporting Information section. See 
Table I for a further description of each mutant including K12V/C117V/P134V 
(H in Table I). 
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Figure 5 
                     
Empirical Phase Diagrams (EPDs) for WT FGF-1 (A), WT FGF-1 with heparin 
(B), and 6 different FGF-1 mutants without heparin (C–H). The EPDs were 
constructed based on intrinsic fluorescence intensity ratio at two wavelengths 
(I305/I330 nm), intrinsic fluorescence intensity, CD at 228 nm, static light 
scattering (SLS) and ANS fluorescence intensity at 480 nm. All FGF-1 mutants in 
this Figure contain a single Trp residue which is quenched at the native state. 
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Figure 6 
                
Empirical Phase Diagrams (EPDs) for four different FGF-1 mutants without 
heparin (I–L). The EPDs were constructed based on intrinsic fluorescence 
intensity ratio at two wavelengths (I305/I330 nm), intrinsic fluorescence intensity, 
CD at 228 nm, static light scattering (SLS) and ANS fluorescence intensity at 480 
nm. FGF-1 mutants in this Figure contain either an unquenched Trp residue in the 
native state or do not contain the Trp residue. See Table I for description of each 
mutant. 
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Supplemental Figures Legend 
Proteins Figures: The following description applies to all FGF1 protein mutants in 
supplemental figures 1 to 11: 
A- Far-UV CD spectra at 10 0C 
B- Far-UV CD signals at 228 nm as a function of temperature. 
C- Intrinsic fluorescence spectra at 10 0C 
D- Intrinsic fluorescence intensity change as a function of temperature 
E- Intrinsic fluorescence peak position change as a function of temperature 
F- Intrinsic fluorescence intensity ratio at 305 and 330 nm (I305/I330) change 
as a function of temperature 
G- Static light scattering intensity change as a function of temperature 
H- ANS spectra at 10 0C 
I- ANS fluorescence intensity change as a function of temperature 
Within each figure, the following applies, pH 3 (black), pH 4 (red), pH 5 (green), 
pH 6 (blue), pH 7 (cyan), pH 8 (purple). 
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Supplementary figure 1: WT FGF-1 data summery. 
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Supplementary figure 2: WT FGF-1 with (3X) Heparin data summery. 
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Supplementary figure 3: L26D/H93G FGF-1 data summery. 
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Supplemental figure 4: SYM6ΔΔ/K12V/P134V data summery. 
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Supplemental figure 5: SYM7ΔΔ/K12V/P134V/H93G data summery 
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Supplemental figure 6: Symfoil-4P data summery 
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Supplemental figure 7: P134V/C117V data summery 
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Supplemental figure 8: C83T/C117V/L44F/F132W data summery 
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Supplemental figure 9: A66C data summery 
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Supplemental figure 10: C83T-C117V-K12V data summery 
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Supplemental figure 11: C117V-K12V data summery 
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Chapter 3 
 High-Throughput Biophysical Analysis and Data 
Visualization of Conformational Stability of an 
IgG1 Monoclonal Antibody (mAb)  
After Deglycosylation  
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3.1 Introduction 
Monoclonal antibodies (mAbs) have emerged as a key category of 
therapeutic protein drugs with over 30 mAbs currently approved in the USA and 
Europe and many hundreds under clinical development.
1, 2
 The commonly used 
IgG mAb includes two light chains and two heavy chains forming a homo-
dimeric, multidomain structure containing an N-linked glycosylation site in each 
of the two CH2 domains found in the Fc portion of the heavy chain.
3, 4
 The 
glycosylation pattern of the Fc region of IgG molecules plays a key role in IgG 
functionality and clearance, where the type and amount of glycan moieties control 
the ability and affinity of the Fc region to bind to the various Fc receptors in 
vivo.
5-11
 These Fc receptors are responsible for Fc effector function activities and 
regulating clearance of IgGs from circulation in vivo.
12-18
   
The extent and type of glycosylation has been shown to influence the 
conformational stability of proteins in general and mAbs in particular.
19
 There are 
several studies examining the effect of deglycosylation on the structure and 
stability of the Fc region of IgGs.
20, 21
 These studies typically use a single 
measurement type (e.g., differential scanning calorimetry) over limited solution 
conditions (e.g., one or two pH values) to examine the effect of varying mAb 
glycosylation patterns.
22-26, 30
 In addition, the protease sensitivity of an IgG (e.g., 
papain digestion), has been used to examine mAb stability, in which more 
cleavage has been noted when the Fc was deglycosylated.
34, 35 
Recent studies have 
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also examined the conformational stability of purified Fc domains as function of 
varying glycosylation.
20, 21, 27-30, 32
 Interactions between the glycan moieties and 
specific residues within the CH2 domains are responsible for stabilizing the 
structure of the CH2 domain, and disruption of these non-covalent interactions by 
partial or full deglycosylation leads to destabilization of the entire domain.
20, 21, 30-
33
 The effect of deglycosylation on the structural integrity of the CH2 domain has 
been examined by a variety of structural analysis including X-ray crystallography, 
56
 SAXS 
40
 and HDX-MS 
54, 55
 as well as examined by molecular modeling.
6, 57
 
The pharmaceutical properties (e.g., storage stability and solubility) of 
mAbs are also affected by glycosylation, although not necessarily in predictable 
ways.  For example, the solubility of an IgG1 was increased dramatically after the 
introduction of an additional glycosylation site on the Fab domain.
36
 In contrast, 
an isolated cryoimmunoglobulin species from human serum, known to have 
dramatically reduced cold solubility, was shown to contain an additional 
glycosylation moiety in the variable region of the antibody.
37
 The aggregation 
propensity of IgGs may increase upon deglycosylation, which has been attributed 
to the destabilization of the CH2 domain as well as exposure of an aggregation-
prone regions within the CH2 domain that are masked in the native IgG by the 
glycan moiety.
28, 38,  39, 59, 60
   
Due to the potential for changes in critical quality attributes for biotech 
drugs as a result of manufacturing and/or formulation modifications, 
121 
 
comparability studies are performed in which the pre and post-change drug 
candidates are evaluated to ensure that these process and product changes do not 
affect the drug’s structure, safety and function.
41-44
 Structural equivalence 
between pre and post-change protein drug candidates is evaluated in a step-wise 
fashion which may include analytical, biological and clinical evaluations.
41
 The 
effect of varying glycosylation profiles on the design of comparability 
assessments of protein therapeutics, including effects on Fc effector function 
activity of mAbs, has recently been reviewed.
42, 45
 
Analytical characterization for comparability evaluations includes 
determination of primary and higher-order structural integrity using a 
combination of methods.
43, 46
  A combination of chromatographic (SE, RP and IE- 
HPLC) and electrophoretic (cIEF, cSDS) methods are typically utilized along 
with mass spectrometry (intact molecular weight, peptide and oligosaccharides 
maps) to characterize protein’s primary structure and post-translational 
modifications (e.g., glycosylation patterns). In contrast, analytical methods 
available to examine higher-order structure are typically lower resolution in 
nature (e.g., CD, fluorescence), ultimately resulting in the requirement for 
functional potency assays to be performed to ensure biological activity.  Since 
accelerated or long term stability studies are typically monitored as part of 
comparability assessments, 
43, 46
 there is a need for new analytical methods for 
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determining the higher-order structure of protein drug candidates that would 
provide a more comprehensive picture of their structural integrity and stability. 
In the past decade, multiple papers have appeared from our laboratories 
describing the ability of empirical phase diagrams (EPDs) to summarize physical 
stability data and use this information for formulation development of therapeutic 
proteins and vaccines.
47-52  
These EPDs are created through the utilization of large 
data sets from high throughput analysis of a protein’s conformational stability as a 
function of environmental stresses (e.g., temperature and pH) by multiple lower-
resolution biophysical techniques (e.g., CD, fluorescence, light scattering, etc.), 
followed by the application of multidimensional mathematical analysis 
techniques, to produce a colored diagram representing structural changes as a 
function of environmental stress. Furthermore, the ability of EPDs to detect major 
conformational stability changes in a series of site-directed mutants of acidic 
fibroblast growth factor (FGF-1) was recently demonstrated.
50
 Recent work has 
also established additional data visualization methods such as radar charts, 
Chernoff faces and comparative signature diagrams to better compare protein 
samples.
51, 53
   
The purpose of this study is to test the feasibility of using high through-put 
biophysical analysis and data visualization methods to rapidly evaluate, over a 
wide range of solution conditions, differences in the structural integrity and 
conformational stability of an IgG1 mAb of varying glycosylation patterns. This 
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work required, for the first time, incorporation of differential scanning calorimetry 
and differential scanning fluorimetry data into the EPD analysis. We also included 
radar chart methods to better visualize conformational stability data differences 
across the IgG1 glycoforms.  
 
3.2 Materials and Methods 
3.2.1 Materials 
An IgG1 mAb solution was received from Janssen R&D/J&J at 40 mg/ml 
and frozen in aliquots at -80
0
 C.  Reagent chemicals were purchased from Sigma–
Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburg, PA). 
 
3.2.2 Methods 
3.2.2.1 Deglycosylation of IgG mAb 
Fully deglycosylated mAb was prepared using PNGase F from Prozyme™ 
(San Leandro, CA).  Samples of mAb were diluted to 10 mg/ml with reaction 
buffer (100 mM Tris, 100 mM NaCl, pH 7.5), and then 20 µl (200 µg) of the 
diluted protein sample was added to 172 µl of the reaction buffer and 8 µl of 
PNGase F to achieve a 1:100 (w/w) enzyme: protein ratio.  The mixture was 
incubated at 37 
0
C for 15 h.  Partially deglycosylated IgG was produced using 
Endoglycosydase F2 (Endo F2) from Prozyme™ (San Leandro, CA).  Samples of 
mAb were diluted to 10 mg/ml using deionized water. Twenty µl (200 µg) of the 
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diluted protein sample was then added to 38 µl of deionized water, followed by 
addition of 10 µl of 5X reaction buffer (250 mM sodium acetate, pH 4.5), and 2 
µl of Endo F2 to the mixture. The mixture was incubated for 1h at 37 
0
C. 
 
3.2.2.2 Electrospray Ionization Mass Spectrometry (ESI-MS)  
To confirm deglycosylation, antibody samples with and without reduction, 
using 10 mM dithiotreitol (DTT), were diluted to 0.25 mg/ml with 0.1% formic 
acid.  Ten µL of this solution (approximately 16 pmoles of intact mAb or 50 
pmoles of Fc monomer) was injected into the sample loop of the LC (Agilent 
Technologies 1200 Series) with a two pump system.  An isocratic loading pump 
carried the sample from the loop to a Protein Concentration and Desalting Micro 
Trap (Bruker-Michrom, Auburn, CA, USA) for 5 min desalting with 0.1% formic 
acid at 200 µL/min. A gradient pump eluted the protein from the trap at 50 
µL/min flow rate using a 5-60 % linear acetonitrile gradient in 3 min followed by 
a 60-95% gradient in 1 min for cleaning the trap onto the electrospray ionization 
(4 kV capillary) source of a time of flight mass spectrometer (model 6220, 
Agilent Technologies).The mobile phases used for gradient elution were 0.1% 
formic acid and 90% acetonitrile /10% water /0.1% formic acid. The mass 
spectrometer was operated in 2 GHz extended dynamic range mode with 
fragmentor voltage of 150V, desolvation gas flow rate of 10 L/min at 325 °C and 
nebulizer pressure of 20 psig.  Mass spectra were acquired over an m/z range of 
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300-3200 with an acquisition rate of 1 spectrum per second with reference mass 
correction. The raw mass spectral data was processed using Agilent Mass Hunter 
Qualitative Analysis (version B.04). The mass spectra were deconvoluted at 
specific mass ranges to search for intact or reduced mAb species. 
 
3.2.2.3 Sample Preparation for Stability Assessments   
Samples were dialyzed overnight at 4
0
 C  using a 10 kDa molecular-
weight cutoff membrane (Pierce, Rockford, IL) against 20 mM citrate-phosphate 
buffer to achieve the targeted pH range (3-8  with one pH unit increment or 3.5-
6.0 with 0.5 pH increments).  The ionic strength in all buffers was adjusted to 
0.15 using NaCl. Protein concentration was determined at each pH using Agilent 
8453 spectrophotometer (Palo Alto, California) and adjusted to 1 mg/ml.  For 
physical measurements, two different sets of experimental parameters were 
evaluated:  (1) for the pH range of 3-8, the temperature was raised from 10 
0
C to 
90 
0
C at 2.5 
0
C intervals using a 180 sec equilibration time, or (2) for the pH 
range of 3.5-6.0, 1.25 
0
C intervals were used as a temperature ramp with a 30 sec 
equilibration time. 
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3.2.3 Biophysical Measurements  
3.2.3.1 Far-UV Circular Dichroism Spectroscopy  
Far-UV Spectra ranging from 260 to 200 nm with a resolution of 1 nm and 
a bandwidth of 1 nm was collected first at 10 
0
C using Chirascan (Applied 
photophysics) equipped with four cells peltier type temperature controller. A 
protein concentration of 0.2 mg/ml using 0.1 cm path length quartz cells with a 
total volume of 200 µl was used. The CD signal intensity change at 217 nm as a 
function of temperature was collected, and buffer subtracted from all protein 
samples. 
 
3.2.3.2 Intrinsic (Trp) Fluorescence Spectroscopy and Static Light Scattering 
(SLS) 
Intrinsic fluorescence and SLS were measured using a dual-channeled, 
four positioned Photon Technology International (PTI) Quantum master 
fluorometer (Brunswick, Ney Jersey) equipped with a turreted peltier temperature 
controller.  A protein sample of 0.2 mg/ml in 0.2 cm path length quartz cell 
containing a total volume of 200 µl was used.  Samples were excited at 295 nm 
with emission spectra collected from 300 to 400 nm at a resolution of 1 nm, 
collection rate of 1 nm/sec, and an integration time of 1 sec. The slit width used 
for both excitation and emission was 4 nm, while 0.25 nm was the slit width used 
for light scattering.  As the intrinsic fluorescence signal was collected, SLS signal 
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was collected simultaneously using 180
0 
angle detector relative to the other, and 
the SLS peak intensity at the wavelength of excitation (295 nm).  Spectra and SLS 
were was followed with temperature increase as describe in detail elsewhere.
32
  
Fluorescence peak position and intensity changes were determined by center of 
spectral mass “MSM” method using Origin™ 7.0 software.  This method shifts in 
the actual peak position of approximately 10 nm, but produces more reproducible 
values of the wavelength maximum.  Buffer spectra were determined and 
subtracted from all protein samples.  
 
3.2.3.3 Extrinsic Fluorescence Spectroscopy with ANS 
Extrinsic fluorescence was measured using a four positioned Photon 
Technology International (PTI) Quantum master fluorometer (Brunswick, Ney 
Jersey) equipped with a turreted peltier temperature controller. The dye 1-analino-
8-naphthalene sulfonate (ANS) was used to detect the exposure of the apolar 
regions of the protein. A protein concentration of 0.2 mg/ml was used; ANS was 
added to the protein to achieve a protein:ANS molar ratio of 1:15 and a total 
volume of 200 µl using 0.2 cm path length quartz cells.  Samples were excited at 
374 nm and emission spectra were collected in the range of 400 to 600 nm with a 
1 nm resolution, 1 nm/sec collection rate, and 1 sec integration time. A slit width 
of 3 nm was used for both excitation and emission. Buffer spectra were 
determined and subtracted from all protein samples.  
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3.2.3.4 Differential Scanning Calorimetry (DSC) 
DSC measurements were carried out using MicroCal™ capillary Auto 
DSC instrument (MicroCal,LLC, Northampton, Massachusetts). A protein 
concentration of 0.2 mg/ml in a total volume of 600 µl was used with a 
temperature ramp from 10 
0
C to 90 
0
C and a scanning rate of 60 
0
C/hr. A pH 
range of 4-6 with 0.5 pH unit increment was evaluated. Buffer thermograms were 
subtracted from the corresponding sample thermograms. DSC thermograms were 
integrated, before being utilized in the construction of the EPD, to get a sigmoidal 
curve, in a step to get a better representation of the data in the EPD.  
 
3.2.3.5 Differential Scanning Fluorimetry (DSF) 
DSF measurements were performed using MX3005P QPCR system 
(Agilent Technologies), with a protein concentration of 0.2 mg/ml and total 
sample volume of 100 µl. SYPRO™ orange purchased from Invitrogen, Inc. 
(Carlsbad, CA) supplied in a concentrated form (5000x) dissolved in DMSO.  The 
dye was diluted to 40x and then added to the protein samples to achieve 1x dye 
concentration for measurements.  Using FAM filter sets, the mixture was excited 
at 492 nm and the emission intensity change with temperature at 516 nm was 
followed. Temperature was raised from 25 
0
C to 90 
0
C using 60 
0
C/hr as a heating 
rate and 1 
0
C as a step size.  Data were transferred to Excel software (Microsoft, 
Redmond, WA) for data analysis.  A pH range of 4-6 with 0.5 pH unit increment 
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was used, and buffers were run and subtracted from all samples.  DSF curves 
were integrated, before being utilized in the construction of the EPD, to get a 
sigmoidal curve, in a step to get a better representation of the data in the EPD. 
3.2.3.6 Construction of Empirical Phase Diagrams (EPDs) and Radar Charts 
 EPDs are constructed to summarize and visualize the conformational 
stability of IgG1 mAbs using data sets from selected experimental techniques as a 
function of pH and temperature.  The experimental measurements are organized 
in the form of a multi-dimensional vector matrix and analyzed by Singular value 
decomposition (SVD) as described in detail elsewhere.
51, 52
 Results are mapped to 
a RGB color scheme and visualized as changes in color which indicate changes in 
the physical states of the protein.  Additional data visualization scheme with radar 
charts was also used to analyze the data as described in detail elsewhere.
51
 A radar 
chart can have any number of polar axes each of which is mapped to an 
experimental technique.  A polygon drawn by connecting all points in the polar 
axes represents changes in the physical states of the protein.  Similar to an EPD, 
difference in the shapes of polygons indicate changes in the conformational state 
of a protein.  Apparent boundaries between states can be assessed visually or by 
use of computational aid such as k-Means clustering.  A detailed explanation of 
radar charts and clustering methods can be found elsewhere.
50
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3.3 Results 
3.3.1 Deglycosylation of the IgG1 mAb  
 The IgG1 mAb used in this study had a glycosylation pattern typically 
observed for recombinant mAbs produced from SP2/0 cells with ~75% consisting 
of G1F, G2F and G0F structures, and the remaining ~25% being spread over 
various charged species (e.g., mono and disialylated glycoforms) as described in 
detail elsewhere.
43
 The ability of the different enzymes to remove the two major 
glycans (G0F, G1F) was monitored by mass spectrometry analysis of the heavy 
chain Fc from reduced mAb samples (Table 1).  Mass spectrometric analysis of 
the reduced mAb samples showed no significant changes to the light chain (data 
not shown) while the heavy chain manifested a molecular weight consistent with 
the specific enzymatic treatments (Table 1). For example, partial deglycosylation 
was achieved by the treatment with endoglycosydase F2 (Endo F2) which cleaves 
between two GlcNAc residues and leaves Asn 297 in the protein backbone 
attached to GlcNAc-Fuc. Full deglycosylation was achieved using N-Glycanase 
(PNGase F) which fully removes the glycan (see Table 1) and deamidates the Asn 
to Asp, adding a negative charge to both CH2 domains. Additional confirmation 
was obtained by SDS-PAGE and capillary isoelectric focusing analysis which 
qualitatively showed the expected shifts in migration of fully deglycosylated mAb 
in terms of molecular weight and charge heterogeneity due to glycan removal 
(data not shown).  
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3.3.2 Initial biophysical characterization of a native and fully deglycosylated 
IgG1 
The secondary structure of the native and fully deglycosylated IgG1 mAb 
was evaluated by far-UV CD analysis from 260 nm to 200 nm at 10 
0
C (Figure 
1A, 2A). Both samples share the same structural features across all pH values in 
the form of a broad negative peak at 217 nm, indicating the expected β-sheet rich 
structure.  By following the CD intensity change at 217 nm with increasing 
temperature (Figures 1B, 2B), the two IgG1 glycoforms show similarity in their 
secondary structure stability behavior at higher pH values (pH 6-8) with an onset 
temperature of ~60 
0
C.  A lower pH, however, (pH range 3-5), the native IgG1 
shows a trend toward enhanced stability compared to its deglysosylated form, 
with ~1 
0
C difference in the onset temperature.  
At 10 
0
C, the native IgG1 produced a higher ANS intensity at pH 3 than 
other pH values, suggesting increased exposure of apolar regions at low pH 
(Figure 1C).  For the fully deglycosyalted IgG1, higher ANS intensity was 
observed at all pH values compared to native IgG1 (Figure 2C). Thermal stability 
was studied by following the ANS intensity change at 486 nm with increasing 
temperature as shown in Figures 1D and 2D. The native and deglycosylated forms 
of the mAb show a similar transition at high pH values (pH 6-8) with one, major 
structural transition observed starting at ~60 
0
C. Differences between the two 
IgG1 forms are observed, however, in more acidic environments (pH 3-5), 
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including an additional structural transition at lower temperatures. At pH 3, the 
first transition begins at approximately 10 
0
C for the native IgG1, while the 
protein is already structurally altered at 10 
0
C for the fully deglycosylated form, 
suggesting that the fully deglycosylated IgG1 is experiencing a higher degree 
structural disruption at pH 3.  In contrast, the second transition starts at ~35 
0
C for 
both samples.  Two structural transitions are seen at pH 4 for both IgG1s, with a 
similar onset temperature for the second transition (~57 
0
C), but a different onset 
temperatures in the first transition (~35 
0
C for the native IgG vs. ~25 
0
C for the 
fully deglycosylated IgG).  The native IgG1 at pH 5 shows only one structural 
transition starting at ~60 
0
C while the deglycosylated form manifest two 
transitions at ~42 and ~60 
0
C. 
Intrinsic (Trp) fluorescence spectroscopy was used to probe the overall 
tertiary structure stability of the native and fully deglycosylated mAb. Comparing 
the two spectra at 10 
0
C, no major differences were observed at all pH values 
(data not shown). By following the intensity change with increasing temperature 
for the IgG1 in the native (Figure 1E) and fully deglycosylated states (Figure 2E), 
similar structural transitions are seen including an initial decrease in fluorescence 
intensity (due to the intrinsic temperature dependent decrease in quantum yield of 
the tryptophan’s indol ring), a second sudden increase in fluorescence intensity 
(indicating the start of a tertiary structure unfolding event), and a third transition 
marked by a sudden decrease in fluorescence intensity consistent with 
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aggregation/precipitation. The major unfolding event (second transition) for both 
IgG1 forms starts earlier at pH 3 (~38 
0
C) and pH 4 (~55 
0
C) compared to other 
pH values.  Approximate 2-3 
0
C stability difference for the IgG1 in the native 
state (~62.5 
0
C) was observed for pH (5-8) compared to the fully deglycosylated 
IgG (~60 
0
C).  Peak position changes as a function of increasing temperature were 
also analyzed. The peak position for the native IgG1 (Figure 1F) was 340 nm 
(shifted from an actual value of 330 nm due to the use of “spectral central of 
mass” method) for all pH values at 10C representative of native/folded tertiary 
structure. The peak position gradually increased with increasing temperature 
followed by a decrease at around 65 
0
C (except at pH 3) suggesting 
aggregation/precipitation. The fully deglycosylated IgG1 (Figure 2F) at 10 
0
C was 
in a partially unfolded state as indicated by the red shifted peak position (345 nm 
at pH 3 and 342 nm for the pH range 4-8 using MSM analysis). With increasing 
temperature, both proteins showed a gradual increase in their peak position as a 
result of gradual unfolding followed by aggregation/ precipitation and 
concomitant loss of signal.  
Figures 1G and 2G show the temperature induced aggregation behavior of 
the native and fully deglycosylated IgG1, respectively, as measured by static light 
scattering. Comparing the two IgG1 forms, pH 3 shows a similar trend with no 
increase in light scattering intensity even up to 90 
0
C, whereas, the native and 
deglycosylated IgG1 at pH 4 starts aggregating at 64.5 
0
C and 62 
0
C, respectively, 
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with a greater intensity upon aggregation for the deglycosylated form. At pH 5 
and 6, native IgG1 starts aggregating at ~62.5 
0
C and ~65 
0
C  compared to ~60 
0
C 
and ~62.5 
0
C for the deglycosylated IgG1, implying a destabilizing influence of 
removal of the sugar moiety.   
The thermal melting curves from CD, ANS, fluorescence peak intensity, 
fluorescence peak position, and SLS analysis were used to generate EPDs for the 
native (Figure 1H) and fully deglycosylated mAbs (Figure 2H). Comparing the 
two EPDs, three major regions are identified that signify different conformational 
states.  The green region represents the IgG1 in its stable native state and the blue 
region in a structurally perturbed, partially unfolded state. The purple/red region 
represents an aggregated state. Both IgG1 forms have similar transition 
temperatures in the native to the unfolded state events (blue region) in the pH 
range of 6-8, suggesting no detectable differences in conformational stability 
between the native and fully deglycosylated IgGs in this pH range. In contrast, 
notable differences in conformational stability between the two IgG1 forms were 
seen under more acidic conditions of pH 3-5. Comparing the native (green) region 
of the EPDs at pH 5 for the two IgG1 forms, a large stability difference is 
observed, in which the native IgG1 starts transitioning to the unfolded state at 
~57.5 
0
C and the fully deglycosylated form at ~47.5 
0
C. At pH 4, conformational 
stability differences are even more dramatic, with transitions to the unfolded state 
appearing at ~47.5 
0
C and ~35 
0
C for the native and fully deglycosylated IgG1, 
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respectively. For both IgG1 forms at pH 3, the structurally perturbed state initiates 
at 10 
0
C with this unfolded state undergoing aggregation at ~50 
0
C. 
 
3.3.3 Optimization of experimental parameters to better compare 
conformational stability of Native and Fully Deglycosylated mAb glycoforms 
Based on the studies above, EPD data analysis permitted a rapid, visual 
assessment of conformational thermal stability differences between the native and 
fully deglycosylated IgG1 in the pH range of 3 to 5. Given the size of the 
temperature steps (2.5 
0
C) and pH steps (one pH unit), however, it was difficult to 
analyze these stability differences in more detail. Thus, a narrower pH range (3.5 
to 6 in 0.5 pH increments) with smaller temperature increments (1.25C) was 
used to generate a new set of EPDs for both IgG1 mAb forms. Using the same 
techniques, a more detailed EPD was generated for native protein (Figure 3A) and 
deglycosylated protein (Figure 3C). The data from these experiments are provided 
in Supplementary Figures S1 and S2. These improved EPDs resulted in 
observation of four structural regions including a blue region, where both IgG1 
forms are in their stable-native like states, a dark black region, immediately above 
the blue region probably representing the IgG’s in a molten globule-like state.  
The third region (green) represents a highly structurally altered, extensively 
unfolded state, while the purple/red region comprising protein that is aggregating 
and/or precipitating. Comparing the blue regions of the two IgG1 forms to each 
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other, we see this region covers most of the native state, but covers a much 
smaller area in the fully deglycosylated form. This more clearly illustrates 
conformational stability differences between the two IgG1 forms. For example, in 
the pH range of 3.5-4.5, a noticeable difference in the structural transition 
temperatures from the native to the molten globular and unfolded states are 
observed. Transition temperature differences were less substantial in the pH range 
of 5-6 in the EPD with an ~2-3 
0
C stability difference between the two IgG1 
forms.   
We used the same data set to generate radar charts, a newly developed 
data visualization method for protein biophysical data.
51 
Radar charts for the 
native and fully deglycosylated IgG1 mAb forms are shown in Figures 3C and 
3D, respectively. The reference radar chart guide to the right of the figure shows 
the position of the five analytical techniques that are being evaluated.  
Consequently, five radii are projecting out from the center of the chart creating 
one larger pentagonal image. According to the clustering analysis (K=3), for both 
IgG forms, the radar charts are divided into three regions, regions I, II, and III.  
These three regions are similar to the three regions describe above with EPD 
analysis (i.e., native-like state, structurally altered state, and more extensively 
altered form with aggregation). Region I is of small quadrilateral shape and 
corresponds to minimal change in the signals, thus representing the more stable-
native like state. Region I covers 60% (Figure 3C) vs. 42% (Figure 3D) of the 
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total area of the radar charts for the untreated and fully deglycosylated IgG1 
mAbs, respectively.   
  
3.3.4 Conformational Stability of Three Different IgG1 mAb Glycoforms 
Analyzed with Optimized Analytical and Data Visualization Methods 
As a final set of experiments, three forms of the IgG1 mAb of varying 
glyscoylation were analyzed: the untreated control, the fully deglycoyslated 
PNGase F treated protein, and a partially deglycosylated form generated by 
treatment with Endo F2 (see Table 1). In addition, as noted above, since various 
biophysical techniques (Figures 1-3) differed in their ability to detect the 
destabilizing effect of deglycosylation, we selected the most sensitive methods 
described above (extrinsic fluorescence spectroscopy with ANS and static light 
scattering) for the additional experiments described below. In addition, we also 
employed differential scanning calorimetry (DSC) and differential scanning 
fluorimetry (DSF) which have previously been shown to be capable of detecting 
conformational stability differences in deglycosylated IgG1 mAbs.
21, 24, 27, 28, 30-33
 
Finally, the pH range of analysis was also narrowed to pH 4.0-6.0 to better focus 
on the structural transition regions and due to complex, irreproducible behavior of 
DSC and DSF results when heated at pH 3.5 and below (data not shown). The 
ANS, DSC and DSF data are discussed below and the SLS data for the three mAb 
samples are provided in Supplementary Figure S3.  
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The thermal melting curves for the native (black), partially (green), and 
fully deglycosylated (red) mAbs in the presence of ANS are shown in Figure 4.  
At 10 
0
C, at all pH values tested, the fully deglycosylated IgG1 has the highest 
ANS intensity value, followed by the partially deglycosylated IgG1. The ANS 
intensity differences between the three IgG1 glycoforms at 10 
0
C decreases as the 
pH increases. As the temperature is increased, two transitions are evident for the 
three IgG glycoforms at lower pH with only a single transition observed at higher 
pH values. The loss of the first transition occurs at pH 5.0, 5.5, and 6.0 for the 
native, partially deglycosylated and the fully deglycosylated IgG1 mAbs, 
respectively. The second thermal transition temperature seems to be less affected 
by the glycosylation state of the mAbs, since the three samples display similar 
transition temperatures (~68C at pH 4.5-6.0 and ~65C at pH 4.0).   
Figure 5 shows DSC thermograms of the three IgG1s at pH 4-6. The 
second and third endothermic peaks observed by DSC are very similar in terms of 
melting temperatures (74 
0
C and 82.5 
0
C, respectively). The first endothermic 
peak onset temperature, however, shows both a solution pH and glycosylation 
pattern dependence. In the pH range of 4 to 5, the transition onset temperature 
initiates earlier in the case of the deglycosylated IgG, followed by the partially 
deglycosylated and then the native IgG1. The latter two samples show similarity 
in their onset temperature, except at pH 4.5 where the partially deglycosylated 
IgG1 seems to be less stable than the native molecule. At pH 5, the first peak 
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starts merging with the second peak for both the native and partially 
deglycosylated IgGs, ultimately forming a shoulder. The first peak for the fully 
deglycosylated mAb, however, remains completely separated from the second.  
At higher pH values of 5.5 and 6, the first transition for both the native and the 
partially deglycosylated IgG1 forms are completely merged into the second peak, 
while the first transition in the fully deglycosylated IgG form remains separated 
from the other thermal transition peaks at pH 5.5.  
Using SYPRO orange as an extrinsic dye which shows increased 
fluorescence upon exposure to more apolar environments such as those associated 
with structural alterations in proteins, the thermal stability of the different IgG1 
samples as a function of pH and temperature was followed (Figure 6). Among the 
three IgG1 mAb samples and pH values examined, a major transition at 70 
0
C was 
consistently observed except for the partially deglycosylated IgG1 at pH 4, in 
which the observed transition is very broad and is seen at a lower temperature (62 
0
C). Multiple additional transitions (prior to the main transition) are evident for 
the three IgG1 samples at pH 4.0. A destabilization effect due to carbohydrate 
removal is evident since both the partially and fully deglycosylated IgG1 forms 
start unfolding at ~28 
0
C compared to the native IgG at ~46 
0
C. At pH 4.5 and 5.0, 
an initial transition is noted at a lower temperature for the partially deglycosylated 
compared to the native IgG1 although they peak at about the same temperature.  
The presence of the multiple transitions for the fully deglycosylated IgG1 at pH 
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4.5 and 5.0, indicates more structurally disrupted states than the other mAb 
samples at lower temperatures. At pH 5.5 and 6.0, two of the IgG1 forms show a 
single major structural transition, with the fully deglycosylated form also 
manifesting a pre-transition at pH 5.5.   
Using the results obtained from the four techniques described above, 
EPDs and radar charts were generated for the three IgG1 samples (Figure 7).  
Comparing the EPDs of the native (Figure 7A), the partially deglycosylated 
(Figure 7B), and the fully deglycosylated proteins (Figure 7C), the three EPDs 
share a common blue and green region. The blue region (based on separate 
evaluation of the data) signifies the region where the protein is in its stable, 
native-like state. The green color defines the region where the protein is in a 
structurally altered state. A third region appears in all the three EPDs, but with 
different colors and different intensities, corresponds to aggregation/precipitation 
of the protein. Comparing the blue (native structure) region across the three IgG1 
glycoforms at pH 5.5 and 6.0, the native and the partially deglycosylated IgG1 
samples have the same transition temperatures near 64 
0
C. The fully 
deglycosylated IgG1, however, starts its transition at lower a temperature (59 
0
C).  
At pH 5.0, the native and the partially deglycosylated IgG1 forms show a 
transition at 63 
0
C and 61 
0
C, respectively.  For the fully deglycosylated IgG1 at 
pH 5.0, additional color elements are observed indicating the existence of a 
partially unfolded, conformationally disrupted state at this pH (see the ANS and 
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DSF data in Figures 4 and 6, respectively).  At pH 4.0 and 4.5, the native IgG1 is 
less stable, with structural transitions at 50 and 55 
0
C, respectively. The partially 
deglycosylated IgG1 at pH 4 and 4.5 develops an additional light blue region, 
consistent with the existence of a partially unfolded state. (See the ANS data in 
Figure 4). The fully deglycosylated IgG1 at pH 4.5 shows a more structurally 
disrupted state compared to the other IgG1 forms, while an additional green 
region is observed for the fully deglycosylated IgG1 form at pH 4.0, indicating 
the existence of the extensively structurally altered state even at lower 
temperatures.   
Radar charts were generated from the same data as shown on the right side 
of Figure 7. Spanning the same pH and temperature range examined with colored 
EPDs, similar regions were identified for the different IgG1 glycoforms indicating 
the existence of different conformational states (in the radar plots, structural 
transitions were identified by clustering analysis with k=3 as described in the 
methods section).  The native-like, stable region for the untreated, control mAb 
(Figure 7A), the partially deglycosylated mab (Figure 7B), and the fully 
deglycosylated protein (Figure 7C) are depicted as dot-like entities (minimal 
structural transitions) and occupy 67, 52 and 40% of the radar chart’s  total area, 
respectively. Based on this simple analysis of the areas in the radar plots 
representative of native-like, stable form of the mAb, the effect of glycosylation 
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on IgG1 conformational stability is readily evident, with the decreased area 
qualitatively proportional to the enzymatic truncation of sugar moieties.     
 
3.4 Discussion 
 In this study, a direct comparison of the structure and conformational 
stability of an IgG1 mAb and its truncated glycoforms was performed with a 
variety of biophysical techniques, over a wide range of solution conditions. Data 
was also analyzed with two vector based technologies. The different glycoforms 
were prepared by enzymatic treatments. Mass spectrometric analysis of the 
reduced IgG1 mAbs (Table 1) directly demonstrated that the partial and full 
deglycosylation was successful since the measured molecular weights of the 
heavy chain of the mAb glycoforms were in close proximity to the expected 
values. The native mAb contained the expected mixture of glycan structures for 
SP20 cells, in which the G2F/G1F, G1F/G1F and G2F/G0F glycosylation patterns 
are the dominant glycosylated forms as described elsewhere.
43
 The partially 
deglycosylated mAb, produced by enzymatic treatment with Endo F2, contained a 
Fucose-GlcNac as a major glycan species structures consistent with the theoretical 
(average) mass. The presence of the fully deglycosylated protein, achieved by 
digesting with PNGase F, was evident from MS analysis (Table 1), where 
complete removal of the glycan and subsequent deamidation of the backbone Asn 
to Asp, was achieved as a result of the enzymatic reaction.   
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 The destabilizing effects of removing the N-linked glycan in the CH2 
domain of the Fc region of IgGs has previously been demonstrated by selected 
techniques under certain conditions. In this regard, the ability of EPDs and radar 
charts to detect changes in conformational stability due to differences in post-
translational modifications of a protein was examined in this work in a “model 
system” using three different glycoforms of an IgG1 mAb. Although this work 
covered a wider range of solution conditions, experimental techniques and data 
visualization approaches, some of the conditions examined here overlap with 
previous studies. The results with the IgG1 mAb of this work are consistent with 
previous reports with other IgG1 antibodies.  For example, as a result of complete 
or partial removal of the CH2 domain N linked glycan, destabilization of the CH2 
domain of an IgG1 has been shown by DSC. 
22, 26, 30, 31, 33
 In addition, an increase 
in fluorescence intensity spectra using intrinsic (Trp) and extrinsic (SYPRO 
orange dye) fluorescence spectroscopy was seen with full deglycosylation.
33  
Differential scanning fluorimetry (DSF) has been used to evaluate conformational 
stability differences of an IgG1 in different formulation buffers.
23
 The effect upon 
complete or partial removal of the N-linked glycan on the conformational stability 
of purified Fc proteins has also recently been evaluated using DSC,
21, 27, 28
 as well 
as CD and extrinsic (ANS) fluorescence spectroscopy.
27
  Results from DSC 
indicated a destabilization effect on the CH2 domain of the Fc protein upon 
complete or partial deglycosylation, while results from CD and extrinsic 
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fluorescence indicated a significant destabilization effect under acidic conditions 
and less of an effect at neutral to basic pH.  
The results of this work demonstrate a two-step methodology to evaluate 
differences in the conformational stability between several mAb glycoforms.  
First, “standard” EPD data analysis was used to screen mAb conformational 
stability using a variety of methods that probe different aspects of structure over a 
wide range of an environmental stresses (e.g., temperature and pH). Second, 
based on these initial results, an additional evaluation was conducted using the 
most sensitive experimental methods, with a focus on a narrower range of 
environmental conditions (near values associated with structural changes in the 
protein), using a combination of EPDs and radar charts for data visualization. For 
example, when comparing the untreated to the fully deglycosylated IgG1, a 
noticeable destabilization effect was first evaluated over a wide range of pH and 
temperature conditions by a variety of biophysical techniques (Figures 1 and 2).  
This initial evaluation showed the destabilization effects under mildly acidic 
conditions with some variability between the different analytical techniques in 
terms of their ability to detect structural changes as a result of deglycosylation.  
Based on these results, data were collected under “zoomed-in” conditions 
focusing on an optimal pH range (4.0-6.0 in 0.5 increments), where notable 
structural changes are detected, combined with 1.25 
0
C temperature steps to 
improve resolution (over the initially used 2.5 
0
C increments). We also 
145 
 
implemented the most sensitive analytical methods including ANS fluorescence 
spectroscopy, DSC, DSF and light scattering (LS). In addition, we added a 
partially deglycosylated mAb glycoform to better assess the sensitivity of this 
methodology.  The “zoomed-in” EPDs and radar charts from these three IgG1 
glycoforms (Figure 7) clearly reflect differences in the major structural variations 
between the three samples.  Radar charts have the advantage of reflecting the 
individual technique(s) which reflect the structural change at an identifiable site in 
the diagram. For the three mAb glycoforms studied, radar charts clearly point to 
an ANS-DSF influence in detected structural changes associated with region II, 
with LS becoming a major tool for monitoring aggregation (Region III) at higher 
temperatures.  
Although this work demonstrates the ability to compare conformational 
stability trends across mAb samples of known glycosylation content, the 
generation of EPDs and Radar charts for more formal evaluations such as 
regulatory comparability studies currently has practical limitations. For example, 
although visualization and rank ordering of structural transitions between samples 
is clearly useful for semi-qualitative comparisons of conformational stability, it 
still requires expert analysis by individual scientists of the individual biophysical 
data sets to confirm (and if necessary adjust) readouts from the initial clustering 
analysis. This is due to a combination of potential effects including noise in raw 
data, propagation of error when combining data sets across different instruments 
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and experiments, and limitations of clustering analysis.
51 
Ongoing work in our 
laboratory is evaluating and addressing these topics including more advanced 
mathematical treatments to potentially allow for statistical comparisons and 
independence from a separate expert review. For example, comparative signature 
diagrams are an alternative approach recently described 
53 
to statistically compare 
differences in spectral readouts from different instruments when evaluating two 
protein samples across different temperatures and pH values.  
In summary, this work combines data sets from multiple biophysical 
techniques that monitor different aspects of a protein’s higher-order structural 
stability as function of environmental stress (e.g., secondary structure by CD, 
tertiary structure by fluorescence spectroscopy, quaternary structure and 
aggregation by light scattering). Data visualization by EPDs and Radar charts 
allows for convenient and rapid analysis of these large biophysical stability data 
sets. We also incorporated conformational stability data from DSC and DSF in 
EPD and Radar charts construction, for the first time, due to the sensitivity of 
these two methods in detecting more subtle structural stability differences 
between the different mAb glycoforms across different solution conditions. By 
assessing conformational stability as a function of environmental stress (pH, 
temperature), subtle differences in structural integrity may potentially be detected 
when these differences are not readily apparent when monitored using lower 
resolution methods under non-stressed conditions (analysis at low temperature at 
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neutral pH). Thus, evaluation of conformational stability differences may not only 
be an effective surrogate to monitor subtle differences in higher order structure 
between protein samples as part of formulation development, but also a useful 
complement to traditional accelerated stability data often used in analytical 
comparability studies. 
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Table 1: Mass spectrometry results of the heavy chain region of reduced samples 
of the IgG1 mAb. First column shows the masses of the PNGase F and Endo F2 
treated IgG1 mAb obtained from MS analysis along with the masses measured for 
the two most abundant glycoforms (G0F and G1F) of the untreated mAb. The 
second, third and fourth columns show observed change in mass, predicted 
change in mass, and modification expected due to enzymatic treatment of the 
IgG1 mAb, respectively. 
 
IgG1 
Glycoform 
Heavy 
Chain 
(Da) 
Δ mass 
observed 
(Da) 
Δ mass 
predicted 
(Da) 
Modification of 
Asn 297 
 
PNGase F treated  
 
49168.3* 
 
- 
 
- 
 
Deglycosylation,  
N → D 
 
Endo F2 treated  
 
49516.8 
 
+348.5 
 
+348.3 
 
+GlcNAc-Fucose 
 
Untreated:** 
    
 
G0F glycosylated 
 
50612.5 
 
+1445 
 
+1444.6 
 
+G0F 
 
G1F glycosylated 
 
50774.7 
 
+1607 
 
+1606.5 
 
+G1F 
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*The theoretical mass of the nonglycosylated mAb heavy chain is 49167.3 Da. 
**G0F, G1F are two main peaks used to follow deglycosylation (Supplemental 
figure 4) 
Abbreviations: N: Asparagine, D: Aspartic acid, GlcNAc: N-acetylglucosamine, 
F: Fucose, G: Galactose, G0F: GlcNAc2Man3GlcNAc2Fuc, G1F: 
GalGlcNAc2Man3GlcNAc2Fuc. 
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Figure 1:  
     
Biophysical characterization of the untreated (control) IgG1 mAb as a function of 
temperature and pH. (A) CD spectra at 10 
0
C, (B) CD intensity change at 217 nm 
with temperature, (C) ANS spectra at 10 
0
C, (D) ANS melting curve at 486 nm,  
(E) Fluorescence intensity vs. temperature, (F) Fluorescence peak position 
changes with temperatures, (G) Static light scattering intensity change with 
temperature, and (H) empirical phase diagram analysis of data. Data shown for 
n=3 measurements. 
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Figure 2:  
       
Biophysical characterization of PNGase treated, fully deglycosylated IgG1 mAb 
as a function of temperature and pH. (A) CD spectra at 10 
0
C, (B) CD intensity 
change at 217 nm with temperature, (C) ANS spectra at 10 
0
C, (D) ANS melting 
curve at 486 nm, (E) Fluorescence intensity vs. temperature, (F) Fluorescence 
peak position changes with temperatures, (G) Static light scattering intensity 
change with temperature, and (H) empirical phase diagram analysis of data. Data 
shown for n=3 measurements. 
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Figure 3:  
       
Empirical Phase Diagram (EPD) and Radar Chart analysis of the conformational 
stability of IgG1 mAb samples. (A) EPD of untreated (control) IgG1, (C) radar 
chart of untreated (control) IgG1, (B) EPD of fully deglycosylated IgG1, and (D) 
radar chart of fully deglycosylated IgG1. The temperature ramp was in 1.25C 
increments.  
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Figure 4:  
     
Normalized ANS fluorescence intensity change as a function of temperature in 
the presence of untreated (control) IgG1 (black line), partially deglycosylated 
IgG1 (green line), and fully deglycosylated IgG1 (red line) from pH 4 to 6. 
Normalized results were generated by fitting the data to be equal to 1 at the 
maxima and to 0 at the minima for incorporation into the EPDs and radar charts. 
Curves shown here are averages of three runs. 
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Figure 5:  
     
Differential scanning calorimetry (DSC) analysis of untreated (control) IgG1 
(black line), partially deglycosylated IgG1 (green line), and fully deglycosylated 
IgG1 (red line) from pH 4 to 6. Normalized heat capacity changes were generated 
by fitting the data to be equal to 1 at the maxima and to 0 at the minima for 
incorporation into the EPDs and radar charts. Curves shown here are averages of 
three runs. 
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Figure 6:  
      
Differential scanning fluorimetry (DSF) analysis of untreated (control) IgG1 
(black line), the partially deglycosylated IgG1 (green line), and the fully 
deglycosylated IgG1 (red line) from pH 4 to 6.  Normalized results were 
generated by fitting the data to be equal to 1 at the maxima and to 0 at the minima 
for incorporation into the EPDs and radar charts. Curves shown here are averages 
of three runs. 
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Figure 7:  
   
Empirical Phase Diagram (EPD) and Radar Chart analysis of the conformational 
stability of IgG1 mAb samples.  Panel A shows the EPD (left) and the radar chart 
(right) for the untreated (control) IgG1. Panel B shows the EPD (left) and the 
radar chart (right) for the partially deglycosylated mAb due to Endo F2 treatment.  
Panel C shows the EPD (left) and the radar chart (right) for the fully 
deglycosylated mAb due to PNGase F treatment.   
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Supplemental Figure S1:  
   
Biophysical characterization of untreated (control) IgG1 mAb showing (A) CD 
spectra at 10 
0
C, (B) CD intensity change at 217 nm with temperature, (C) ANS 
spectra at 10 
0
C, (D) ANS melting curve at 486 nm, (E) Fluorescence intensity 
and peak position changes with temperatures, and (G) Static light scattering 
intensity change with temperature. Temperature ramp was in 1.25C increments.  
Curves shown here are averages of three runs.   
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Supplemental Figure S2:               
   
Biophysical characterization of fully deglycosylated IgG1 mAb showing (A) CD 
spectra at 10 
0
C, (B) CD intensity change at 217 nm with temperature, (C) ANS 
spectra at 10 
0
C, (D) ANS melting curve at 486 nm, (E) Fluorescence intensity 
and peak position changes with temperatures, and (G) Static light scattering 
intensity change with temperature. Temperature ramp was in 1.25C increments.  
Curves shown here are averages of three runs. 
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Supplementary Figure S3:          
   
Static light scattering intensity changes as a function of temperature for the 
untreated (control) IgG1 (black line), the partially deglycosylated IgG1 (green 
line), and the fully deglycosylated IgG1 (red line) from pH 4 to 6. Normalized 
results were generated by fitting the data to be equal to 1 at the maxima and to 0 
at the minima for incorporation into the EPDs and radar charts. Curves shown 
here are averages of three runs. 
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Chapter 4 
 Global physical stability assessments of IgG1-Fc 
proteins:  effects of glycosylation site occupancy 
and site 297 charge variations  
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4.1 Introduction 
 Monoclonal antibodies (mAbs) are well established as the leading class of 
protein-based drugs due to their high target specificity and long half lifes.
1, 2 
The 
majority of mAbs developed to date are IgG1proteins, consisting of four 
polypeptide chains (two heavy and two light chains) that arrange into 12 Ig 
domains that form into a Y-shaped molecule with two antigen binding (Fab) 
regions and one crystallizable (Fc) region. The homodimeric, horseshoe shaped, 
Fc region contains two interacting CH3 domains in the C-terminus end and two 
CH2 domains in the N-terminus end of the molecule. The two CH2 domains 
interact with each other through two buried N-linked glycosylation sites located at 
Asn 297 of each CH2 domain.  
 Glycosylation of the Asn 297 residue is one of the most common post-
translational modifications found within mAbs. In the past few years, we have 
seen rapid growth in our understanding of the role of glycosylation in with regard 
to both biological activity and pharmaceutical properties. Conformational changes 
of the CH2 domain, as a result of fully or partially removing the glycan residues, 
have been found responsible for altering the functionality 
3
, stability 
4-7
 (chemical 
and physical) and pharmacokinetic profile 
8
 of various mAbs. Additionally, 
protease resistance (using papain) has been shown to be significantly lowered in 
deglycosylated mAbs.
9-10
 These observations have been attributed to 
conformational differences due to the loss of both glycan-glycan and glycan-
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protein backbone non-covalent interactions upon deglycosylation, this results in 
the deglycosylated mAb to adopt a more open conformational state. 
   Mass spectrometric analyses of glycopeptides from mAbs have revealed 
significant heterogeneity in terms of glycosylation patterns of both currently 
marketed mAbs and those under development, depending on a variety of factors 
including the antibody type, expression systems and cell culture conditions.
11-15
 
Among these glycoforms are the high mannose (HM) glycans consisting of 3 to 
12 mannose units connected to two core GlcNAc units (N-acetyl glucosamine). In 
one study, an analysis of the glycan heterogeneity in Rituximab (a currently 
marketed drug for the treatment of non-Hodgkin’s lymphoma) revealed that 1.7-
5.4 % of the glycans present were a HM nature.
 16
 Mabs containing HM glycans 
are known to have faster clearance time compared to glycans having either 
GlcNAc, galactose or sialic acid units at the termini of the polysaccharide.
17, 18
 
The effect of having enriched or depleted levels of HM IgG1 within a 
heterogeneous mixture of IgG1 glycoforms was shown to not affect the physical 
stability of the mAb preparation.
19 
Asymmetric mAb glycosylation (single arm 
glycosylation) has been reported for an IgG1 containing a single glycosylation in 
the Fab region.
20
 This results in the IgG1 losing its divalent binding capacity to its 
antigen. Asymmetrically glycosylated IgG1 in the CH2 domain was characterized 
by S Ha et. al. (2011) 
21
 with functional and stability differences between the 
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asymmetrically and the fully glycosylated IgG1 reported as a result of 
conformational changes in the CH2 domain. 
  In this work, IgG1-Fc glycoforms containing well defined, homogeneous 
glycosylation patterns, produced from a Pichia pastoris yeast expression system 
followed by purification and specific enzymatic treatments, were utilized to more 
directly address the effect of glycosylation site occupancy and amino acid 
substitution (at Asn 297, the N-linked glycosylation site in CH2 domain) on the 
structural integrity and conformational stability of an IgG1-Fc. The physical 
stability of this series of Fc glycoproteins was examined by high throughput 
biophysical analysis using multiple analytical techniques combined with data 
visualization tools (empirical phase diagrams or EPDs and radar charts).  By 
using large physical stability data sets acquired from multiple high throughput 
low-resolution biophysical techniques as a function of environmental stresses (pH 
and temperature), differences in the structural integrity and conformational 
stability in this series of Fc glycoforms were detected. These stability trends, as a 
function of site occupancy and amino acid substitution in the Fc glycoforms, were 
not necessarily observed using the same biophysical techniques under non 
stressed conditions. As a result, evaluating the conformational stability 
differences between the different IgG1-Fc glycoproteins may serve as a surrogate 
to monitor differences in higher-order structure between IgG1-Fc samples, an 
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approach that could potentially be useful for analytical comparability studies.  
  
4.2 Materials and Methods 
4.2.1 Materials 
 Both the human IgG1-Fc sequence (comprising 446 amino acids with a 
theoretical molecular weight of 50132.92 Da) and a point mutant of the IgG1-Fc 
protein (with 446 amino acids and a theoretical molecular weight of 50160.96 Da) 
were prepared and expressed using a yeast expression system.
22
 The 
nonglycosylated variant of the IgG1-Fc was made by mutating the N-linked 
glycosylation site at Asn 297 (EU numbering) to Gln 297, thus eliminating the 
Asn-X-Thr glycosylation site within the CH2 domain. This was achieved through 
PCR site-directed mutagenesis, followed by transfecting the yeast with the 
mutated plasmid after sequencing it for verification as described elsewhere.
22
 
After expression, purification and concentration of the different IgG1-Fc 
glycoproteins (as described below), samples were dialyzed into the storage buffer 
(10 % sucrose, 20 mM histidine, pH 6.0) and frozen at -80 
0
C in aliquots of 0.5 
mL. For the initial characterization of the IgG1-Fc proteins (SDS-PAGE, mass 
spectroscopy and SE-HPLC), samples were analyzed without further dialysis. For 
biophysical characterization (far-UV circular dichroism, intrinsic/extrinsic 
fluorescence spectroscopy and turbidity measurments), samples were dialyzed 
against 20 mM citrate phosphate buffer (pH 4.0-6.0, 0.5 increments) and adjusted 
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to an ionic strength of 0.15 with NaCl. Other chemicals and reagents not 
described below were obtained from Sigma–Aldrich (St. Louis, MO), Fisher 
Scientific (Pittsburg, PA), Invitrogen (Carlsbad, California) or Becton Dickinson 
and Company (Franklin Lakes, NJ).   
 
4.2.2 Methods 
4.2.2.1 Expression and purification of the IgG1-Fc proteins 
 IgG1-Fc proteins were cloned and then expressed using a methylotrophic 
Pichia pastoris yeast expression system as described previously.
22
 Yeast were 
first grown at 25 
0
C for 72 hr in 2 mL of growth media composed of tissue culture 
media containing 1% yeast extract, 2% peptone, 5% glycerol and 100 µg/mL 
Zeocin (YPD/Zeocin culture media). This step was followed by inoculating the 2 
mL culture into 50 mL of YPD/Zeocin culture media for another 72 hr at 25 
0
C. 
The 50 mL culture was then inoculated into a 1 L spinner flask containing YDP 
media, 0.00004% biotin and 0.004% histidine. The media was kept at 25 
0
C and 
aerated at a rate of 1 L/min through a sterilized glass sparger connected to 0.2 µm 
sterile filter. Twenty-five mLs of methanol were added in a drop wise fashion 
every 12 hr for a total period of 72 hr. 
  This 1 L of yeast containing culture media supernatant was harvested by 
centrifugation at 7000 rpm for 15 min at 4 
0
C followed by pH adjustment to 7.0 
with 0.1 M NaOH or 0.1 M HCl , which was kept for ~7 hr at 4 
0
C. The 
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supernatant was then filtered and loaded onto a protein G column pre-equilibrated 
with 20 mM sodium phosphate that was adjusted to pH 7.0. Protein G column was 
packed in-house to make a 10 mL bed volume as described elsewhere.
23
 The 
IgG1-Fc protein was then eluted using a 100 mM glycine solution adjusted to pH 
2.7, and subsequently dialyzed against 20 mM sodium phosphate buffer adjusted 
to pH 7.0 at 4 
0
C overnight. 
 To separate the differentially glycosylated forms of the IgG1-Fc, two 
different purification methods were used. First, a cation exchange 
chromatography (CEX) method using ProPac WCX-10 semi-preparative (9 x 250 
mm) column, (Dionex, Sunnyvale, CA) was developed. The column was 
equilibrated with Buffer A (20 mM sodium acetate pH 4.8) for 5 column volumes 
(CV). The protein G purified IgG1-Fc solution was then loaded onto the cation 
exchange column. Chromatographic separation was then performed in a linear 
gradient from 0 to 1M NaCl (10 CV) using Buffer B (20 mM sodium acetate pH 
4.8, 1 M NaCl). Two mL fractions were collected throughout the gradient. Peaks 
were observed and collected corresponding to the diglycosylated and 
monoglycosylated IgG1-Fc proteins (which are primarily used in this study and 
represented ~80%, and 15% of the material, respectively) in addition to an 
aglycosylated IgG1-Fc form (~5% of the material). After analyzing column 
fractions with SDS-PAGE to confirm glycoprotein identity, the two collected IgG 
178 
 
Fc glycoforms were concentrated, dialyzed against 10% sucrose, 20 mM histidine 
pH 6.0 and frozen at -80 
0
C until further use. 
 A second, scaled-up purification process involved a hydrophobic 
interaction chromatography (HIC) method using a HiScreen fast flow phenyl 
sepharose column (4.7 mL bed volume and 7.7 X 100 mm bed dimensions, GE 
Healthcare) was adopted. The HIC column was equilibrated with Buffer A (20 
mM sodium phosphate, 1M ammonium sulfate pH 7.0) for at least 5CV. The 
protein G purified IgG1-Fc solution was then loaded onto the HIC column. 
Chromatographic separation was then conducted in a linear gradient from 1.0 to 0 
M ammonium sulfate (10 CV) using Buffer B (20 mM sodium phosphate, pH 
7.0). Ten mL fractions were collected throughout the gradient. Two peaks were 
observed and collected corresponding to the diglycosylated and monoglycosylated 
glycoforms of the IgG1-Fc proteins. After analyzing column fractions with SDS-
PAGE, the collected glycoforms were concentrated, dialyzed against storage 
buffer (10% sucrose, 20 mM histidine pH 6.0) and frozen at -80 
0
C until further 
use.  
 The nonglycosylated (QQ) IgG1-Fc mutant protein was expressed using a 
methylotrophic Pichia pastoris yeast expression system in a similar fashion to 
that described above. Yeast containing culture media supernatant was harvested 
by centrifugation at 7000 rpm for 15 min at 4 
0
C followed by a pH adjustment to 
7.0 with 0.1 M NaOH or 0.1 M HCl. This product was kept for ~7 hr at 4 
0
C. The 
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supernatant was then loaded onto a protein G column and the nonglycosylated 
(QQ) IgG1-Fc protein was eluted using the same conditions as described above. 
Nonglycosylated (QQ) IgG1-Fc protein was also passed through phenyl sepharose 
column using the same conditions as described above. After analyzing column 
fractions with SDS-PAGE to confirm glycoprotein identity, the nonglycosylated 
(QQ) IgG1-Fc glycoform was concentrated, dialyzed against 10% sucrose, 20 
mM histidine pH 6.0 and frozen at -80 
0
C until further use. 
4.2.2.2 Deglycosylatation of Diglycosylated and Monoglycosylated IgG1-Fc 
proteins 
 The purified diglycosylated and monoglycosylated forms of the IgG1-Fc 
were deglycosylated using PNGase F enzyme (made in-house as described 
elsewhere).
24
 Samples in storage buffer were thawed, treated with PNGase F in a 
protein to enzyme ratio of 500:1 (w/w) and incubated for 6 hr at 25 
0
C.  .   
 
4.2.2.3 Electrospray Ionization-Mass Spectrometry 
 IgG1-Fc proteins were analyzed by electrospray ionization mass 
spectrometry (ESI-MS).  ESI spectra of reduced protein samples (15 mM 
dithiothreitol, pH 7.0, room temperature) were acquired on a SYNAPT G2 hybrid 
quadrupole / ion mobility / Tof mass spectrometer (Waters Corp., Milford, MA). 
The instrument was operated in a sensitivity mode with all lenses optimized on 
the MH+ ion obtained from Enkephalin. The sample cone voltage was 30eV. 
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Argon was admitted to the trap cell that was operated at 4eV for maximum 
transmission. Spectra were acquired at 9091 Hz pusher frequency covering the 
mass range from 100 to 3000 u and accumulating data for 1.5 seconds per cycle. 
Time to mass calibration was made with Nal cluster ions acquired under the same 
conditions. Samples were desalted on a reverse phase C4 column, 1 cm, 1 mm 
I.D. (Vydac, Midland, Canada, 300 A pore size. The 5 µm particles were packed 
by Micro-Tech Scientific) using a NanoAcquity chromatographic system (Waters 
Corp., Milford, MA). The solvents used were A (99.9% H2O, 0.1% formic acid) 
and B (99.9% acetonitrile, 0.1% formic acid). A short gradient was developed 
from 1 to 70% B in 4 min with a flow rate of 20 µl/min. Masslynx 4.1 software 
was used to collect the data. The MaxEnt 1routine was used for processing data to 
convert peaks of multiply charged protein ions into uncharged deconvoluted 
protein spectra. 
4.2.2.4 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE)  
 Samples were made by mixing 20 µg of the protein with 10µl of Sodium 
dodecyl sulfate. Five µl of dithiotheritol (50 mM) was added for sample 
reduction. Samples were then incubated at 80 
0
C for 2 min and loaded onto a 
NuPAGE 4-12 % Bis-tris gel (Invitrogen, Carlsbad, California) using 20x MES as 
a running buffer. The running time was 65 min at 160V. After the run, gels were 
rinsed with water, stained with Coomassie blue for an hour and then destained 
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using 10 % methanol, 10 % glacial acetic acid solution. Protein molecular weight 
standards (BIO-RAD, Hercules, CA) were loaded for molecular weight 
estimation. Bands densitometry measurements were performed using the imageJ 
program (NIH). Briefly, individual gel lanes were highlighted for analysis in 
which high band intensity corresponds to high peak area from which the purity of 
each sample was calculated as described in detail elsewhere.
25, 26
    
4.2.2.5 Western Blot analysis 
 After protein separation by SDS-PAGE, gels under reducing and non-
reducing conditions were transferred onto a polyvinylidene fluoride (PVDF) 
membrane (Bio-RAD, Hercules, CA) using 25 mM Tris, 192 mM glycine, 20 % 
(v/v) methanol buffer (pH 8.3). Non-specific binding was blocked using 5 % 
nonfat milk dissolved in Tris-buffered saline (pH 7.5) for 3 hr at 4 
0
C followed by 
the addition of an anti-IgG-Fc specific secondary antibody that was alkaline 
phosphatase labeled (Thermo scientific, Waltham, MA). The mixture was 
incubated overnight at 4 
0
C followed by washing the PVDF membranes with Tris-
buffered saline containing 0.05 % Tween 20. Protein bands were visualized by 
NBT/BCIP substrates (Thermo scientific, Waltham, MA) which yield an intense 
black/purple precipitate when reacted with alkaline phosphatase. 
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4.2.2.6 Size-Exclusion High-Performance liquid Chromatography (SE-
HPLC) 
 Experiments were performed using a Shimadzu high-performance liquid 
chromatography system equipped with a photodiode array detector and a 
temperature controlled autosampler. A Tosoh TSK-Gel Bioassist G3SWxL column 
(7.8 mm ID x 30.0 cm L) and a corresponding guard column (TOSOH 
Biosciences, King of Prussia, Pennsylvania) were used for Fc protein 
characterization. Initially, the SEC column was equilibrated for at least 10 CV 
with the running buffer (200 mM sodium phosphate, pH 6.8) and under the 
running conditions (30 
0
C column temperature and 0.7 mL/min flow rate). Gel 
filtration molecular weight standards (Bio-Rad, Hercules, CA) were used for 
column calibration. Protein samples at a concentration of 0.5 mg/ml were injected 
in a volume of 35 µL, and a 30 min run time was used. Peaks quantification was 
carried out using instrument software. 
 
4.2.2.7 Far-UV Circular Dichroism Spectroscopy 
 Far-UV CD spectra ranging from 260 to 200 nm were collected, with a 
resolution and bandwidth of 1 nm, using a Chirascan specrtopolarimeter (Applied 
Photophysics, Surrey, United Kingdom) equipped with four cell holder and peltier 
type temperature controller. For all measurements, 200 µl of a protein 
concentration of 0.2 mg/ml was placed into a 0.1 cm path length quartz cuvette.  
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Proteins were run in triplicate and corresponding buffer blanks were run and 
subtracted from each sample. 
4.2.2.8 Intrinsic (Trp) Fluorescence Spectroscopy  
 Intrinsic (Trp) fluorescence was measured using a Photon Technology 
International (PTI) Quantum master fluorometer (New Brunswick, New Jersey) 
equipped with a four position cuvette holder and a turreted peltier temperature 
controller. A protein sample (200 µl) of 0.2 mg/ml in 0.2 cm path length quartz 
cuvette was used. Samples were excited at 295 nm with emission spectra 
collected from 310 to 400 nm at a resolution of 1 nm, collection rate of 1 nm/sec, 
and an integration time of 1 sec. Temperature was raised in increments of 1.25 
0
C 
from 10 to 90
0
C. The slit widths used for both excitation and emission were 6 nm. 
Fluorescence peak position changes were determined by a center of spectral mass 
“MSM” method using Origin™ 7.0 software. This method shifts the actual peak 
position approximately 10 nm, but produces more reproducible values of the 
wavelength maximum. Proteins samples were run in triplicate and corresponding 
buffer blanks were run and subtracted from each sample spectrum. 
4.2.2.9 Differential Scanning Fluorimetry (DSF)  
 DSF measurements were performed using MX3005P QPCR system 
(Agilent Technologies). A protein concentration of 0.2 mg/ml in a total sample 
volume of 100 µl was used. SYPRO™ orange dye purchased from Invitrogen, 
Inc. (Carlsbad, CA) supplied in a concentrated form (5000x) dissolved in DMSO 
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was diluted to 40x and then added to the protein samples to achieve 1x dye 
concentration for measurements. Using FAM filter sets, the mixture was excited 
at 492 nm and the emission intensity change at 516 nm was followed. The 
temperature was raised from 25 to 90 
0
C using 60 
0
C/hr as a heating rate and 1 
0
C 
as a step size. Data were transferred to Excel software (Microsoft, Redmond, 
WA) for data analysis. Proteins samples were run in triplicate and corresponding 
buffer blanks were run and subtracted from each sample. 
4.2.2.10 Turbidity measurments 
 Temperature induced protein aggregation was followed using a Cary 100 
UV-Visible spectrophotometer (Varian Inc, Palo Alto, California) equipped with 
a 12 cell holder with peltier type temperature controller. A protein concentration 
of 0.2 mg/ml in a total volume of 200 µl was used in 1 cm path length quartz 
cells. For all measurements, a wavelength of 350 nm was used to monitor light 
scattering (optical density) and the temperature was raised in increments of 1.25 
0
C from 10 to 90 
0
C. Proteins samples were run in triplicate and corresponding 
buffer blanks were run and subtracted from each sample. 
4.2.2.11 Construction of Empirical Phase Diagrams (EPDs) and Radar 
Charts 
   The three-index Empirical Phase Diagram and Radar Chart data 
visualization methods were used to describe biophysical stability characteristics 
of the various Fc proteins. Detailed descriptions of the construction of both three-
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index EPDs and radar plots are published elsewhere.
27
 In this work, three 
biophysical data sets were used for data visualization: Sypro Orange fluorescence, 
Trp peak position fluorescence, and optical density at 350 nm. These three 
techniques were chosen for EPD construction because they displayed clear 
thermal transitions; in contrast, circular dichroism thermal stability data did not 
show clear transitions (data not shown). For the three index EPDs, the Sypro 
Orange fluorescence stability data were mapped to the color red, Trp fluorescence 
peak position stability data to the color green, and optical density stability data to 
the color blue. The combination of these RGB values produced a single color at 
each point in pH and temperature coordinates. For each technique and protein, the 
minimum value was mapped to the loss of the color component, and the 
maximum value was mapped to the full color intensity. The resulting color map 
was generated: The color black indicates minimum values of all three techniques, 
which can be interpreted as the structure closest to the native state (least amount 
of structural change). The green or red color appears within the three index EPD 
as the Trp fluorescence peak positions changes (displays red shift) or Sypro 
Orange binding increases, respectively. The blue appears when high turbidity is 
measured by optical density values at 350 nm. To determine common regions 
within the three index EPD, a k-Means clustering algorithm is first applied to each 
EPD to identify boundries of similarly color regions. The resulting clusters can 
scatter as small blocks of colors, especially over the structurally altered regions. 
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Then, using visual assessments and comparisons to the raw physical stability 
profiles for each instrument, only certain commonly observed clusters were 
selected. Radar charts were generated to display similar characteristics (changes 
in readouts from each of the three biophysical instruments) for each of these 
commonly observed clusters. The same three analytical techniques and min-max 
range were used for preparing radar charts. The minimum value was mapped to 
the center of the radar chart, while the maximum value was mapped onto the outer 
circumference. All values within the cluster were averaged from multiple runs and 
values were connected to yield a final polygon to represent a specific structural 
state. 
 
4.3 Results 
4.3.1 Initial characterization of the different IgG1-Fc glycoforms 
  A pictorial presentation of the five different types of IgG-Fc proteins 
(diglycosylated, monoglycosylated and three different non-glycosylated forms) 
examined in this study is presented in Figure 1. High mannose (HM) IgG1-Fc 
glycoforms were expressed in yeast and purified using a combination of Protein G 
and either cation exchange or hydrophobic interaction chromatography. First, an 
IgG1-Fc bearing HM glycans at both CH2 domains (~80 % of the amount 
purified) designated diglycosylated IgG1-Fc was identified. Second, an IgG1-Fc 
containing HM glycan at a single CH2 domain (~15 % of the amount purified) 
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labeled monoglycosylated IgG1-Fc was found. In addition, IgG1-Fc proteins with 
variations in amino acid residues at site 297 of the CH2 domain were prepared. 
IgG1-Fc with Asp/Asp and Asp/Asn residues were made by treating the 
diglycosylated and monoglycosylated IgG1-Fc proteins with the enzyme PNGase 
F. PNGase F cleaves the glycan residue(s) and converts Asn to Asp, adding one or 
two negative charges to the IgG1-Fc molecules. Finally, a N297Q IgG1-Fc 
mutant, with Asn/Asn substituted with Gln/Gln through site directed mutagenesis, 
was also expressed and purified (Figure 1).  
  To confirm the correct masses for each of the purified IgG1-Fc 
glycoproteins, mass spectrometric analysis of reduced samples was performed 
(Table 1 and supplementary Figure S1). The nonglycosylated (QQ) Fc mutant had 
a mass of 25,077 Da, in close agreement (+ 3 Da) with the mass predicted from 
the sequence. MS analysis of diglycosylated IgG1-Fc protein revealed a mass of 
26,766 Da reflecting a predominant Man 8 glycosylation form, in close agreement 
to the predicted mass (26,769.5 Da). Additional, peaks with additional one, two, 
three and four mannoses were also present indicating glycoforms with 9, 10, 11 
and 12 mannoses, respectively, but in lower abundance (see supplemental Figure 
S1).  The monoglycosylated IgG1-Fc protein had two distinct peaks with masses 
of 25,062 and 26,766 Da in agreement with nonglycosylated and Man 8 
glycosylated arms of the glycoprotein. A heavier peak reflecting the presence of 
Man 9 IgG1-Fc glycoform was detected as well (see supplemental Figure S1). 
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Upon PNGase F enzymatic treatment of the diglycosylated and monoglycosylated 
IgG1-Fc samples, a mass of 25,063 Da was observed for each protein indicating 
fully deglycosylated Fc proteins.  
 SDS-PAGE gel analysis for the IgG1-Fc samples under reducing 
conditions is shown in Figure 2A. The diglycosylated Fc protein showed a single 
band at around 28 kDa. Slightly lower MW of around ~ 26 kDa were observed, as 
expected, for both the nonglycosylated DD (PNGase treated) and nonglycosylated 
mutant (QQ) Fc proteins (in lanes 2, 3 and 5, respectively). Monoglycosylated Fc 
protein (lane 3) had two bands at ~28 and ~26 kDa confirming the presence of 
glycosylated and nonglycosylated IgG1-Fc arms. Upon PNGase F treatment of 
the monoglycosylated Fc, the glycosylated arm (previously seen at ~28 kDa) 
disappears and a major band is seen instead ~26 kDa. Both monoglycosylated 
(with and without PNGase treatment) have a second band at ~39 kDa. The purity 
of the IgG1-Fc protein samples (under denaturing conditions) was determined by 
densitometric analysis of reduced SDS-PAGE gels (Table 2). Diglycosylated, 
nonglycosylated DD and the nonglycosylated mutant (QQ) were determined to 
have ~97 % purity. The monoglycosylated Fc protein (and the corresponding 
nonglycosylated DN form derived from PNGase treatment of the 
monoglycosylated Fc) showed somewhat lower purity values of ~84% (see 
discussion section). Size exclusion high performance liquid chromatography (SE-
HPLC) was then used to evaluate purity (under non-denaturing conditions) to 
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determine if aggregates were present in IgG1-Fcs samples after purification 
(Figure 2B shows representative SEC chromatograms). The purity of the IgG1-Fc 
samples was determined, as shown in Table 2, and results indicate the Fc protein 
samples are primarily monomeric (91.1-96.6%) with some aggregates present 
across the IgG1-Fc samples (1.8-8.2%). The remaining area can be accounted for 
by the presence of small amounts of fragments at 0.2-2.0% (data not shown). The 
monoglycosylated Fc proteins contained ~3.4-4.0% aggregates and showed either 
similar or somewhat lower aggregate levels compared to the diglycosylated and 
nonglycosylated Fc samples (see Table 2).    
 
4.3.2 Structural integrity at ambient temperature conditions 
 The overall secondary structure of the five IgG1-Fc proteins was evaluated 
at 10 
0
C by far-UV circular dichroism (CD) analysis from 260 to 205 nm under at 
various pH conditions (Figure 3). The CD spectrum of the diglycosylated and 
nonglycosylated mutant (QQ) IgG1-Fc proteins show a clear minimum at 217 nm 
that is apparent under all pH conditions tested indicating a β-sheet rich structure, 
as expected from immunoglobulin folded domains. The same overall β-sheet rich 
secondary structure is seen for the nonglycosylated DD at pH 4.0-4.5, whereas, at 
pH 5.0, 5.5 and 6.0 a constant decrease in CD signal is observed indicating some 
alteration in the protein secondary structure under these pH conditions. For the 
monoglycosylated IgG1-Fc protein, a different CD spectrum is observed 
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compared to the other Fc protein samples with a positive hump present at 212 nm 
that increases in intensity as the solution pH increases. This could potentially be 
attributed to an increasing influence from type I β-turns. When the 
monoglycosylated IgG1-Fc protein was deglycosylated using PNGase F 
(nonglycosylated DN), more native-like structural features in the CD spectra were 
detected, in the form of a minimum at 217 nm, across all pH conditions examined. 
These results indicate the monoglycosylated Fc protein is in a structurally 
perturbed state, and that upon deglycosylation, the effect is at least partially 
reversible with the regaining of native-like secondary structure seen by CD 
(monoglycosylated vs. DN nonglycosylated forms of the Fc protein in Figure 3).  
The CD spectra intensity signals as a function of increasing temperature were 
monitored. Due to data noisy data, however, as well as the lack of intensity 
change as a function of temperature for many of the Fc proteins (e.g., 
monoglycosylated as well its deglycosylated form), the CD thermal melting 
curves were not further employed in this study (data not shown).    
 The structural integrity of the overall tertiary structure of the five IgG1-Fc 
proteins was then evaluated using intrinsic (Trp) fluorescence spectroscopy 
(Figure 4). Diglycosylated and nonglycosylated mutant (QQ) IgG1-Fc proteins 
manifest fluorescence spectra at pH 4.0, with relatively high peak intensities, and 
λmax values of 333.8 and 332.1 nm, respectively. As the pH is raised, the λmax 
starts shifting to lower wavelengths (with λmax values of 329.6 and 330.6 nm 
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accompanied by relatively lower peak intensity), indicating the average Trp 
residues in a more apolar environment, and presumably more folded state. For the 
nonglycosylated DD IgG1-Fc protein, the λmax does not shift to lower wavelength 
as the solution pH is raised, remaiing at ~333 nm, suggesting that deglycosylated 
protein remains in the same structure, presumably an effect due to deglycosylation 
and amino acid substitution (Asn to Asp at site 297). Monoglycosylated IgG1-Fc 
protein, however, shows a small red shift in λmax as a function of increasing 
solution pH, indicating potentially less stability at pH 6.0 (vs. pH 4.0), whereas 
the nonglycosylated DN behaves more like the diglycosylated and QQ 
nonglycosylated mutants it does show a noticeable blue shift in λmax as the pH is 
raised from pH 4.0 to 6.0 (~334 to ~330 nm). These intrinsic fluorescence 
spectroscopy results, similar to the CD results above, indicate that 
monoglycosylated Fc protein is in a structurally perturbed state, and that upon 
deglycosylation, the effect is at least partially reversible (see the data for 
monoglycosylated vs. DN nonglycosylated forms of the Fc protein in Figure 4 at 
pH 4.0 vs. pH 6.0).   
4.3.3 Physical stability of IgG1-Fc proteins as a function of pH and 
temperature   
The conformational stability of the tertiary structure of the five IgG1-Fc 
proteins was evaluated using a combination of intrinsic (Trp) fluorescence and 
extrinsic fluorescence (i.e., differential scanning fluorimetry, DSF) spectroscopy 
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(see Figure 5 A and B). Figure 5 shows the average results from three replicates 
while the same physical stability data are shown in Supplemental Figure S3 A and 
B with corresponding standard deviation error bars from triplicate measurements. 
The conformational stability of the five Fc proteins was first evaluated by 
following changes in λmax as a function of increasing temperature (Figure 5A). It 
should be noted that the λmax values in Figure 5A are shifted by about 10-15 nm 
compared to the actual values (see Figure 4), due to the use of a spectral central of 
mass method as described in the methods section. Diglycosylated and 
nonglycosylated mutant (QQ) both had relatively low λmax peak positions at the 
starting temperature across the pH conditions tested (~339-340 nm using the 
MSM method) with higher thermal stability being observed for the diglycosylated 
IgG1-Fc protein. The nonglycosylated DD IgG1-Fc protein, with λmax peak 
positions of ~340 nm, showed a subtle, steady increase in peak position as 
temperature was raised followed by a more dramatic increase in peak position. 
The monoglycosylated and nonglycosylated DN forms had λmax peak positions of 
~340-341 nm with little to no detectable shift in peak position as the temperature 
increases, except for the monoglycosylated Fc protein at pH 6.0 where a transition 
curve is detected (Figure 5A). In DSF analysis, SYPRO orange dye was used as a 
probe for detecting structurally disrupted proteins, seen in the form of increased 
fluorescence intensity upon exposure to apolar environments due to structural 
alternations and/or aggregate formation (See Figure 5B). Diglycosylated IgG1-Fc 
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was the most thermally stable protein manifesting two thermal transitions 
(presumably sequential unfolding events of the CH2 and CH3 domains). This was 
seen across most of the pH conditions tested (except at pH 4.0) with an observed 
increase in thermal stability as a function of increasing pH. Additionally, 
fluorescence peak intensity at the starting temperature in the range of pH 5.0-6.0 
is decreased compared to the values at the lower pH conditions. For the 
monoglycosylated Fc protein at pH conditions between 4.0 and 5.5, and 
nonglycosylated DN protein at pH between 4.0 and 5.0, single thermal transition, 
consistent with a more structurally disrupted CH2 domain. Two thermal 
transitions were seen for the nonglycosylated mutant (QQ) and the 
nonglycosylated DD Fc proteins under most of the pH conditions tested, except at 
pH of 4.0 and 4.5, again consistent with the presence of a more structurally 
altered CH2 domain under lower pH conditions compared to higher pH. 
 Temperature induced aggregation was evaluated by monitoring optical 
density changes at 350 nm as a function of increasing temperature and pH (Figure 
5C). Differences between the IgG1-Fc proteins were observed in terms of the 
onset temperature of aggregation as well as the profile of the optical density 
transitions. Diglycosylated IgG1-Fc protein did not show detectable thermal 
transitions in optical density across all pH conditions tested. The 
monoglycosylated Fc protein, on the other hand displayed a single transition in 
optical density at pH 4.0, 4.5 and 6.0 starting at 21, 33, and 76 
0
C, respectively, 
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whereas, at pH 5.0 and 5.5, two transitions were detected with the first transitions 
starting at 45 and 79 
0
C and the second at 52 and 75 
0
C, respectively. For the 
nonglycosylated mutant (QQ), a single thermal event of increasing optical density 
was detected at ~79 
0
C at pH 5.0-6.0, with no thermal transitions noted at lower 
pH values of pH 4.0 and 4.5. Similarly, the nonglycosylated DD Fc protein 
showed no detectable thermal transition at pH 4.0, a single thermal transition in 
optical density starting at 78 
0
C at pH 4.5, and at 82 
0
C for pH 5.0, 5.5 and 6.0. In 
contrast, the nonglycosylated DN Fc protein manifested two optical density 
thermal transitions under all pH conditions examined with increasing thermal 
stability being observed as a function of increasing pH. At pH 4.0, the 
nonglycosylated DN protein showed an increase in optical density starting from 
10 
0
C followed by a second major increase at 69 
0
C. At pH 4.5, 5.0 and 5.5, an 
initial increase in optical density was detected at 40, 46 and 52 
0
C, followed by a 
second increase at 75, 78 and 74 
0
C, respectively. Two adjacent transitions in 
optical density were seen at pH 6.0, with the first transition initiating at 57 
0
C 
followed by a second transition at 74 
0
C.    
4.3.4 Conformational stability evaluations using various data visualization 
techniques 
 Using the physical stability data acquired from differential scanning 
fluorimetry, intrinsic fluorescence spectroscopy (peak position), and turbidity 
measurments, three index EPDs (see Supplemental Figures S4-S8) and radar 
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charts (see Supplemental Figure S4-S8 and Supplementary Figure S9) were 
constructed for each of the individual IgG-Fc proteins. These supplemental 
figures show the contributions from each of the individual biophysical 
instruments to the observed changes in conformational integrity as a function of 
pH and temperature. For ease of comparison, a summary figure was constructed 
showing the overall results from each of the five individual IgG-Fc proteins 
merged into one display (Figure 6). The five color plots in Figure 6 highlight five 
regions with similar structural characteristics designated regions A-E, as observed 
in the three-index EPDs for the five different IgG1-Fc proteins with various 
glycosylation occupancy (diglycosylated, monoglycosylated) as well as the 
nonglycosylated forms of the Fc protein containing amino acid variations (QQ, 
DD and DN) in the CH2 domain. In addition, as shown in the legend box in Figure 
6, radar plots were prepared to better define the five different conformational 
regions (regions A through E) that can be observed in each of the five Fc proteins 
under the various pH and temperature conditions.    
Region A represents a state in which the protein exists in its most native-
like conformation. As shown in the radar chart legend in Figure 6, there are 
minimal changes in signals for each of the three biophysical techniques (intrinsic 
Trp and extrinsic SYPRO orange fluorescence spectroscopy as well as turbidity at 
OD 350nm), which results in a black color for region A as shown in the EPDs for 
the five Fc proteins in Figure 6.  For region B, there are small changes in the 
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signals from the biophysical instruments, which represents protein with a slightly 
altered conformation (minor increases in SYPRO orange fluorescence intensity 
and Trp fluorescence peak position) which manifest as a dark green color in the 
EPDs shown in Figure 6. Regions C and D represents more altered 
conformational states with either a substantial increase in SYPRO orange 
fluorescence intensity (Region C as a dark red color) or notable changes in Trp 
fluorescence peak position (Region D as a green color). Finally, Region E 
represents an aggregated state of the Fc protein with increased signal in optical 
density at 350 nm (see also the radar chart) as shown as a blue color in Figure 6.   
 A comparison of the IgG1-Fc proteins with variations in glycosylation 
occupancy (see the vertical direction in the three color plots on left side of Figure 
6) shows different degrees of structural integrity and conformational stability. At 
low temperatures, the diglycosylated Fc protein at pH 5.5 and 6.0 is present in a 
native-like structural state (black color, region A). A structural transition to a 
structurally altered state (dark red, region C) starts as Fc diglycosylated Fc protein 
reaches temperatures around 48 
0
C in this pH range. At lower temperatures in the 
pH range of 4.5 and 5.0, the diglycosylated Fc protein is present in a slightly 
altered conformation (dark green, region B), where it transitions to a more 
extensive altered structures at temperatures of 38 and 44 
0
C, respectively. At pH 
4.0 at all temperatures, the diglycosylated protein is present in this more 
structurally altered structural state. Diglycosylated protein did not show any 
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detectable aggregation by optical density measurements, thus no region E was 
observed in the EPD for the fully glycosylated Fc protein.  
 The nonglycosylated Fc mutant (QQ) at lower temperatures and at pH 5.5 
and 6.0 also shows a native like region (black color, region A). Thermal transition 
temperatures to the structurally altered region C (dark red color), however, initiate 
at lower temperatures (35 and 44 
0
C, respectively) compared to the diglycosylated 
protein (Figure 6). Additionally, the nonglycosylated mutant (QQ) at pH 4.5 and 
5.0 exists at a more extensive structurally altered conformational region, unlike 
the diglycosylated protein which shows a more native-like conformation in this 
pH range (B region, dark green). In addition, Region E (blue color), representing 
the Fc protein at an aggregated state is detected for the nonglycosylated mutant 
(QQ) at elevated temperatures in the pH range of 5.0 to 6.0.   
In comparison to the di- and non- glycosylated forms, the 
monoglycosylated Fc protein at low temperatures from pH 4.5 to 6.0, exists in a 
structurally altered Region D (green color) as shown in Figure 6. Thus, no native 
like state (Region A, black color) can be detected. A region representing 
aggregated protein (region E, blue color) is also seen at high temperature for the 
monoglycosylated Fc. The monoglycosylated Fc protein was the least stable 
compared to the diglycosylated and nonglycosylated (QQ) Fc proteins with no 
stable region A being detected and lower temperature thermal transitions noted 
depending on the pH and biophysical readout.   
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 A comparison of the three different nonglycosylated IgG1-Fc proteins 
with variations in the amino acid residue in site 297 (also see Figure 6) also shows 
different degrees of structural integrity and conformational stability. The 
nonglycosylated DD and nonglycosylated DN Fc proteins, containing two and 
one Asp 297, respectively, were created by PNGase F enzymatic treatment of the 
corresponding di- and mono- glycosylated Fc molecules (See Figure 1). The 
nonglycosylated mutant (QQ) with two Gln residues was also prepared and 
evaluated as a nonglycosylated Fc protein containing a nuncharged amino acid 
residue at the 297 site. As shown in Figure 6, the nonglycosylated DD IgG1-Fc 
protein at a pH between 5.0 and 6.0 exists in an altered state (region D, green 
color). A small region of aggregated protein (region E, blue color) is detected at 
higher temperature. The nonglycosylated DN Fc protein shows an enhanced 
structural integrity at pH 6.0, compared to the nonglycosylated DD form where a 
more native like conformation (region B, dark green) is detected. A structurally 
altered state (region D, green) is observed for the nonglycosylated DN protein at 
pH 5.0 and 5.5 (similar to that seen for the nonglycosylated DD form). A 
relatively large region of aggregated protein (region E, blue color) is present at 
high temperature for the nonglycosylated DN protein, indicating that this form is 
most prone to aggregation upon heating. Finally, the nonglycosylated mutant 
(QQ), as already discussed above, defines a region where the proteins exists in a 
native-like conformation at pH 5.5 and 6.0 that is not seen for the nonglycosylated 
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DD or DN species.  In summary, the presence of a charged amino acid residue at 
site 297 in the CH2 domain (through the conversion of Asn to Asp as a result of 
the PNGase F enzymatic treatment) had a measurable influence on the IgG-1 Fc 
conformational stability. Comparing the nonglycosylated DD to the 
nonglycosylated mutant (QQ), a stability advantage was detected for the 
nonglycosylated mutant (QQ) with a stable, native like region A being detected 
and higher temperature thermal transitions noted depending on the pH and the 
method of detection employed.   
 
4.4 Discussion 
 Comparability exercises are routinely performed in the biopharmaceutical 
industry as a result of manufacturing process changes (e.g., cell culture or 
purification steps) or alteration in final product presentation (e.g., formulation 
composition or different packaging material) for protein based drugs under 
development or currently marketed.
28, 29
 In these studies, the critical quality 
attributes of the pre and post-change protein-drug are evaluated in a head-to-head 
fashion to better understand the effect (if any) of the process or product changes 
on key comparability elements such physiochemical integrity, storage stability, 
functionality, immunogenicity and pharmacokinetics. With regard to 
physiochemical characterization, numerous advances have been made in terms of 
characterization of a protein’s primary structure and post translational 
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modifications through multiple chromatographic (size exclusion, reverse phase 
and ion exchange HPLC) and electrophoretic (capillary isoelectric focusing and 
capillary sodium dodecyl sulfate) methods typically applied with mass 
spectrometric detection (intact molecular weight, peptide maps, and 
oligosaccharides maps). Challenges regarding the development of analytical 
techniques for the structural determination of higher order structures still remain, 
however, resulting in the requirement for functional potency assays to ensure 
biological activity as a surrogate to demonstrate the protein is properly folded. 
Although multiple high-resolution analytical techniques have been used for the 
characterization of the higher order structures of proteins, ranging from nuclear 
magnetic resonance (NMR)
30
, X-ray crystallography 
31
, small angle x-ray 
scattering (SAXS) 
32
 and hydrogen-deuterium exchange mass spectrometry 
(HDX-MS),
33-36  
multiple practical drawbacks such as the requirement of isotope 
labeling, generation of protein crystals, interference of excipients, and/or the 
complicated and time consuming nature of these approaches have limited their 
use in biocomparability studies.  
Alternatively, comparing the physical stability profile of proteins using 
lower resolution techniques may be useful complement to higher sensitivity 
analytical methods such as NMR and hydrogen-deuterium exchange mass 
spectrometry to examine subtle differences in protein structure in formulated drug 
product dosage forms. The effect of variations introduced into the glycan structure 
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of an IgG1mAb, through enzymatic glycan truncation, protein structural integrity 
was recently evaluated in our laboratory by this alternative approach using more 
readily available biophysical instruments (e.g., fluorescence spectroscopy, light 
scattering and differential scanning calorimetry).
37
 By using a combination of 
lower resolution biophysical techniques to study the physical stability of mAb 
glycoforms over a specific pH and temperature range (at 0.5 pH intervals from 4-
6 and 1.25 
0
C temperature increments from 25-90
0
C), combined with recently 
developed data visualization tools, structural and conformational stability 
differences between the different IgG1glycoforms were demonstrated. In this 
study, a comprehensive evaluation of the overall structural integrity and 
conformational stability of five different IgG1-Fc glycoproteins using multiple 
biophysical methods across a wide range of pH and temperature conditions is 
undertaken and comparisons are made between their corresponding global 
physical stability profiles (three index EPDs and radar charts).  
First, initial characterization of the five well-defined  glycoforms of IgG1-
Fc (Figure 1) was carried out using a combination of mass spectrometry (MS), 
sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE), size exclusion high 
performance chromatography (SE-HPLC) and spectral characterization (CD and 
fluorescence spectroscopy) to evaluate mass (degree of glycosylation), purity and 
overall structural integrity prior to initiating physical stability studies. The five 
proteins had measured masses in close agreement to their expected masses due to 
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their glycosylation status (Table 1 and supplementary Figure S1). The five 
proteins were shown to have relatively high purity (~91-97%), in primarily 
monomeric forms as seen from SE-HPLC analysis (Table 2 and Figure 2A) with 
some relatively low levels of aggregation and fragmentation, under non-
denaturing conditions. Purity under denaturing conditions was analyzed by SDS-
PAGE under reduced conditions and showed values ranging from ~97-99% for 
the diglycosylated Fc derived proteins and ~84% for the monglycosylated Fc 
derived proteins (Table 2 and Figure 2B). One of the minor impurity bands was 
accounted for by the presence of residual PNGase remaining from the 
enzymatically treated Fc samples (see Figure 2B; lane 7).  The gels were further 
analyzed by non-reduced SDS-PAGE and Western Blot analysis (see 
Supplemental Figure S2).  All five samples showed the expected migration for the 
major bands (i.e. Fc protein) in non-reduced gel. The migration of the second 
minor protein band (~39 kDa) found in the monoglycosylated derived proteins 
was not affected by PNGase enzymatic treatment or by reduction with DTT (and 
did not react with the anti-human IgG-Fc antibody by western blot analysis). This 
impurity could not be further removed despite Protein G affinity purifications 
combined with cation exchange or HIC columns. These differences in the 
purification behavior between di vs. mono- glycosylated IgG-Fc proteins are the 
subject of ongoing work in our laboratories. Similar levels of ~80% purity were 
recently reported for a monoglycosylated IgG1 mAb.
21
 In summary, since the 
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impurity was a relatively minor band on SDS-PAGE, was not readily observed by 
SEC analysis, the monoglycosylated derived Fc proteins were determined to be 
sufficiently pure for subsequent biophysical analysis performed in this work. 
 The secondary and tertiary structure of the five proteins using circular 
dichroism (CD) and intrinsic Trp fluorescence spectroscopy was then evaluated 
(Figures 3 and 4, respectively). The diglycosylated and nonglycosylated mutant 
(QQ) were both present in a more native-like structure, especially at pH 5-6 (as 
determined by λmax values and CD minima near 217 nm). Monoglycosylated Fc at 
all pH conditions tested was structurally disturbed as indicated by the altered CD 
spectra shape and the red shifted λmax values. Interestingly, upon deglycosylation 
of the monoglycosylated Fc (creating the nonglycosylated DN form), the Fc 
protein showed some recovery of native like secondary structure, more similar to 
the CD spectra of the diglycosylated Fc form with increasing solution pH. This 
observation further supports the hypothesis that lower purity level of the 
monoglycosylated Fc does not the interpretability of the measurement of 
structure.  
The physical stability of the five IgG1-Fc proteins were then evaluated as 
a function of pH and temperature using a combination of biophysical techniques 
including extrinsic and intrinsic fluorescence spectroscopy (i.e., DSF with Sypro 
Orange and Trp fluorescence peak position) and optical density (turbidity) 
measurements to evaluate the influence of varying glycosylation levels and amino 
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acid residues substitutions (site 297). IgG1-Fc proteins with varying glycosylation 
occupancy levels showed differences in their conformational and colloidal 
stability with the diglycosylated IgG1-Fc being the most stable protein followed 
by the nonglycosylated mutant (QQ). Perhaps surprisengly the monoglycosylated 
IgG1-Fc manfiested the lowest relative physical stability (Figure 5). In terms of 
the effect of amino acid substitution and negative charge introduction at site 297 
in the CH2 domain, the nonglycosylated QQ, DN and DD forms of the IgG-Fc 
were evaluated using the same biophysical techniques. Compared to the 
nonglycosylated DD and DN, the nonglycosylated mutant (QQ) demonstrated 
increased conformational stability (Figure 5).    
 Using the physical stability data sets acquired from DSF, fluorescence 
peak position and optical density measurements as a function of pH and 
temperature, data visualization methods were employed to further examine subtle 
conformational stability differences between the five different IgG1-Fc proteins.  
To the best of our knowledge, the effect of glycosylation site occupancy on IgG 
Fc physical stability has only been reported in one limited study by Ha et. al. 
(2011), which evaluated the thermal stability of an asymmetrically glycosylated 
(single arm glycosylated) IgG1 using one method (differential scanning 
calorimetry) at one pH value (pH 6.0).
21
 The CH2 domain of the fully 
glycosylated IgG1 was thermally more stable than the CH2 domain of the 
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asymmetrically glycosylated IgG1 by ~1 
0
C, with no detectable change in 
transition temperatures involving the other IgG1 domains.   
For the IgG Fc glycoforms evaluated in this work, three index EPDs and 
radar charts (Figure 6) for the IgG1-Fc with different glycosylation site 
occupancy were prepared (Figure 6) and were able to detect similar structural 
state among the three IgG1-Fc proteins with different conformational stabilities. 
Region A (Black color), where the proteins exist in a more native-like 
conformation as determined by these three biophysical methods, was only 
detected for the diglycosylated and nonglycosylated QQ at pH 5.5 and 6.0.  In 
addition, a higher transition temperature to an altered conformational form (region 
C) was observed for the diglycosylated protein in this pH range. Diglycosylated 
protein at lower temperatures and pH conditions (4.5 and 5.0) was present in a 
slightly altered conformational state (region B), a conformational state that the 
nonglycosylated QQ protein doesn’t seem to access, reflecting the important role 
glycosylation may play in stabilization of the CH2 domain in acidic 
environments
7
. Due to fluorescence λmax peak position values shifting to higher 
wavelengths relative to the diglycosylated and nonglycosylated QQ, the 
monoglycosylated Fc protein at pH 5.5 and 6.0 was determined to be present in an 
altered conformational state (region D). The monoglycosylated Fc protein was 
then deglycosylated, and showed recovery of native like structure under these 
conditions.   
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Conformational stability differences between the nonglycosylated IgG1-Fc 
proteins with variations in amino acid substitutions at site 297 (QQ, DN and DD) 
were detected as well. Nonglycosylated QQ was the only Fc protein that existed at 
a native-like conformation (region A) at low temperatures at pH 5.5 and 6.0, 
whereas, nonglycosylated DN and DD both existed in a slightly and more 
extensively altered forms (regions B and D) suggesting the important role charge 
may play in the conformational stability of the CH2 domain of these Fc proteins 
and potentially in mAbs in general.
38-40
  
 In summary, by assessing large data sets concerning conformational 
stability as a function of environmental stress (pH, temperature), subtle 
differences in IgG1-Fc glycoform structural integrity were detected. These 
differences were not readily apparent under non-stressed conditions (i.e. lower 
temperatures at more neutral pH). Thus, the use of conformational stability data 
combined with advanced data visualization methods may be an effective surrogate 
to monitor subtle differences in higher order structure due to post-translational 
modifications such as glycosylation and amino acid substitution/mutation. During 
analytical comparability studies of protein drugs within their pharmaceutical 
dosage forms, it is essential to gather higher order structural information without 
altering formulation conditions (such as protein concentration, pH, ionic strength, 
excipients, etc.). Biophysical analysis of conformational stability using lower 
resolution techniques in a high throughput setup, combined with EPD/radar chart 
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analysis for data visualization, may be a useful complement to higher sensitivity 
analytical methods such as NMR and hydrogen-deuterium exchange mass 
spectrometry to examine subtle differences in protein higher order structure in 
formulated drug product dosage forms.  
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Table 1:  Mass spectrometry analysis of reduced monomeric forms of the purified IgG-Fc proteins. The Molecular weight 
column shows the masses of the reduced non-glycosylated IgG1-Fc obtained from MS analysis along with the masses measured 
for the most abundant glycoforms (man8-GlcNAc2) of the glycosylated Fc. The values for calculated change in mass, and 
predicted change in mass are also shown. Based on these results, the modification expected due to enzymatic treatment and/or 
glycan variation of the IgG1-Fc proteins is then presented.  
 
a 
D, aspartic acid; N, asparagine; Q, glutamine; GlcNAc, N-acetylglucosamine; Man, Mannose. 
b 
The theoretical mass of the reduced, non-
glycosylated IgG1-Fc protein is 25,066.39 Da. 
c  
Man 8-12-GlcNAc2 glycoforms were observed during MS analysis for the di-glycosylated IgG1-
Fc. Man 8-9 GlcNAc2 glycoforms were observed for the mono-glycosylated IgG1-Fc.
 
 
 
IgG1-Fc proteins 
Molecular 
Weight 
(Da) 
Δ Mass 
observed 
(Da) 
Δ Mass 
predicted 
(Da) 
Reduced Fc fragment Modifications 
a
 
Arm 1 Arm 2 
N
o
n
-g
ly
co
sy
la
te
d
 
Ig
G
1
-F
c 
Mutant (QQ) 25,077 +11 +14 N → Q N → Q 
Mono-glycosylated 
+ PNGase F (DN) 
25,063 
b
 -3 +1 
Deglycosylation 
N → D 
N 
Di-glycosylated 
+ PNGase F (DD) 25,063
 b
 -3 +1 
Deglycosylation 
N → D 
Deglycosylation 
N → D 
G
ly
co
sy
la
te
d
 
Ig
G
1
-F
c 
Mono-glycosylated
 c
 
26,766 / 
25,062
 b
 
+ 1,700/ 
- 4 
+ 1,703.5/ 
0 
+Man8-GlcNAc2 N 
Di-glycosylated
 c
 26,766 + 1,700 + 1,703.5 + Man8-GlcNAc2 + Man8-GlcNAc2 
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Table 2:  Purity values for the different glycosylated and nonglycosylated IgG1-
Fc proteins determined under denaturing (reduced SDS-PAGE) and non-
denaturing (SE-HPLC) conditions.  
 IgG1-Fc proteins 
Purity 
SDS-PAGE 
a
 
SE-HPLC 
b
 
Monomer 
c
 Aggregate 
c
 
N
o
n
-g
ly
co
sy
la
te
d
 
Ig
G
1
-F
c 
Mutant (QQ) 99 % 96.6 % 1.8 % 
Monoglycosylated 
+ PNGase F (DN) 
84 % 93.7 % 4.0 % 
Diglycosylated 
+ PNGase F (DD) 
99 % 91.1 % 8.2 % 
G
ly
co
sy
la
te
d
 
Ig
G
1
-F
c 
Mono-glycosylated 84 % 95.3 % 3.4 % 
Di-glycosylated 97% 91.8 % 7.8 % 
 
a 
SDS-PAGE purity was determined from densitometry measurements of the reduced gel in figure 
2. 
b
 SE-HPLC % measurements are an average of three runs. Fragments observed were between 0.2 
and 2 %. 
c
 Standard deviation observed for the monomer and aggregation peaks was ~ 1.0% and 0.6 %, 
respectively.  
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Figure 1:  Summary of the five different IgG1-Fc proteins examined in this study.  
The left side shows the two glycosylated forms of the Fc protein (diglycosylated 
and monoglycosylated), while, the right side shows the three different 
nonglycosylated IgG1-Fc protein variants (two from PNGase treatment of 
glycoforms and one point mutant). Identity of amino acid residue at site 297 in the 
CH2 domain (Asn, Asp, Gln) and the nature of glycoforms (Man, mannose and 
GlcNAc, N-acetylglucosamine) are indicated in the figure.  
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Figure 2:  Purity of IgG1-Fc proteins under denaturing and non-denaturing 
conditions.  (A) SDS-PAGE gels of IgG1-Fc samples under reduced conditions, 
(B) representative SE-HPLC chromatograms.   
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Figure 3:  Far-UV CD spectra from 205-260 nm at 10 
0
C for the two different Fc 
glycoforms (di- and mono glycosylated) and three different nonglycosylated 
IgG1-Fc samples (QQ, DD, NN) across pH range of 4.0-6.0. See Figure 1 for a 
pictorial summary of the five Fc proteins examined.   
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Figure 4: Intrinsic (Trp) fluorescence spectra at 10 
0
C for the two different 
glycosylated (di- and mono glycosylated) and three different nonglycosylated 
forms (QQ, DD, NN) of the IgG1-Fc across the pH range of 4.0- 6.0. The λmax 
values are also shown for each protein at each pH condition.  See Figure 1 for 
pictorial summary of the five Fc proteins examined.    
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Figure 5: Thermal melting curves for the two different glycosylated (di- and 
mono glycosylated) and three different nonglycosylated forms (QQ, DD, NN) of 
the IgG1-Fc across the pH range of 4.0-6.0. Biophysical measurements include 
(A) Intrinsic Trp fluorescence, (B) Extrinsic Sypro Orange fluorescence 
spectroscopy and (C) optical density at 350 nm. See Figure 1 for pictorial 
summary of the five Fc proteins examined.  
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Figure 6: Three index EPDs for the two different glycosylated (di- and mono 
glycosylated) and three different nonglycosylated forms (QQ, DD, NN) forms of the 
IgG1-Fc.The legend box contains radar plots defining the five different conformational 
stability regions observed in the five different Fc proteins. Region A (Black) and B (Dark 
green) represent region where the protein exist in a native-like and slightly altered 
structures, respectively. Regions C (Dark red) and D (Green) represent regions where the 
Fc proteins exist at an altered structural state as seen from an increase in SYPRO orange 
and Trp fluorescence signals, respectively. Region E (Blue) represents a region where the 
Fc proteins are in an aggregated state as seen by an increased optical density signal.   
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Supplementary Figure S1: Mass spectrometry data acquired for the reduced 
forms of the different IgG1-Fc proteins. See Table 1 for nomenclature describing 
the different IgG1-Fc proteins and summary of results.   
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Supplementary Figure S2:  SDS PAGE (A) and Western Blot (B) analysis of 
non-reduced IgG1-Fc samples and SDS PAGE (C) and Western Blot (D) analysis 
of reduced IgG1-Fc samples. See Figure 2A for nomenclature describing the 
different IgG1-Fc proteins and results of the reduced SDS-PAGE gel.   
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Supplementary Figure S3: Thermal melting curves with standard deviation error 
bars (n=3) for the two different glycosylated (di- and mono glycosylated) and 
three different nonglycosylated forms (QQ, DD, NN) forms of the IgG1-Fc as 
measured by (A) intrinsic Trp fluorescence, (B) extrinsic Sypro orange 
fluorescence (DSF), and (C) turbidity at 350 nm.    
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Supplementary Figure S4: Three index EPDs and radar chart results for the 
diglycosylated IgG1-Fc protein. On the upper left side, the influence of each 
technique (DSF in red, Trp fluorescence peak position in green and optical 
density in blue as shown in upper right figures) is visualized resulting in black 
color representing no detectable change on the Fc protein structure. On the 
bottom, the individual radar charts show contribution from each of the same 
instruments (see legend at the bottom), and in roman numerals states are shown 
mapping the different conformational regions as seen in the three index EPD. 
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Supplementary Figure S5: Three index EPD and radar chart results for the 
monoglycosylated IgG1-Fc protein. On the upper left side, the influence of each 
technique (DSF in red, Trp fluorescence peak position in green and optical 
density in blue as shown in upper right figures) is visualized resulting in black 
color representing no detectable change on the Fc protein structure.  On the 
bottom, the individual radar charts show contribution from each of the same 
instruments (see legend at the bottom), and in roman numerals are shown 
mapping the different conformational regions as seen in the three index EPD.
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Supplementary Figure S6: Three EPD and radar chart results for the 
nonglycosylated mutant (QQ) IgG1-Fc protein. On the upper left side, the 
influence of each technique (DSF in red, Trp fluorescence peak position in green 
and optical density in blue as shown in upper right figures) is visualized resulting 
in black color representing no detectable change on the Fc protein structure.  On 
the bottom, the individual radar charts show contribution from each of the same 
instruments (see legend at the bottom), and in roman numerals are shown 
mapping the different conformational regions as seen in the three index EPD. 
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Supplementary Figure S7: Three index EPD and radar chart results for the 
nonglycosylated (DD) IgG1-Fc protein. On the upper left side, the influence of 
each technique (DSF in red, Trp fluorescence peak position in green and optical 
density in blue as shown in upper right figures) is visualized resulting in black 
color representing no detectable change on the Fc protein structure.  On the 
bottom, the individual radar charts show contribution from each of the same 
instruments (see legend in the bottom), and in roman numerals are shown 
mapping the different conformational regions as seen in the three index EPD. 
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Supplementary Figure S8: Three index EPD and radar chart results for the 
nonglycosylated (DN) IgG1-Fc protein. On the upper left side, the influence of 
each technique (DSF in red, Trp fluorescence peak position in green and optical 
density in blue as shown in upper right figures) is visualized resulting in black 
color representing no detectable change on the Fc protein structure.  On the 
bottom, the individual radar charts show contribution from each of the same 
instruments (see legend in the bottom), and in roman numerals are shown 
mapping the different conformational regions as seen in the three index EPD.  
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Supplementary Figure S9: Summary Radar plot showing the individual radar 
chart results at each temperature and pH condition tested for the two different 
glycosylated (di- and mono glycosylated) and three different nonglycosylated 
forms (QQ, DD, NN) of the IgG1-Fc. The legend summarizes contribution from 
each biophysical instrument. 
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Chapter 5 
 Summary, conclusions and future work 
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5.1 Summary and conclusions 
 Since the introduction of recombinant DNA technology in the late 1970’s, 
an increasing number of protein-based therapeutics has been approved by 
regulatory agencies with approximately 200 therapeutic proteins currently 
available to address a wide variety of medical conditions. The size and 
complexity of protein drugs, however, increases their susceptibility to chemical or 
structural modifications due to process and product changes, which could have a 
negative impact on the shelf-life stability, potency or immunogenicity profile.  
Thus, a thorough evaluation and characterization of the structural integrity and 
conformational stability of therapeutic proteins is an essential task for the 
successful development of a biopharmaceutical product. 
 In recent statements by Dr. Steven Kozlowski,
 1
 the director of the office 
of biotechnology products in the FDA, describing some of the current difficulties 
encountered in characterizing therapeutic proteins during clinical development, he 
stated:  “New or enhanced analytical technologies and measurement systems and 
standards that can more accurately and precisely assess the higher order 
structure and attachments of biologics would provide additional assurance of the 
quality of biologics” as well as “Improved analytical methods would enable 
quicker and more confident assessments of the potential effects of changes in the 
manufacturing process, equipment, or raw materials”. In these statements, the 
need to develop better analytical methodologies to more accurately characterize a 
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protein therapeutic’s higher order structural integrity as part of comparability 
exercises was expressed by Dr. Kozlowski, providing a summary of the current 
analytical challenge that needs to be met in the future to ensure the successful 
introduction of new manufacturing processes including biosimilars.  
    Although NMR, X-ray crystallography, cryo EM and H/D exchange mass 
spectrometry are powerful, higher resolution analytical techniques that can 
provide structural details about a protein’s folded structure and dynamics, there 
remains many practical limitations in their wide spread use (e.g., large molecular 
weight of proteins, presence of formulation components, cost and analytical 
complexity) as part of formulation development and comparability studies. With 
that being said, the need for new and novel approaches to better monitor the 
higher order structural integrity of proteins in pharmaceutical dosage forms during 
comparability studies is of great interest.  
 Lower resolution biophysical techniques such as circular dichroism (to 
monitor overall secondary structure of proteins), intrinsic/extrinsic fluorescence 
spectroscopy (to monitor tertiary structure of proteins), differential scanning 
calorimetry (to monitor protein thermal stability), as well as static light scattering 
and turbidity assays (to monitor protein aggregation) are more commonly used 
techniques to evaluate the higher-order structural integrity and conformational 
stability of protein-based drugs during development. No one single analytical 
technique, however, provides sufficient information to establish the overall 
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higher-order structural integrity of such complex macromolecules as proteins. 
Therefore, the use of more than one lower resolution biophysical technique is 
generally needed for better characterization. The multidimensional nature of 
physical stability data gathered from multiple biophysical techniques, especially 
when used in a high throughput mode allowing for analysis of multiple solution 
conditions, makes analysis and visualization of larger data sets problematic. 
Advanced data visualization methods such as empirical phase diagrams (EPDs) 
and radar charts were used in this dissertation to summarize experimental 
biophysical data acquired from high throughput experiments and visualize the 
macromolecule’s physical stability behavior across a wide range of environmental 
stress and solution conditions. 
 High throughput biophysical analysis of proteins, combined with analysis 
of the large data sets of their physical stability using various advanced data 
visualization techniques (EPDs and radar charts), was evaluated in this 
dissertation as a way to compare the structural integrity of different versions of 
the same protein to each other (as would be done in comparability studies). Using 
varying mutants and glycoforms of different proteins (with different molecular 
weights, hydrodynamic sizes, post-translational modifications, and inherent 
thermodynamic stability), the structural differences in the form of known “major 
alterations” (i.e., different point mutations) or “minor alterations” (i.e., different 
post translational modifications) were specifically introduced into three different 
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proteins: FGF-1 (chapter 2), IgG1 mAb (chapter 3), and IgG1-Fc protein (chapter 
4). The various forms of these different proteins were extensively characterized in 
terms of physical stability properties using multiple low-resolution biophysical 
techniques to monitor different aspects of the higher-order structural across a 
wide range of pH and temperature conditions. These large data sets of biophysical 
data were then used to construct EPDs and radar charts for data visualization and 
structural comparisons between the different variants of the different proteins. 
 In the second chapter, the conformational stability profile of wild type 
recombinant FGF-1 (a protein which requires binding to heparin for its mitogenic 
activity and physicochemical stability) with and without heparin was compared to 
physical stability profile of 10 different FGF-1 mutants. The overall goal was to 
evaluate the extent to which the heparin dependence of FGF-1 solution stability 
could be reduced or eliminated. Comparisons were made in terms of structural 
integrity and conformational stability across varying values of solution pH and 
temperature using multiple biophysical techniques through the use of data 
visualization employing empirical phase diagrams. Results indicated that four of 
the FGF-1 mutants (K12V/C117V, C83T/C117V/ L44F/F132W, A66C, 
K12V/C117V/P134V) without heparin displayed high physiochemical stability 
and similar bioactivity to the FGF-1 WT in the presence of heparin. These FGF-1 
mutants were highlighted as potentially good candidates for future therapeutic 
applications from a pharmaceutical stability and biological potency point of view. 
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 In the third chapter, the structural integrity and conformational stability of 
an IgG1 monoclonal antibody (mAb), after partial or complete enzymatic removal 
of the N-linked Fc glycan, were compared with the untreated mAb over a wide 
range, as well as a narrower range, of temperatures and solution pH, again using 
multiple biophysical techniques with data visualization employing both EPDs and 
radar charts. Subtle-to-larger stability differences between the different 
glycoforms were observed. Differential scanning calorimetry and differential 
scanning fluorimetry showed an improved ability to detect differences in the 
physical stability of these mAb glycoforms and were utilized in a final round of 
physical stability comparisons. On the basis of these results, a two-step 
methodology was demonstrated in which conformational stability of a mAb 
glycoform is first screened using a wide variety of instruments and environmental 
stresses, followed by a second evaluation with optimally sensitive experimental 
conditions, analytical techniques, and data visualization methods. With this 
approach, glycosylation influences on the structural integrity and conformational 
stability of an IgG1 mAb was characterized and better defined. Fully glycosylated 
mAb was shown to have significantly improved stability over the partially and 
fully deglycosylated forms, especially in terms of the conformational stability of 
the CH2 domain where the N-linked glycosylation site resides. 
 In the fourth chapter, a variety of IgG1-Fc proteins with different 
glycosylation site occupancies (diglycosylated, monoglycosylated and 
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nonglycosylated QQ) and different amino acid residues with charge differences 
(nonglycosylated DD, nonglycosylated DN and nonglycosylated QQ in the CH2 
domain) were produced and purified. These Fc glycoforms were first 
characterized using multiple electrophoretic, chromatographic and biophysical 
techniques, followed by extensive biophysical characterization of physical 
stability under stressed conditions. As seen from the results presented in the third 
chapter, glycosylation site occupancy played a significant role in the Fc protein’s 
structural integrity and conformational stability. Diglycosylated Fc protein was 
shown to be structurally more stable than the nonglycosylated QQ Fc protein, 
with thermal transition temperatures from the native-like to a structurally altered 
conformational states occurring at higher temperatures for the diglycosylated 
protein across different pH values. These results further confirmed the 
destabilizing effect of deglycosylation on Fc protein’s physical stability. To our 
surprise, the monoglycosylated Fc protein was inherently unstable compared to 
the other two proteins, where it existed in structurally altered conformational state 
even under ambient environmental conditions of temperature and solution pH. 
Comparisons of the non-glycosylated Fc proteins containing amino acids with 
different charges at the N-linked glycosylation site within the CH2 domain, were 
performed as described in this chapter as well. Nonglycosylated DD (with two 
Asps), nonglycosylated DN (with one Asp), generated from the PNGase F 
enzymatic treatment of the diglycosylated and monoglycosylated IgG1-Fc 
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proteins, respectively, were compared to the uncharged, nonglycosylated QQ 
(with two Glns) in terms of their structural integrity and conformational stability. 
Nonglycosylated DD Fc protein (with two negative charged amino acid residues 
in the CH2 domain) was found to be conformationally unstable across the pH and 
temperature conditions tested compared to the uncharged nonglycosylated QQ Fc 
protein (which exists in a native-like structural state at lower temperatures and at 
neutral pH conditions). Nonglycosylated DN Fc protein (containing one charged 
amino acid residue) illustrated an intermediate physical stability, with a slightly 
altered conformational state being detected at low temperatures at pH 6.0, 
whereas, it existed at a altered structural state at lower pH conditions.  
In summary, using this approach, differences in conformational stability of 
various FGF-1 mutants, IgG mAb glycoforms, and IgG1-Fc glycoforms were 
detected under environmental stress conditions that could not necessarily detect 
differences in structural integrity using the same biophysical techniques under 
ambient conditions (i.e., no stress). Thus, an evaluation of conformational 
stability differences may serve as an effective surrogate to monitor differences in 
higher-order structure between protein samples during physiochemical 
comparability studies. 
5.2 Future work 
 Despite the successful use of EPDs and radar charts to enhance of 
understanding of the structural integrity and conformational stability of different 
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forms of the same protein many analytical challenges still remain. For example, 
improving our understanding of the precision of EPD phase transitions using 
clustering methodologies remains as a major challenge for using EPDs and radar 
charts for comparability applications. Other challenges include successfully 
incorporating additional biophysical techniques to better identify different 
conformational aspects of the protein’s structures as well as better understanding 
the relationship of these stressed stability data with long term storage stability 
would be of great interest. 
 In terms of improved analytical precision, although both major and subtle 
differences in the structural integrity and conformational stability between the 
different versions of three different proteins were readily detected using EPDs and 
radar charts methodologies, better defining the precision of the phase transition 
stands as a challenge that needs to be addressed. During structural comparisons 
between two or more proteins, it is of great importance to establish if the 
differences observed between proteins are greater than the differences between 
multiple measurements of the same protein. This challenge could be addressed in 
the future through the introduction of mathematical models that could incorporate 
the observed variability during data collection into the EPDs and radar charts 
displays. Such incorporation of precision would enhance the conclusions made 
regarding similarity or dissimilarity between proteins during evaluations of their 
physiochemical stability as part of analytical comparability studies.  
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In terms of new analytical techniques, over the past few years, higher-
resolution methods such as, hydrogen/deuterium exchange mass spectrometry 
(H/DX-MS) has evolved into a versatile technique for investigating structural, 
dynamic and pharmaceutical stability aspects of proteins, a methodology that is 
currently being employed for such investigations in our laboratory.
2, 3
 Evaluating 
both global conformational stability (from EPDs and radar charts) and local 
dynamic information (from H/DX-MS) of proteins for more complete 
understanding of the possible correlation between protein stability and flexibility 
is of a great interest. Such an understanding should not only improve comparisons 
of stability as part of comparability assessments, but may also enable the more 
rational design and optimization of protein formulation conditions (e.g., selection 
of stabilizing excipients).  
 Finally, during the formulation development of biopharmaceutical 
products, long term stability studies are conducted under the intended storage 
conditions to evaluate protein’s physical and chemical stability over time. Studies 
assessing the possible use of EPDs and radar charts, which provide a summary of 
conformational stability data under accelerated conditions, as a predicative tool 
for long term stability of proteins could be evaluated in future work. If proven to 
be predicative, EPDs and radar chart profiles of protein physical stability could 
compliment accelerated stability studies more commonly utilized as part of 
comparability assessments.  
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